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Summary
The tumour suppressor gene p53 is pivotal in the regulation of program cell death
(apoptosis), and point mutations within the gene represent the most common
genetic alterations in human cancers. This process can result in the overexpression
and! or accumulation of mutated and! or wild-type p53 protein within the cell.
Cytotoxic T lymphocytes (CTL) playa critical role in the immune defense by
recognising peptidelMHC complexes on the surface of virally infected or tumour
cells followed by lysis. Therefore, p53-derived peptides are potential candidates
for immunisation strategies designed to induce anti-tumour CTL in patients.
Conformational changes in the p53 protein, generated as a result of point
mutations, frequently expose the 240 epitope, RHSVV (amino acids 212-217). It
is possible that peptides in this region could be processed and presented in a
different manner to the wild type protein and therefore, have the potential to be
recognised by tumour specific CTL.
In this study 15 peptides derived from the 240 epitope of the wild type p53
protein, amino acids 193-237, and peptides which are located nearby, and possess
binding motifs for HLA-A2, were assayed for their ability to stabilise HLA-
A2*0201 (HLA-A2) molecules in an MHC class I stabilisation assay. T2 cells
processing pathway is defective and as a result produce mainly empty HLA-A2
molecules, which are unstable and quickly recycled. However when a peptide,
possessing binding properties, is added exogenously it stabilises the complexes
which can then be detected by immunofluorescence. Out of all the peptides tested
seven (AA position 187-197, 188-197, 193-201, 196-204,217-225,263-272,264-
272) showed strong binding affinities for the HLA-A2 molecules (FR>1.5) at
260C with 5 peptides (187-197; 193-200; 217-224; 263-272 and 264-272) also
stabilising the complexes at 370C. Three of these p53 peptides (188-197, 196-203
and 217-225) have not previously been identified. Since out of these three peptide
217-225 stabilised HLA-A2 molecules with the highest FR, it was chosen for the
generation of CTL in vitro, using peptide 264-272 as a positive control.
Dendritic cells were generated from HLA-A2+ donors and, after peptide-pulsing,
were co-cultured with autologous CD4+-depleted T cells in vitro. The two primary
CTL thus generated (CTL-217, and CTL-264) were capable of specifically killing
peptide pulsed T2 or JY but not either cells alone. These cells express wild-type
p53 protein. In order to determine whether these peptides were endogenously
processed, and test the hypothesis that different mutants with different pS3 protein
conformation would generate different peptides at the surface of the cell bearing
them, a panel of target cells was generated. HLA-A2+ SaOs -2 cells were
transfected with p53 cDNA containing a point mutation at either position 175 (R
~H) or 273 (R~H) (SaOs-2/175 and SaOs-2/273). Two HLA-A2 negative cell
lines, A431 and SKBr3, naturally expressing p53 mutated at positions 273 and
175, respectively, were transfected with HLA-A2 cDNA. The results showed that
both primary CTL were capable of killing SaOs-2/175 and SKBr3-A2 cells which
bear the same mutation but not SaOs-2/273, A431-A2 or SKBr3 cells transfected
with control vector. This suggests that these peptides were presented on the
surface of SaOs-2/175 and SKBr3-A2 cells in a conformation dependent manner
and are potentially useful for inclusion in cancer vaccines.
Key questions are whether patients whose tumours harbour a pS3 mutation have
demonstrable precursor CTL or whether they can be induced, and whether there is
an association between the p53 gene mutation, HLA type and disease progression.
In an attempt to answer some of these questions the immunological status of
HNSCC patients with respect to p53 was studied by analysis of p53 serum
antibody, and analysis of p53 protein expression by immunohistochemistry, when
tumour samples were available. Results showed p53 accumulation in 6/10 of
HNSCC and presence of anti-p53 antibodies in 2 out of 10 of these patients' sera,
and 2 out of 14 of the totals of patients.
Cellular immune responses to p53 by CTL and proliferation although intended
could not be done because of shortage of materials (protein and PBMC).
Therefore some of these questions remain unanswered and are open to further
studies.
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I.Introduction
MHC antigens are implicated in presenting target antigens for immune recognition and
generating an immune response. Indeed epitope mapping of tumour antigens for MHC
class-I and more recently class-II restricted binding motifs followed by subsequent
immunisation with these peptides has induced immune responses in murine models as
well as in humans against cancer expressing the antigen. This introductory chapter will
present an account for tumour antigens presentation and their identification.
The task of the immune system is of two-fold. First it has to recognise any pathogen or
other foreign material potentially harmful followed by an appropriate immune reaction
destined to eliminate them. All cells of a given human being bear on their surface
something in common that make them different from any other being, with the exception
of twins. On their surface a group of proteins is present which are unique to each
individual. These molecules are called HLA standing for Human Leukocyte Antigen in
human and more generally referred to as the Major Histocompatibility Complex (MHC).
These were first discovered when skin-graft rejections in mice were studied. These are of
two classes, MHC class-I molecules and MHC class-II molecules. Class-I molecules are
normally expressed on most nucleated cells (and on erythrocytes and platelets in some
species) whereas class-II molecules are mostly restricted to antigen-presenting cells (e.g.
dendritic cells, activated macrophages, B-cells and vascular endothelial cells). The level
of MHC molecules is, however, modulable and their expression on cells can be changed
by cytokines. Interferon-gamma (IFN-y) and tumour necrosis factor-alpha (TNF-a) are
powerful inducer of MHC antigen expression on many cell types, which would otherwise
express MHC molecules only weakly (Andalib, et al., 1995).
1.1 MBC Structure and Function
1.1.1 MBC Structure
1.1.1.1 MBC Class-I Molecule
MHC class-I antigen structure consists of a 44KDa heavy chain, encoded by a number of
genes on chromosome 6 (Trowsdale, et al., 1991) and composed of three extracellular
domains (alpha-I, -2, -3), a transmembrane region and a cytoplasmic tail at the carboxyl
terminus. Alpha-l and -2 domains form a peptide-accommodating groove made-up of
two antiparallel a-helices and overlaying a platform of antiparallel l3-strands located on
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the top surface of the molecule. A non-polymorphic light chain of 12 KDa
32microglobulin (32-m), encoded by chromosome 15 (Goodfellow, et aI., 1975) is non-
covalently attached to the heavy chain (6) (Figure l.a). Peptides are tightly bound in the
groove and interact with both Nand C termini and a subset of its amino-acid side chains,
to MHC residues (Bjorkman", et aI., 1987). The complex formed is extremely stable
with high affinity interaction. Two or three amino-acids position (anchor residues) are
present, in the bound peptide, usually restricted to a vary narrow subset of amino-acid,
leading to particular 'binding motifs' for each allele (See Section 3.1.2.1). Although,
most MHC class-I peptides are of 8-11 amino-acids and derived from the endogenous
processing of protein made inside the cell, some peptides arising from the degradation of
exogenous protein are released from the APC phagosomes into the cytosol and are
presented by MHC class-I molecules (Harding, et aI., 1994). The MHC class-I
processing pathway process is explained in Section 1.1.2.1.
The human class-I region contains three major loci, called HLA-A, -B, -C, which direct
the synthesis of class-I proteins. Three other genes (HLA-E, -F, -G) encode for 'minor'
alleles, whose function are not fully determined yet. Each locus exists as allelic variants
of MHC genes and is co-dominantly expressed. The frequencies of the principal alleles
are as follows: HLA-A2 is present in 49.1% of Caucasians, HLA-Al is present in 26.4%
and HLA-A3 is present in 24.7%.
1.1.1.2 MBC Class-TI Molecule
MHC class-Il antigens, encoded by chromosome 6 (Trowsdale, et al., 1991), are very
similar to MHC class-I molecule. They are composed of heterodimeric membrane-
integral glycoproteins, with tightly but non-covalently linked alpha (of about 34KDa)
and beta (of about 28KDa) glycoprotein chains, each having a transmembrane domain
and carboxyl terminal cytoplasmic tail (Figure I.b) (Germain, et aI., 1994). The peptide-
binding domain, forming open-ended pockets, shows greater degree of flexibility in the
length of peptides that can accommodate within the groove. These vary from 11-25
amino acids and in contrast to MHC class-I peptide interaction specific residue
interactions are formed throughout the extended peptide (Stern, et al., 1994). The
molecule is highly polymorphic and in man at least three isotypes (IaA-DR, -DP, -DQ)
are co-expressed. In general, class-Il MHC molecules bind peptides derived from
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proteins that have been taken-up by antigen presenting cells (APe) through an endocytic
process, but not always. This process is also discussed in Section 1.1.2.2.
1.1.2 MBC Function
Apart from its role of aiding the immune system in distinguishing 'self from 'non-self
MHe class-I and class-II molecules also function to collect peptides produced from
endogenous cell protein, and transport them to the cell surface, where they can be
surveyed by T-cells.
1.1.2.1 MBC Class-I Molecule
Most class-I binding peptides come from nuclear and cytolytic proteins (Benham, et aI.,
1995). Proteins are processed in the cytosol by the major-cytosolic proteolytic complex,
the proteasome, which exists as both a 20S and 26S form (Benham, et aI., 1995). Two
of its subunits LMP2 and LMP7 (Low Molecular Mass Polypeptide) are encoded by the
MHC gene complex (Glynne, et aI., 1991), which are responsible for the generation of
small peptides. These peptides are transported via two heat shock proteins (HSP), of 70
and 90 KDa respectively, which needs ATP for each transfer (Srivastava, et aI., 1994).
Peptides are then subsequently transported into the endoplasmic reticulum (ER) by TAP
(transporter associated proteins), these consist of two subunits, TAPI and TAP2. TAP
proteins are structurally similar to the protein family of ATP driven membrane
transporters, (a member of which is the P-glycoprotein involved in multidrug resistance
of cancer cells (Spies, et aI., 1990). TAP proteins in turn transfer the peptides to another
HSP of 96 KDa, called 'gp96', into the lumen of the ER (Deverson, et aI., 1990; Spies,
et al., 1990; Srivastava, et al., 1993/1994). Finally peptides are delivered to empty
complex MHC class-l/Bz-rn, complex which occurred earlier (Ortmann, et aI., 1994).
82-rn, like the invariant chain for class-II molecules, plays an important role in the
proper folding of the heavy chain since in the case of mutant cell line Daudi, that lacks
82-m, virtually no cJass-I molecules were expressed on its cell surface. In this case the
unproperly folded heavy chains never left the endoplasmic reticulum and were rapidly
degraded (Restifo, et aI., 1996).
The dimerization of MHe class-I molecule and 82-m, prior to peptide binding, appears
to be mediates by a 90 KDa protein called calnexin (!P90) in human which then with the
7
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help of yet another transmembrane glycoprotein called tapasin facilitates their association
with TAP molecules (Ortmann, et aI., 1994). This association allows dimmers to gain
access to cytosol derived peptides before they get diluted or degraded in the lumen of
the ER (Grandea Ill, et aI., 1995). In the human mutant T2 cell line, which has a
homozygous deletion of the WfC class-II region located on chromosome 6 including
the TAP genes, normal presentation of endogenously processed peptides does not take
place even though cells produce high amounts of heavy chain class-I and 132-m.Mostly,
empty HLA-A2 isotypes are expressed, suggesting an important role of TAP molecules
in antigen processing pathway (Towsend, et a!., 1989; Anderson, et aI., 1991). However
when peptides are added exogenously, they bind to empty HLA molecule thereby
stabilising the complex MHC / 132m. Yet in some cases other molecules apart from
TAPs may be responsible for the antigen processing pathway. Followed by peptide
binding, the complex is released and transported through the golgi apparatus to the cell
surface (Figure 1.2). ER to golgi transport often requires correct tertiary or quaternary
structure; inappropriately folded or unassembled proteins appear to be retained
intracellularly either by inclusion in aggregates or by specific ER proteins such as
calnexin or Binding protein (BIP). Calnexin and BIP, the latest being a member of the
heat shock protein of 70 KDa (HSP 70), belong to group of molecules called molecular
chaperones. Their predominant role, as stated, appears to be the prevention of
intermolecular association between incorrectly unfolded polypeptide chains (Hartl, et al.,
1994). Its dissociation correlates with the completion of a distinct stage in folding. Thus
calnexin seems to participate in regulating the intra-cellular transport of class-I
molecules, probably by regulating assembly of intermediates since a close correlation
between the rates of calnexin and the arrival of class-I molecule in the Golgi has been
found (Degen, et aI., 1992).
1.1.2.2 MBC Class-D Molecule
MHC class-II molecules usually present exogenous antigens. These are internalised via
the endocytic pathway and are subject to gradual degradation by a succession of
enzymes active at different pH. Proteases cathepsin Band D, active in the early
endosome (pH 6-6.5) (Guagliardi, et aI., 1990), are then joined by lysosomal enzymes in
the late endosome (which are less active due to non-optimal pH of 5-5.5), and finally by
9
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fully active lysosomal hydrolases in the lysosome (pH 4.5-5) (Ohkuma, et aI., 1978).
Cathepsin B is necessary and may be sufficient for antigen processing alone (Takahashi,
et aI., 1989), although the progressively decreasing pH of the endocytic pathway which
activates most proteases plays an important part (McCoy, et aI., 1989). Newly
synthesised class-II molecules with their associated invariant chain are delivered to early
endosomes where they remain until the invariant chain is removed (Brodsky, et a!.,
1991). The invariant chain is a glycoprotein, of 31-43 KDa, with an extra-cellular
carboxyl terminus, a single transmembrane domain and an amino-terminal cytoplasmic
tail and is encoded by chromosome 5 in human (Brodsky, et aI., 1991) (Figure l.c), It
has many functions, and among them is the protection of peptide-binding sites from the
binding of peptides prior to the designated physiologic site (Hammerling, et aI., 1990~
Busch, et aI., 1996). This keep class-I and class-II pathways distinct and avoid the
degradation of class-II molecule by activated prot eases where the molecule is likely to
bind peptides.
One other role of the invariant chain is to maintain the integrity of class-II molecule
conformation. In its absence molecules folding differently are retained in the ER where
they form aggregates in association with other molecular chaperons (Peterson, et aI.,
1990). Analogous to its role in c1ass-I assembly, discussed earlier, calnexin also retains
alpha and beta chains of class-II molecule, enabling them to assemble and stabilise with
the Ii in the ER (Williams, et al., 1995). When the invariant chain is removed by
proteolysis, class-II molecule becomes competent to bind peptides. Once complexed
with peptides, the molecule is then released from either early or late endosome,
transporting peptide to the cell surface. Internalisation and recycling of class-II
molecules provides a second opportunity for empty class-II molecules to bind peptides.
These processes therefore promote peptide exchange, with the possible involvement of a
70-Kd peptide-binding protein of the heat shock protein family (HSP) (Vanbuskirk, et
aI., 1989) (Figure 1.3).
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1.2 Tumour Antigens
As previously stated, the task of the immune system is two-fold. Once it has
differentiated self from non-self and normal from abnormal cells, an 'immune' response
then has to distinguish 'abnormal' from 'normal' cells. How this is achieved depends
upon the type of molecular presentation by MHC molecules. MHC class-II molecules
plus relevant peptides are recognised by immune cells bearing a CD4 marker (Figure
l.4a), also referred to as 'helper- T cells' because they enhance antibody production by
activating B cells, promote other T-cell responses, and activate a variety of other
immune effector cells (e.g., macrophages). MHC class-I molecules plus relevant peptides
are recognised mostly by CD8 bearer T-cells (Figure 1.4.b) through their TCR (T-cell-
receptor) (Figure l.4.c), which requires to be of the same haplotype as the MHC
molecule in question (MHC compatibility). This interaction, is necessary, but insufficient
to lead to T cell activation (clonal expansion and differentiation) and destruction of the
'abnormal' cell by both the perf orin / granzymes pathway (proteolyses) and the Fas / fas
ligand-activated pathway (apoptosis) (Doherty, 1993). Indeed naive T-cells require not
only receptor binding, ensuring antigenic specificity but also a second signal delivered by
co-stimulatory molecules such as CD80 (also called B7.1) and CD86 (also called B7.2)
on the surface of APC via their interaction with CD28/CTLA-4 for activation. B-
lymphocytes, macrophages or dendritic cells can deliver this second signal. T-cells
reacting with self-protein have been eliminated priot maturation by clonal deletion early
in the development. T-cells are unable to respond to self-antigens since most cells cannot
deliver this second co-stimulatory signal and instead induce tolerance where the T-cell in
question is rendered anergic (Gimmi, et al., 1993). CD8+ T-cells are very effective cells
which perform an immune surveillance function, effectively monitoring the contents of
virtually all cells by detecting peptides that are presented in complex with MHC class-I
molecules and displayed at the cell surfaces.
The evolution of a normal cell into a cancer cell is a complex multi-stage process that
occurs at a molecular level leading eventually to the emergence of a clone of cells which
no longer has the same growth control restraints that effect normal cells. Among all the
molecular changes occurring in cancer cells are activation of oncogenes by mutation,
rearrangements, transduction, or inactivation of tumour suppressor genes by mutation or
deletion; and/or aberrantly glycosylated, aberrantly expressed or up-regulated self-
molecules. All these changes may give rise to tumour associated antigen,
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which are expressed by both normal and tumour cells but in higher quantity on tumour
cells or to specific tumour antigen, which are only expressed by tumour cells.
1.2.1 Tumour Associated Antigens
Tumour associated antigens can be defined as antigens expressed by normal cells at
particular stages of differentiation that are re-activated during the tumorigenic process or
antigens express by normal cells that are overexpressed in tumour cells.
One mechanism by which oncogenes are activated in human cancers is gene
amplification, which leads to increased expression of a normal self-protein that acts to
drive cell proliferation. HER/neu proto-oncogene is amplified and overexpressed in 20-
40% of invasive breast cancer. It encodes a receptor-like transmembrane glycoprotein
with a relative molecular mass of 185Kda (p185) that is highly homologous to the to
epidermal growth factor receptor (Bargman, et al., 1986). Its function seems to be
increasing activity of tyrosine-specific kinase (Coussens, et al., 1985). CD4+ T-cells and
antibodies have been shown to be present in the sera of patients with HER-2/neu-
positive breast cancers (Disis, et al., 1994). Tumour infiltrating lymphocytes (TIL) from
patients lll..A-A2+ with ovarian cancer when expanded in vitro have demonstrated
tumour-specific lysis in an HLA-A2 restricted manner (Yoshino, et aI., 1994).
Some mutations occurring in the genome, as said, are irrelevant to the tumoral
transformation but can induce the activation of genes not normally active in normal cells.
This may then leads to new peptides expressed and complexed with a MHe class-I
molecule on the cell surface. These mutations may also generate mutated protein that
once processed will generate binder peptides thatd-d n<* birdbefore. That is exactly what
happened when T. Boon (Boon, 1993), after exposing a culture of mouse tumour cells
to a potent mutagen, transferred the clonal populations into tumour-free mice. Mice
infected with the non-exposed tumour cells developed tumour almost always, while
those infected with the mutagen-treated clones did not produce any malignancy. These
cell clones were called Tum - for tumour negative. Yet, it was only in 1987 that the
phenomenon was understood and three Tum- genes identified. Point mutation in two of
the Tum- gene had rendered the affected peptide capable of binding to MHC molecules
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and therefore recognisable by the host T-cells. The gene responsible for the tumour-
rejection antigen (P815A) was then sequenced and called PIA. They also discovered
that genes silent in normal cells can be activated by point mutations and this leads to
exposure of new epitopes that can be targeted by host T-cells.
Since then a number of tumour associated antigens have been discovered (Boon, et aI.,
1994) and at present three main tumour associated antigen groups can be described from
the widely studied melanoma tumours.
The first group, testis-specific antigens, consists of developmental antigens that are not
expressed by adult tissue, except testis, but are re-expressed in malignant cells, are all
encoded by chromosome X, and belong to either of these families: MAGE, BAGE,
GAGE, NY-ESO-l and PRAME. MAGE-I, -2, -3 are expressed by melanomas (35, 58
and 60% respectively) (Brasseur, et al., 1995) but also by other tumours such as breast
cancers (Brasseur, et aI., 1992), lung cancers (Weynants, et aI., 1994), gastric carcinoma
(Inoue, et ai., 1995), and bladder carcinoma (Patard, et ai., 1995). Their precise function
is still unknown. Peptides encoded by MAGE-l have been found to be presented by
lll..,A-AI or HLA-Cw(*)1601 and have been reported to induce specific cytolytic T-
lymphocytes that recognise tumour cells expressing MAGE-l gene (Salgaller, et al.,
1994~ Van der Bruggen, et al., 1994). Peptides encoded by MAGE-3, and presented by
HLA-A2 or -AI, have also been found to generate CTL (Van der Bruggen, et al., 1994;
Gaugler, et aI., 1994).
The second group consists of differentiation antigens specific to the melanocyte lineage
(tyrosinase, gpl00lPmelA, and MART-l/MelanA). These antigens are expressed by
tumour cells as well as by normal adult melanocytes but are in much higher level in
melanoma cells. Tyrosinase is an enzyme that transforms tyrosine into
dihydroxyphenylalanins (DOPA) an intermediate product in the synthesis of melanin.
Tyrosinase has been shown to be recognised by HLA-A2 and -A24 restricted T-cell
clones (Wolfel, et ai., 1994~ Robbins, et aI., 1994) and by CD4+ 'l-cells from TILS
(Topalian, et al., 1994). MART-l gene, standing for melanoma antigen recognised by T-
cells, encodes a protein that contain a hydrophobic region of 21 amino-acids long. This
region may represent a transmembrane region (Kawakami", et al., 1994/1996). Peptides
from MART-l have been reported to be specifically recognised by HLA-A2 restricted
TILS (Kawakami", et ai., 1994). gpl00 antigen is a type 1 transmembrane glycoprotein
that may be involved in melanin synthesis. Peptides derived from the gp 100 have been
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shown to be recognised by HLA-A2 restricted anti-melanoma CTL line and TILS
(Bakker, et aI., 1995).
The third group consists of the mutated or aberrantly expressed antigens including
MUM-I, CDK4, beta-catenin, gpIOO-in4, pI5 and N-acetylglucosaminyltransferase V
(Kirkin, et aI., 1998). Other tumour-associated antigens include wild-type peptide
epitopes of aberrantly expressed genes including cell cycle control genes such as cyc1in
D and E, or DNA repair genes such as p53. All of them may be very useful tools for
future immunotherapy.
1.2.2 Specific Tumours Antigens
Among all oncogenes activated by point mutations, members of the ras gene family are
the most frequently involved in human cancer and widely studied for their potential use
for immunotherapy. The ras family consists of three related genes: ras H, ras K, and ras
N, and encode inner membrane-bound proteins (p21 RAS). In human tumours, point
mutations, i.e. replacement of one nucleotide by another one, are sufficient to convert
normally functioning ras proto-oncogenes to potent oncogenes that efficiently induce
neoplastic transformation. These mutations alter single amino acids (AA) at critical
regulatory positions of the ras protein (p21) usually at residues 12 or 61 (Cooper, et al.,
1992). Thus a single AA substitution may create novel antigenic determinants which can
be specifically recognised by host T-cells. Substitution of arginine for normal glycine at
residue 12 has indeed shown to elicit specific MHC-c1ass- II T-cells response (Peace, et
al., 1991) whereas substitution of glycine for aspartine at residue 13 did generate a
class-I T-cell response being HLA restricted (Fossum, et al., 1995).
Carcinogens are known to cause random mutations in the genome and
methylcholonthrene is one of them. In methylcholonthrene-induced sarcomas, tumour
cells express specific antigens that are unique to each tumour induced with the same
component. Two tumour specific antigens have been isolated, one of 82 KDa and the
other one of about 86 KDa, from the methylcholonthrene-induced sarcoma and both had
tumour rejection activity specific for the tumour induced (DuBois, et al., 1986).
Abnormal rearrangements of the genetic material like translocation of chromosomes, as
said, can also activate oncogenes. In leukaemias and lymphomas additional
translocations occur regularly, and in the case of chronic myelogenous leukaemia (CML)
the 5' end of the c-abl proto-oncogene located on chromosome 9 is replaced by bcr gene
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sequences on chromosome 22. The new chromosome is called Philadelphia chromosome
(Ph) (Urban, et al., 1992). The expression of which results in the production of an
aberrant fusion protein, a tyrosine kinase with tumorigenic properties (McLaughin, et
aI., 1987). Therefore the new protein may be immunogenic if it is appropriately
processed intracellularly and if the resulting peptides possess the structural
characteristics necessary to bind to both MHC molecule and T-cell receptor within that
individual. T cells were shown to proliferate when incubated with dendritic cells pre-
pulsed with l l-mer peptide from the b3/a2 bcr/abl fusion protein (Mannering, et aI.,
1997).
Viral encoded gene products are strongly immunogenic and fall into a class of proteins
that appear to facilitate cellular transformation. These potential tumour specific antigens
represent obvious choices to evaluate for T-cell reactivity and against which to direct
immune T-effector cells. Human papillomaviruses (HPV) are small DNA viruses that are
associated with 90% of all cancers of the cervix. Approximately 70 different types of
HPV have been identified but only 8 are capable of infecting the lower genital tract,
transmitted during sexual intercourse. In pre- malignant lesions viral DNA appears to be
episomal and replicates independently of cellular DNA, cells are able to produce mature
viral proteins. Change to malignancy involves the integration, in a random fashion, of
viral DNA into onJseveral chromosome sites. It is associated with the loss of ability to
produce viral particles. Studies have found that E6E7 portion of viral genome IS
constantly transcribed and these are known to carry information concerning
immortalisation and transcription of a target cell. E6 and E7 are viral proteins expressed
only by cancer cells, they constitute therefore specific tumour antigens potentially
recognisable by host T-cells. Cells transfected with the E7 gene of HPV-I6 were
specifically rejected by mice immunised with MHC class-I, syngeneic fibroblasts
expressing the same HPV gene and injection of antibodies specific for CD8+ cells
prevented the rejection (Chen, et aI., 1991). Tumours expressing the E6 antigens were
also specifically killed by immunised mice CD8+ cells in a MHC restricted pattern (Chen,
et aI., 1992).
The Epstein-Barr Virus (EBV) is directly implicated in the formation of immunoblastic
B-celllymphoma, Burkitt's lymphoma, and nasopharyngeal carcinoma (Masucci, et aI.,
1993). EBV nuclear protein appear to be required for the maintenance of the
transformed state and their expression is selectively retained in tumour cells as for many
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viral proteins (Masucci, et a/., 1993). EBV peptides have been shown to elicit class-I-
restricted CD8+ T-cell immune response (Muuray, et aI., 1992).
Adenovirus products such as adenovirus S El A gene products have also been shown to
generate specific CD8+ CTL immunity against an El A transformed syngeneic cell line in
H-2b mice and these in vivo primed CD8~ T cells could be adoptively transferred and
were capable of mediating the complete regression of El A-induced tumours grown in
nude (nu/nu) mice (Kast, et aI., 1989).
Breast, colon, and pancreatic adenocarcinomas all express aberrantly glycosylated mucin
encoded by MUCI gene, thereby revealing previously cryptic mucin peptide epitopes.
Mucin are large heavy glycosylated proteins expressed and secreted by ductal epithelial
cells (Burchell, et a/., 1987). Their structure consists of a long polypeptide core, formed
by a multiple tandem repeats of amino-acid sequences, surrounded by O-linked
carbohydrate moieties (Roussel, et a/., 1988). CTL against normally cryptic epitopes
present in the 20 amino-acids tandem repeats on both breast and pancreatic tumour
targets have been generated in a MHC-unrestricted manner (Jerome, et aI., 1991).
The identification of tumour associated antigen has been possible by the progress made
in molecular biology since the work of Thierry Boon and co-worker in 1991 where DNA
from cancer cells were removed, cleaved and spliced into plasmids, carrying a drug
resistance gene. Cosmids were then mixed with millions of cells known to have lost the
antigen. Cells were then exposed to toxic drug and the survivors, containing the gene of
interest, allowed to expand. Samples were in tum exposed to T-lymphocytes specific for
the antigen. The DNA of the cells capable of inducing a CTL response were removed
and sequenced. This technique has lead to the identification of a numbers. of tumour
associated antigens mentioned earlier. It is, however, important to stress out that these
discoveries were only made possible because CTL were available to detect antigen in
transfected cells.
Amongst all the tumour associated and specific antigens, pS3 is recognised for its
importance both as proto-oncogene or when mutated as an oncogene. In addition pS3
has a potential role in immunotherapy against cancer, this is discussed below.
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1.3 p53 Gene
1.3.1 p53 Function
p53 gene is a tumour suppressor gene located on chromosome 17 at band 1301 (Levine,
et al., 1991). It encodes a nuclear 53 KDa phosphoprotein whose half-life is very short
in normal cells, 5-20 minutes. Normal pS3 acts as a transcriptional factor (Fields, et al.,
1990) of different genes by forming tetramers which bind to specific DNA sequences. It
is involved in apoptosis, in the control of cellular differentiation and appears to positively
or negatively regulates the expression of particular genes in the cell.
The normal pS3 serves to protect the genome and so has been called "the guardian of the
genome" (Lane, et aI., 1992). As a consequence of DNA damage induced by Cisplatin,
Mitomycin C, Etoposide regulator (Fritsche, et al., 1993) or U.V irradiation (Hall, et aI.,
1993) pS3 levels increase, leading to p53 accumulation which in tum induces the
transcription of the Wafl gene localised on chromosome 6p21.2 (El-Deiry, et aI., 1993).
The p21 Wafl increase leads to inhibition of the cyclinlCdk mediated phosphorylation of
pRb (Dulic, et aI., 1994) and also inactivates the DNA replication machinery by binding
to proliferating cell nuclear antigen (PCNA) and DNA polymerase gamma (Waga, et aI.,
1994), and as a consequence cells are arrested late in the G 1 phase of replication
(Kastan, et aI., 1991). p21 belongs to a family of cell cycle inhibitory proteins but none
of the others however has-been found to be regulated by pS3 (El Deiry, et aI., 1991).
Tumour cells with mutated or absent p53 genes lose the ability to arrest in G 1 following
ionised radiation (IR) (Kastan, et aI., 1991) or G2 following DNA damage (Allday, et
al., 1995) and if normal p53 has some anti-proliferative properties its mutated
counterpart however faik to block the progression of cell division and occasionally even
promotes cellular proliferation (Martinez, et aI., 1991). p53 accumulation has been
shown to be the result of an increased half-life of the protein rather than an increase in
the protein synthesis since no mRNA augmentation was detectable after XRT treatment
(Kastan, et al., 1991). Another study showed that the overexpression of the temperature
sensitive pS3 Val 135 mutant transfected into non-tumorigenic murine myeloid precursor
cell line, which is IL-3 and serum dependent for survival, accelerated apoptosis when
cells were IL-3 deprived (Blandino, et aI., 1995). Similarly the transfection of pS3 under
control of a metallothionein MT-1 promoter in human colon tumour-derived cell line EB
when stimulated by addition of zinc chloride resulted in a high level of pS3 and induction
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of apoptosis of cells grown in culture dishes as well as those grown in nude mice (Shaw,
et aI., 1992). Overexpression of pS3 in normal cells either arrests cell growth and/or
induces apoptosis in response to certain stimuli. However p53 gene and its protein are
not essential for cellular viability. Indeed a family of transgenic mice with both pS3
alleles destroyed by an insertional mutation was still able to produce viable offspring,
even though in two-thirds of them cancer developed over a three-to-six month period
being mainly lymphomas (Donehover, et aI., 1992). On the other hand MDM2 (Murine
Double Minute) null mice (which possess functional pS3) are not viable, embryos dying
before the day 5.5 of development (Montes de Oca Luca, et aI., 1995). In contrast mice
with neither pS3 nor MDM2 develop normally (Jones, et aI., 1995). MDM-2 is a murine
gene that has originally been cloned from a spontaneous transformed BALB/c 3T3 cell
line and that has been found to increase tumorigenic potential of cells when
overexpressed (Cahilly-Snydler, et aI., 1987~Fakharzadeh, et al., 1991). Wild-type p53
protein has shown to directly stimulate the MDM-2 product expression by binding to an
element located on the first intron of the MDM-2 gene (Wu, et aI., 1993). MDM-2
product, a 90 KDa protein, then complexes with pS3 protein (wild type and mutated
one) and blocks further p53 function, which results in less MDM-2 (Wu, et aI., 1993)
and other proteins being made. Factors that modify that balance by increasing MDM-2
levels (via gene amplification for e.g.) will then promote cell proliferation in the other
hand inactivated MDM-2 would lead to growth arrest or apoptosis as it has been
observed when MDM-2 gene was removed (Montes de Oca Luca, et al., 1995).
Since p53 mRNA half-life is long (Dony, et al., 1985) making transcriptional regulation
rather ineffective, this is one way of controlling cellular p53 activity levels, avoiding
accumulation of p53 that would lead to apoptosis after IR exposure for example.
Inactivation of p53 may also be the result of other mechanisms such as protein-protein
complexes with the transforming protein of tumour viruses such as SV40 and
adenoviruses or Eb protein or as said complexes with MDM-2 protein; As a result p53
protein conformation is stabilised and its half-life increased, leading to accumulation
within the cell. Different conformations of normal p53 depending on the state of the cell
(quiescent or mitotic) have been reported (Milner, 1994). Two antibodies have shown to
recognised specifically either the normal conformation (PAb 1620) or the mutated one
(PAb240). P53 is mainly regulated post-transcriptionally and phosphorylation at serine
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389 and in general increased phosphorylation has shown to be correlated with the
suppressor form ofp53 protein (Milner, 1994).
Apart from the WAFI and MDM-2 genes other genes also positively regulated by p53
have been reported amongst them are Bax and bcl-2 (Miyashita, et aI., 1995), GADD45
(Kastan, et aI., 1992), and cyclin G (Zauberman, et aI., 1995).
1.3.2 p53 as Specific Tumour Antigen
p53 gene is present in all cells and mutation within the gene represent the single most
common alteration identified so far in many types of human cancers, which is for some
an early event. Point mutations, predominant mechanism of pS3 protein inactivation are,
for 95% of them located in four evolutionary conserved domains. Codons 175,248,273,
and 281 represent the most frequently mutated codons and some are more commonly
found in certain types of human cancers. p53 Peptides expressed at the surface of cancer
cells with a single amino-acid substitution represent ideal candidates for tumour
targeting immunisation since they would only be present at the surface of tumour cells.
Some of these peptides have been identified and used to successfully immunise animals,
which developed p53-specific CTL capable of specifically recognising mutated p53
peptide with a single amino-acid substitution but not its wild-type counterpart
(Gabrilovich, et aI., 1995). More over these p53-derived peptides immunised animals
were more resistant to tumour challenge (Noguchi, et aI., 1994). The main challenge
remains however to generate a CTL response, which would recognise and destroy a
tumour already established. This has partially been achieved in animals bearing palpable
tumours after repeated immunisation with pS3-peptide-pulsed dendritic cells
(Gabrilovich, et al., 1997). Tumour growth was much more efficiently inhibited when
IL-12 was given along with the dendritic cells, only the addition of IL-12 resulted in
CTL generation (Gabrilovich, et al., 1997).
In addition significant CTL responses specific for mutant pS3 have been observed in
patients with breast cancer (Gabrilovich, et al., 1995). These data strongly suggest that
mutated pS3 peptides are immunogenic and could potentially be used for in vivo
vaccination. Although these 'mutant-derived' peptides would make highly specific
tumour vaccines, with no toxicity for healthy cells, they are also patient-specific making
this vaccine a difficult, expansive and time-consuming one. On the other hand a single
peptide-based vaccine using pS3 wild type epitopes would target a wide variety of
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tumours expressing different mutated pS3 proteins. pS3 protein, as mentioned earlier, is
expressed in all cells, which means that pS3 peptides are to some extend expressed at the
surface of all of them and are regularly surveyed by CTL. These would however not be
activated since any self-reacting CTL would have been destroyed in the thymus or
rendered tolerant in order to prevent autoimmunity. One might therefore think it wrong
to produce a vaccine with self-peptides. However one has to remember that wild-type
pS3 protein expressed in normal cells has a very short half-life, around 20 minutes, and
as a consequence, few peptides would have had the time to be produced. When
however, pS3 protein is stabilised as a result of mutation or as a result of complexes
formed with other proteins, it accumulates within the cell which can and has been
detected by immunohistochemistry. This would produce more peptides than should
otherwise be and CTL, that do not normally react to self-peptide, would undergo clonal
expansion and mediate cytolysis following recognition of high expression pS3-peptides.
Vierboom and co-worker have indeed demonstrated that when mutant pS3 protein was
overexpressed, processed and presented by MHC class-I molecules on the surface of
murine tumour cells, tolerance was broken, and malignant cells recognised as 'abnormal'
were killed by CTL generated against wild-type pS3 peptide sequences (Vierboom, et
a/., 1997).
Interestingly CTL precursors have been reported in normal individuals suggesting an
ongoing immune response against cells expressing increased level ofpS3 protein (Ropke,
et a/., 1995). Moreover antibodies against p53 protein have been found in a number of
cancers bearing a mutation within the pS3 gene. Such a humoral response requires
antigen processing and presentation by APC as well as helper T-cell (Soussi, et a/.,
1994) and all patients from whom a T-cell response was detected also had p53
antibodies, reinforcing the idea that tolerance can be broken as a result of pS3
overexpression (Tilkin, et a/., 1995). Therefore wild-type p53 protein appears to be
antigenic when express at high level and is the target for CTL after processing during the
normal tumorigenesis process. There are different explanations for the non-destruction
by the immune system of all tumours with a mutated p53. Cancer cells have indeed, been
shown to evade the immune surveillance through different mechanisms. These include
loss of MHC expression, generation of antigen-loss tumour variants, downregulation of
antigen processing machinery and expression of local inhibitory molecules, such as
tumour necrosis factor and Fas ligand. However, as far as pS3 is concerned, the lack of
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effective immune response towards cancer cells, in vivo, is at least not due to antigen
loss since mutated pS3 protein is expressed throughout the tumorigenisation process;
from the smallest primary lesion to widespread metastatic disease (Sameshina, et aI.,
1992). One possible reason could be that tumour cells require its continued presence in
order to maintain their malignant phenotype. As for the other possible mechanisms of
escape, p2-m mutations or defect in TAPs have been observed in some cancers but
remains a relatively rare event in solid cancers (Chen, et aI., 1996 a and b). The decrease
in MHC molecules has also been demonstrated in some cancers but is low and can be
overcome by low doses of IFN-y (Doyle, et aI., 1985). pS3 'Wild-type' peptides-based
vaccine therefore represents a very promising tool for immunotherapy against cancers.
Subtle mutations can affect the conformation of the entire protein, altering the structural
integrity of domains far removed from the sites of mutation. As a result pS3 is blocked in
the promoter form leading to abnormal proliferation and cell transformation. Such
conformational change may lead to exposure of normally cryptic epitopes or interfere
with the normal processing pathway of the protein. Substitution of proline at codon 273l~~....Pto\)
appears to have such an effect on the protein (Milner, 1994).
More generally pS3 gene hotspot mutations have been classified into two categories. (i)
Those which induce a conformational change in p53 protein to a mutant conformation,
for example the point mutation at amino-acid position 175; and (ii) those which retain
the wild type conformation, for example the point mutation at position 273 (Milner, et
al., 1990/1995). Conformational changes in the p53 protein are frequently recognised by
the monoclonal antibody PA240, due to unfolding of the protein and exposure of the
240 epitope, RHSVV (residues RHSVVV 212-217). It is therefore possible that
peptides in this region are preferentially processed from conformational mutants rather
than wild-type conformation protein and if they are naturally processed and presented at
the cell surface of tumour cells in the context of MIlC class-I, they could be useful as
targets for CTL tumour specific immunotherapy for a wide range of cancers.
CTL only respond when antigen presenting cells (APC) express the same HLA class- I
allele as the host from which the T-cells are derived and it is necessary to determine,
whether specific epitopes from p53 protein bind to specific HLA haplotypes.
In a previous study thirty-seven overlapping peptides (34 nonamers, 2 ten amino-acids
in length and one eleven AA in length) from the 240 epitope region were synthesised
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(residues 193-237), and investigated using a flow cytometry based MHC stabilisation
assay for their ability to bind HLA-A2 and HLA-A3 molecules. In this study further
pS3 peptides were tested for their capacity to bind to MHC class-I antigens using the
T2 cell line expressing HLA-A *0201 (HLA-A2) molecules. Peptides found to bind
were then assessed for their ability to generate anti-pS3 CTL using first whole PBMC
as APC then dendritic cells. Tumour cells HLA-A2 positive or transfected with the
HLA-A2 gene and expressing either conformational mutant pS3 proteins or wild-type
conformation pS3 proteins, either 'naturally' or transfected with mutated pS3 gene,
were used as targets.
This study assessed the potential of pS3 epitopes as a target for CTL and their use in
immunotherapy programms against human cancers.
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2.1 MATERIALS
2.1.1 General laboratory reagents and equipment
a) Glassware
Pyrex glassware was washed in RBS detergent, rinsed several times in tap water,
and finally in de-ionised water, dried in a hot air oven at 80DC, before sterilisation
at 160°C for 2 hours.
b) Plastic and disposable equipment
Item
'Universal' tubes
1.5 Cryovials
10ml / 30mls Plastic pipettes
15ml centrifuge tubes
lSml, SOmlPolypropylene tubes
25cm2, 75 cm2 Tissue culture Flasks
5ml Bijoux
6-, 12-, 24-, 48-, and 96-well plates
90mm Petri dishes
CI0 tips for Gilson p2/p 10 pipettes
Cuvettes for electroporation
Disposable scalpels
Ependorf tubes
FACS Tubes
Supplier
Bibby Striline
Nalge
Costar
Bibby Sterilin
Costar
Costar
L.I.P
Costar
Phillips Harris Scientific
Gilson Medical Electronics
Equibio Ltd
Swarm-Morton
Glass coverslips
Latex examination gloves
Lumaplate™ -96
Paper Tissue
Plastic and glass Pasteur pipettes
Slides (For cytospin and immunostaining)
Sterile disposable scalpels
Sartedt
Elkay
Chance-Proper; BDH
Ansell Medical
Canberra Packard
lamont
Scientific Laboratory
BDHMerck
Swann- Morton
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Sterile syringes and needles
Topseal™-S microplate heat sealing film
White tips for automated pipette
Yellow and blue pipette tips
c) Equipment
Item
96 well Plate Harvester- Filtermate 196
Centrifuges
Cytospin Centrifuge
DynaBead Separation Unit
Electrophoresis Gel Tanks
FACSort
Gamma Counter - Topcount TM
Incubators
Microscopes
Plate Sealer - Micromate 496
Shaker Incubator
UN/VIS Spectrometer
Becton Dickinson
Supplies
Canberra Packard
Sarstedt
Sarstedt
Supplier
Canberra Packard
Beckman GPR
Shandon Cytospin 2
DYNA
Bio Rad~ BRL
Becton Dickinson
Canberra Packard
Sanyo Gallenkamp
Leitz Dialux light microscope
Canberra Packard
Sanyo Gallenkamp
Perkin Elmer
d) Chemicals Reagents
Unless otherwise stated all chemicals used in the preparation of solutions and
buffers were of high and mostly of Analar grade (BDH Merck Ltd).
Item
2-mercaptoethanol
Bromophenol Blue
Calcium Chloride
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Supplier
Gibco Life Technologies
BDHMerck
BDHMerck
Chloroform
DePex Mounting Medium
Ethanol
Glacial Acetic Acid
Glucose
Glycerol
Isoamyl Alcohol
Liquid Nitrogen
Manganese Chloride
Methanol
Paraformaldehyde
Phenol
Potassium Acetate
Potassium Bicarbonate
Presept
RBS
SeaKem Agarose
Sodium Acetate
Sodium Chloride
Sodium Dodecyl Sulfate
Sodium Hydroxide
Tris-Chloride
Tryptone
Tween 20
Yeast Extract
BDHMerck
BDHMerck
BDHMerck
BDHMerck
BDHMerck
BDH Merck
Sigma
British Oxygen Company
Sigma
BDHMerck
BDH Merck
Fisons
BDH Merck; Sigma
Sigma
Johnson and Johnson
Chemical Concentrated
FMC Bioproducts
BDHMerck
BDHMerck
Fisons
BDHMerck
BDHMerck
Difco
Promega
Unipath
e) Water
All water used in this study was of ultrapure quality (> 18 Ohms) unless otherwise
stated and was obtained from an installed Permulab deionising water system.
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2.1.2 Materials and Solutions for Tissue Culture
a) Cell lines
Cell line Type Source Culture media used Adherent or 1
name suspension
line
JY Lymphoblastoid CRC Paterson RPM! + 10% FCS Suspension
Institute, Manchester
K562 Erythro- ICRF, London RPMI + 10% FCS Suspension
leukaemic
T2 Lymphoblastoid Gift from Paterson RPMI + 10% FCS Suspension
Institute
Rosi Lymphoblastoid Gift from Ludwig Iscove's + 10% FCS Suspension
Institute
Jesthom Lymphoblastoid Gift from BTS RPMI + 10% FCS Suspension
SaOs-2 Osteosarcoma Department of Dulbecco's + 10% FCS Adherent
IHuman metabolism
clinical Biochemistry,
Sheffield
A431 Head and Neck ECACC MEM + insulin + 10% Adherent
FCS
SKBr3 Breast ATCC McCoy's SA Adherent
MCF-7 Breast ICRF, London Dulbecco's + 10% FCS Adherent
carcinoma
b) Growth Media
- AIM-V Medium
was purchase from Life Technologies Ltd and contained glutamine, streptamycin
sulphate (50 mcg/ml) and gentamin sulphate (10mcg).
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- Dulbecco's medium
Foetal calf serum (FCS): This was purchased from Life Technologies Ltd and
stored at 80°C.
- ISCOVES and McCoy's 5A Media
Were purchased from Life Technologies
-MEMMedium
This was purchased from Sigma and supplemented with 20mM L-Glutamin.
- RPMI Medium
Was purchased from Imperial Laboratories
c) Mycoplasma Testing
All cell lines were periodically tested by Mrs. Janet White (Institute for Cancer
Studies, Sheffield) for mycoplasma contamination, with a DNA hybridisation
assay using a Gen-probe rapid detection kit (Gen-Probe Incorporated).
d) Trypsin
Trypsin (Gibco Life Technologies Ltd.) was prepared as a sterile 2.5% v/v
solution in saline, diluted to 0.25% v/v solution with PBS, and stored at -20°C
prior to use and thereafter at 4°C.
e) Versene
Ethylenediaminetera-acetic acid (EDT A) (BDH Merck Ltd) was prepared as a
0.02% w/v solution in PBS, autoclaved at 10 p.s.i for 10 minutes, and stored at
4°C.
f) Bovine Serum Albumin (BSA)
This was purchased as a 30% solution from Advanced Protein Products,
subsequently diluted to a 10% solution by adding 100rnl BSA to 200 ml sterile
PBS, and then kept at 4°C.
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g) Phosphate ButTered Saline (PBS)
Oxoid Phosphate Buffered Saline tablets (Unipath Ltd) were dissolved in distilled
water as per manufacturer instructions (1 tablet per 100mI water), and sterilised
by autoclaving at 15 p.s.i for 15 minutes.
h) Trypan Blue
Trypan blue powder was prepared as a 0.1% w/v solution in PBS. Residual,
undissolved powder was removed by filtration prior to autociaving at 15 p. s.i for
15 minutes.
2.1.3 Materials for MBC Stabilisation Assay • \0""
(d.;~ClhJC~ ,'" lOO.. 0"" I
With the exception of the Flu peptide, all peptides were synthesised and dissolved in
10% DMSO, 90% PBS + BSA 0.1% to a peptide concentration of approximately 20mM
and stored at -20°C in 10111aliquots.
2.1.4 Materials for Flow Cytometry
a) 1% Paraformaldehyde solution
This was prepared by adding l g of paraformaldehyde powder to 100mI PBS,
~~.1..
with the pH adjusted by adding few drops of O.4M NaOH solution. This solution
was placed in a water-bath at 37°C for l-2hrs for the paraformaldehyde to
dissolve; and then kept in glass bottle at 4°C.
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b) Antibodies
Antibody Specificity Amount used Obtained from
HB-S2 HLA-A2 and HLA-B27 1st Batch: 2SIlI of 1/10 The supernatant
dilution derived from a
2nd Batch: 7SIlI Neat hybridoma cell line
This was a kind gift
from Dr. 1.
Bartholemew.
Paterson Labs.,
Manchester.
FITC Goat anti-mouse F(ab')2 lOOll1of 11100 dilution Bradsure
IgG conjugated to the Biologicals
fluorescent molecule
Fluorescein
isothiocyanate used as
secondary antibody
DO-7 Wild- Type and Mutant 30111of 1110 dilution Dako
IgG2b pS3 protein 1/100 dilution for
immunostaining
Class-I HLA-A, -B, and -C 10111 Dako
IgG2a
Conjugated
Class-II HLA-DR, -DP, and -DQ Sill Dako
IgG2a
Conjugated
CDS4 ICAM-I Will Dako
Ig01
Conjugated
CD86 B7.2 Sill Dako
IgGl
Conjugated
CDSO B7.1 Sill Dako
IgOl
Conjugated
CD14 CD14 Sill Dako
Ig02a
CDla CDla Sill Dako
IgOI
All antibodies were non-conjugated mouse antibodies, unless otherwise stated,
and dilutions were made in PBSIBSA 0.1%. Isotype controls for each antibody
were used at the same concentration.
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2.1.5 Materials for Transfections
a) Liposomes
All of them were purchased from Life Technologies.
b) Buffers
- CM 1 buffer was prepared as follows:
10 mM Sodium Acetate (pHS. 6)
50 mM Manganese Chloride
5 mM Sodium Chloride
- CM2 buffer was prepared as follows:
10 mM Sodium Acetate (pH5.6)
5 mM Manganese Chloride
5% Glycerol
- Qiagen Maxi-Prep Buffer Composition
ButTer Composition Storage
Buffer PI sOmM Tris-HCI (pH 8.0) 4°C
(Re-suspension buffer) 10mMEDTA
100~g/m1 Rnase A.
Buffer P2 200mMNaOH RT
(Lysis buffer) 1% SDS.
Buffer P3 3.OM potassium acetate RT
(Neutralisation Buffer) (pHs.S).
BufferQBT 750mMNaCI
(Equilibration Buffer) 50 mM MOPS (pH 7.0) RT
15% ethanol
0.15% Triton X-lOO
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Buffer QC
(Wash Buffer)
1.0 MNaCI;
50 mM MOPS (pH 7.0)
15% ethanol.
RT
Buffer QF
(Elution Buffer)
1.25 M NaCI RT
50 mM Tris-HCI (pH 8.5)
1 mMEDTA.
c) Selection Antibiotics
Geneticin (G418) purchased from Gibco Life Technologies Ltd. was added to
the medium of transfected cells at a pre-determined optimum concentration.
Ampicillin
d) GTE solution
50mM Glucose
10mMEDTA
25mM Tris-HCI, pH 8.0
The solutions were prepared in batches of 100ml, autoclave and stored at 4°C.
e) NaOH/SDS solution
0.2NNaOH
1% SDS
Water
This solution was prepared immediately before use
f) 3M Sodium Acetate solution
SM solution ofNa acetate
Glacial acetic acid
Water
The solution was stored at 4°C.
60 ml
Il.S ml
28.5 ml
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g) DNA Loading buffer
The solution was prepared by dissolving 0.25g of bromophenol blue and 40g of
sucrose in 100 ml of distilled water. The solution was mixed overnight, filtered
and the pH adjusted to 7.0.
h) TrislEDTA (TE) and Tris/Acetate/EDTA (TAE)
The solution was prepared as follows
10 mM TrisHCI (pH 8.0)
1 mMEDTA
TAE buffer was prepared as above with addition of Glacial Acetic Acid.
Both solutions were stored at RT.
i) E. coli XLI Blue
Was purchased from Invitrogen and stored at -20°C prior to use.
j) Ethidium Bromide
Ethidium bromide solution was prepared by dissolving ethidium bromide In
distilled water to give a final concentration ofO.2mg/ml.
k) Ligase
Ligation of DNA fragments was performed with a T4 DNA ligase purchased
from Boehringer Mannheim (U.K). This ligase was stored at -20°C prior to use.
I) Luria Bertani (LB) medium
LB medium was prepared as follow:
Distilled water
Tryptone
Yeast Extract
Sodium Chloride
Sodium Hydroxide
1 litre
109
5g
5g
1 ml
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The pH was adjusted to 7.5 with sodium hydroxide. The solution obtained was
autoclaved at 15 p. s.i for 15 minutes and stored aRT. For the preparation of agar
plate l.5 % bacto-agar (Difco Laboratories) was added to the above recipe and
after cooling, ampicillin selecting antibiotic (Sigma Aldrich Chemical Company
Ltd.) was added.
m) Freezing Mixture
The solution was prepared as follow:
LB 66%
Glycerol 40%
Sterile Mg2~ 1I2Sth volume
kept at 4°C.
n) Molecular Size Marker
A IKb DNA ladder suitable for sizing linear double stranded DNA fragments
from 500 bp to 12 Kb was purchased from Gibco Life Technologies Ltd. In 10
mM Tris HCI (pH7.S), 50 mM sodium chloride and 0.1 mM EDT A, and stored
at -20°C prior to use.
0) Phenol Chloroform
Was prepared as follows:
Phenol
Chloroform
Isoamyl alcohol
25 parts
24 parts
1 part.
p) Plasmid vectors
- Bluescript SK was kindly supplied by the Immunex Corporation.
- P53 cDNA, mutated at either amino-acid position 175 (Arg->His) or 273 (Arg-
>His), subcloned into a pBR322 derived plasmid and under the control of the
human CMV promoter were a generous gift from Prof T. Soussi (Marie-Curie,
France).
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- The HLA-A2 cDNA subcJoned pcDNAJ (Invitrogene) was a generous gift
from Dr. Robbins, NIH, USA
- Reporter Plasmid: pCMV -13 was purchased from Pharmacia.
q) Rnase
Rnase, Dnase free, was purchased from Boehringer Manheim (U.K) Ltd. and
stored at _20DC prior to use.
r) Restriction Enzymes
Both enzymes and buffer were purchased from Boehringer Manheim (U.K) Ltd.
and stored at _20DC prior to use.
s) Staining Reagents
In situ I3-Galactosidase staining of transfected cells:
Stock solutions
20mglml Xgal in dimethylformamide
50mM potassium ferricyanide
50mM potassium ferrocyanide
Storage conditions
-20°C in propylene
tube, in the dark
4°C
4°C
Working solutions
Fixative solution
PBS containing 2% formaldehyde
0.05% glutaraldehyde
Stain solution
PBS containing 5mM potassium ferricyanide
5mM potassium ferrocyanide
2mMMgCh
Substrate/Stain solution
1mg/ml Xgal in stain solution.
Used immediately
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2.1.6 Materials for Blood Separation
a) Heparin
Was purchased from c.p Pharmaceuticals
b) J-Prep
Was purchased from VH-Bio
2.1.7 Materials for LAK Assay
a) PBMC
Were obtained after from blood separation from healthy donors.
b) Interleukin-2 (IL-2)
Was a generous gift from Glaxo Pharmaceuticals
2.1.8 Materials for CTL Generation and Chromium Release Assay
a) Mitomycin C
Mitomycin C was obtained from Sigma Aldrich Chemical Company Ltd under
the form of powder (2mg) and was dissolved in Sml of PBS and stored in
aliquots of Iml wrapped in aluminium at -20°C.
b) Recombinant Cytokines
All interleukins were diluted in PBS supplemented with 0.1% BSA to the desired
concentration and stored at -70°C prior to use.
- Interleukin-2 (IL-2)
Was a generous gift from Glaxo Pharmaceuticals
- Interleukin-4 (IL-4)
Was purchased from Peprotech
- Interleukin-7 (IL-7)
Was purchased from Peprotech
- Interleukin-12 (IL-12)
Was purchased from Hoffman, La Roche
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- Interferon Gamma (IFN-y)
Was a kind gift from NCI Biogen
- Tumour Necrosis Alpha (TNF-a)
Was a kind gift from Strangeways Laboratories
- (GM-CSF)
Was purchased from La Roche
c) Antibody
Monoclonal antibody MA2.I specific for HLA-A2 and HLA-B 17 molecules was
obtained as supernatant from a hybridoma cell line Purchased from the ATCe.
d) Radio-isoptope
51Chromium in the form of sodium chromate (I85 Megabecquerels in 5 ml) were
purchase from Amersham International Ltd.
2.1.9 Materials for Immunohistochemistry
a) APES Slide Coating Solution
A 1% solution of APES in acetone was used to coat glass slides. This solution
was prepared in a fume cupboard, by adding 3ml of 3-aminopropyltriethoxysilane
(APES) solution (Purchased from Sigma) to 300ml acetone in a glass trough.
b) Tumour Specimens and Cryostat Sections
Head and Neck squamous cell carcinoma (HNSCC) tumour tissue was obtained
from consented patients undergoing surgery at the Royal Hallamshire Hospital,
Glossop Rd, Sheffield. Tumour tissue, after collection from the Department of
Pathology, was snap frozen in liquid nitrogen, prior storage at -70°C.
Tumour material was positioned within aluminium foil cylinders placed on cork
mats, and embedded in OCT compound, using isopentane, liquid nitrogen, and
Cryospray 22 (chlorodifuoromethane) coolant (Bright Instruments Co. Ltd.).
Sections were cut using a Bright Instrument Crystat (Model OTFIAS), and a
228x38x6mm tungsten tipped knife (Bright Instruments).
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c) VECT ASTAIN ABC Kit
Was purchased from Vector Laboratories.
d) PAPpen
Was purchased from Binding Site Limited
e) Scott's Tap Water
Was prepared as follows:
Sodium Bicarbonate (BDH)
Magnesium Sulphate (BDH)
Tap Water
8.7Sg
SOg
2.5 litres
f) Haematoxylin
Was purchased from BDH
g) Picolyte Resin
Was purchased from Phase Separations
2.1.10 Materials for Immunofluorescence
a) TBS
The solution, for one litre, was prepared as follows
Tris 6.0SSg
NaCI 8.766g
pH was adjusted to 7.5 with Hel
b) 2% Blocking Reagent
The solution was prepared as follows
Tween 20 O.lg
TBS
1M NaOH
100mi
lml
The mixture was microwaved for 50 seconds before addition of 2g Boehringer
Blocking Agent. The solution was stirred until dissolved. The pH was adjusted to
7.5 with 1M NaOH once the solution has cooled down to RT.
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c) DAPI
4', 6-diamidino-2-phenylindole (DAPI) was purchased from Sigma and diluted
to 1: 1000 in TBS from stock solution 0.5mglmI. The solution was stored at 4°C.
d) Fluorescent Mounting Medium
Was purchased from Dako
2.1.11 Materials for Mixed Lymphocyte Reaction
Radio- Isotope
3H-thymidine was purchased from Amersham International Ltd as 1ml solution
with a radioactive concentration of 37 Mbq/ml, and stored at 4°C.
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2.2 Methods
2.2.1 MBe Stabilisation Assay
2.2.1.2 Principle
Cell line 174.CEM T2 (T2) is a human lymphoblastoid cell line (174.CEM T2) defective
in processing. These cells express 'empty' HLA-A2 molecules, due to homozygous
deletion of the MHC class-II region located on chromosome 6 including the TAP 1 and
TAP2 genes, which encode the peptide transporter proteins. Although these cells express
high levels of cytoplasmic MHC class-I heavy chains and p2m no complexes can be
detected at the surface of the cell. This is due to the fact that no peptide reached the
endolasrnic reticulum and empty class-Up2m complexes expressed at the cell surface are
very unstable and are rapidly degraded and recycled. However, if a peptide, added
exogenously, possesses some binding properties, it will stabilise the complex, which can
then be detected by antibody staining.
2.2.1.2 Method
Confluent T2 cells were washed twice in serum free RPMI-1640 culture medium and
counted with Trypan blue to exclude non viable cells. Cells were then resuspended at a
concentration of 4.106 cells/ml of medium. 40 III (160 000 cells) of T2 cells were put
into aU-bottom 96 wells tissue plate culture. Then 10111 of the appropriate peptide
concentration (1001lM, 10J..lM or 101lM) were added to wells. The Flu peptide
(GILGFVFTC) was used as a positive control, at the same concentration and the
fluorescence of the cells with DMSO (treated as a peptide) was taken as a negative
control. The plate was then incubated overnight (minimum of 18 hours) at 26°C in 5%
C02. T2 cells were then harvested from each well into separate tubes by adding 200111 of
cold PBSIBSA (0.1%) mixing thoroughly and transferred to the appropriate FACS
tubes. This was repeated and the cells washed with cold PBSIBSA to block any
unspecific sites.
2.2.2 Flow Cytometry
2.2.2.1 Principle
Flow cytometry can broadly be described as the cytological analysis and measurement of
a cell suspension as particules flow in a liquid stream passing through a beam light. The
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cells are channelled into a fine core stream and then passed through a laser beam, one
cell at a time to be analysed.
The light emitted can be refracted or simply deviated. The angle at which the emergent
light is bent and how long the cell takes to pass through the laser beam allow the size of
the cell to be determined. This is measured by a forward scatter detector in the direct
path of a laser beam and is thus termed Forward Scatter (FSc). As the cell passes
through the laser beam, some of this light is reflected back from the cell in multiple
directions because a cell may have a high level of intracellular organelles. The rougher or
more irregular or granular a particle is the more it will scatter the illuminating beam to
the side. This Side Scatter (SSe) light is measured be a detector placed behind the
stream, at right angle to the laser beam.
As well as measuring the size and granularity of a cell, flow cytometry is used to detect
fluorochromes conjugated to antibodies against a protein of interest. Here fluorescein
isothiacyanate (FITC) is used either as secondary antibody or conjugated to the first
antibody. When the cells are passed through the correct wave length laser beam and
excite the dye, longer wavelengths of light are emitted by the fluorescein molecules
which are then detected. The amount of light measured is proportional to the number of
fluorescein molecules bound to the cell.
2.2.2.1 Method
a) Preparation of Cells for intra-cytoplasmic Antigen Detection
Cells to be analysed were washed in PBSIBSA (0.1%), counted using a Trypan blue
exclusion assay (See Section 2.2.2.2) and resuspended at Ixl06 cells per FACS tubes.
Excess PBSIBSA (0.1%) was added to each tube and centrifuged at 400g for 5 minutes.
The supernatant was removed and cells were fixed by addition of 200J...l.Iof 1%
paraformaldehyde for 10 to IS minutes at RT. Excess PBSIBSA (0.1%) was added to
tubes and centrifuged at 400 g for 5 minutes. Cells were then permeabilised by addition
of 200J,.LIof 70% methanol for 5 minutes at RT. Excess PBSIBSA (0.1%) was added to
tubes and centrifuged at 400 g for 5 minutes. Antibody staining and antigen detection
were performed as described below.
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b) Immunofluorescence Staining
The quantitative determinations of the presence of either stable cell surface peptidelMHC
complexes following T2 peptide binding assays or surface molecules of any cells were
performed by indirect immunofluorescence and by direct immunofluoresce when primary
antibody was already conjugated to FITC.
Cells to be analysed were washed in PBSIBSA (0.1%), counted using a trypan blue
exclusion assay (See Section 2.2.2.2) and resuspended at 0.5 to lxlO6 cells per FACS
tubes. Excess PBS/BSA (0.1%) was added to each tube and centrifuged at 400g for 5
minutes. The supernatant was removed, cells were resuspended and primary monoclonal
antibody was added to each FACS tube. Optimal concentrations for each primary
antibody are listed in Section 2.1.4b. Tubes were then incubated at 4°C for 30minutes.
All cells were then washed twice in cold PBSIBSA (0.1%). Afterwards 100111of a 1:100
dilution of second antibody FITC-Iabelled F (ab')2 fragments of goat anti-mouse IgG
were added to all tubes when primary antibody was not already conjugated and tubes
were then put at 4°C for another 30 minutes. Cells were then washed twice in cold
PBSIBSA. After the last centrifugation at 400g for 5 minutes the pellet was resuspended
in 300fll of PBSIBSA or serum free medium. Cells were fixed by addition of 300fll of
1% paraformaldehyde if FACS analysis was not done the same day and left at 4°C until
analysis.
Following excitation by the light source of the Flow Cytometer, the fluorescence emitted
by the FITC was then detected and measured for a large number of cells of the test, and
converted into digital form. Data was only collected for the live cells of the sample,
which were first gated.
The Fluorescence Ratio, for the T2 peptide-binding assay, was calculated from the
median channel fluorescence (rncf) data for each peptide as follows:
(Median Channel of Fluorescence (mct) test peptide)
(Median Channel of Fluorescence (mcf) DMSO
Where DMSO was the 'True' negative control for the assay.
Fluorescence Ratio =
FR > 1 were considered as positive.
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2.2.3 CTL Generation Assays
2.2.3.1 Blood Separation
60-120mls peripheral blood was obtained from healthy volunteers and placed
immediately into a bottle containing heparin at 100U/ml. This was diluted I:l in sterile
PBS. 30mls aliquots were layered onto ISmls J-Prep in a SOmIs tube for separation.
Tubes were then centrifuged at 400g with brakes off The leukocyte interface was
carefully collected into fresh pre-chilled tubes. The tubes were filled with chilled PBS
and spun down at 600g with acceleration and brakes on for 15 minutes at 4°C. The
supernatant was discarded and the cells were resuspended in chilled PBS and then
transferred into one tube. This tube was then filled with chilled PBS and spun down at
400g at 4°C for 6 minutes under the same conditions. The supernatant was discarded and
the cells were resuspended in 1 to 3mls of AIM- V before counting with Trypan blue.
2.2.3.2 Trypan Blue Exclusion Assay
For PBMC, cells were counted by adding 100~J.lof the cell suspension to 0.6% glacial
acetic acid. This was pipetted thoroughly and 100111added to 900lli Trypan blue
solution. Cell line cultures were diluted in Trypan blue alone before counting. Cells were
counted using a haemocytometer, with the cell count being number of cells counted in
four squares divided by four, timesthe dilution factor. This gives the number of cell x 104
per mI.
2.2.3.3 Induction of CTL using PBMC as APC
OD Day 0: 120mls of blood were taken from healthy HLA-A2+ donors and PBMC were
6
separated using J-prep as described in Section 2.2.3.1. Sx10 PBMC (in 200J..lI)were
then put into a 24-well-plate with 50flg of peptide. The plate was put at 37°C for lhr.
Then 1.8ml of AIM-V medium, containing IL-7 at 25nglml (final concentration in the
wells) and KLH at 5flglml (final concentration in the wells) were added to each well and
the plate was put back at 37°C.
OD Day 3: IOU/ml of IL-2 with or without 16.5 U/ml (final concentration) of IL-12
were added to each well.
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On Day 7: CD4'" cells were removed from wells depending on method followed as
described below:
Cells from 2 or 3 wells were pooled, washed and resuspended in l ml of PBS. Anti-CD4
antibody, which were coupled with magnetic-beads, were added to the cells at a ratio of
+ +
7: 1 (7 beads for 1 CD4 cells, normal PBMC contain about 40% CD4 cells). The tube
was then put on a carrousel at 4°C for 30 minutes. CD4'" cells were separated, after
addition of 8rn1s of cold PBS + 2% FCS, by putting the tube against a magnetic source.
The supernatant containing all CD4- cells was transferred into a fresh tube and spun
down. Cells were resuspended in 1ml of AIM-V and counted. These cells were then
transferred into a new well of a 24-well plate. On the same day cells were also
restimulated. Autologous PBMC and allogeneic PBMC from HLA-A2+ donors were
thawed out, washed with PBS and resuspended in 1ml of AIM- V with 50Ilg/ml of
peptide (all PBMC were kept separated until the end). Cells were incubated for Ihr at
26°C. 4mls of AIM- V along with 250111of FCS, 8111of ~2-m (2001l1g/rnl) and 100111 of
Mitomycin C (400Ilg/ml) were then added to the cells. These were incubated for 2 hours
at 37°C_ Cells were then washed twice with PBS, resuspended in lrnl of AIM-V and
counted with Trypan blue. The cell concentration was adjusted to lxl0
6
cellslrnl and lrnl
placed in each well. 10 Vlml of Il-2 (final concentration) +1- 16.5 Vlml (final
concentration) JL-12 were added to the cells and 1rnl of it was added to each well.
On Day 14: Cells were semi-cloned and restimulated. Cells from each well were washed
in PBS, resuspended in l ml of AIM-V and counted. 100~d of a concentration of 5xl0
4
cellslml was seeded in each well of a 96 well-plate. The remaining cells were used as
bulk cultures. Stimulator cells consisted of autologous PBMC and PBMC from two
HLA-A2+ donors. These were thawed out, washed in PBS and resuspended in 1ml of
AIM-V. 50Ilg/mi of relevant peptide were added to the cells and the tubes were put at
26°C for 1 hour. 4mls of AIM-V medium was then added to each tube as well as 250111
of FCS, 8111 of J32-m and 100111of Mitomycin C. Tubes were then put at 37°C for 2
hours. All cells were then washed twice with PBS, resuspended in 1rnl of AIM-V and
counted. Rosi cells were Mitomycin C treated following the same protocol as for the
other cells and used as feeder cells. The cells were then mixed together to a final
6
concentration of 1x10 cellslrnl consisting of at least 20% autologous cells, 10-20% Rosi
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cells and 30% of each Hl.A matched PBMC from 2 Donors. 10 Vlml IL-2 in the well +1-
16.SVlml final concentration oflL-12 was added to the mixture. lrnl of the restimulating
mixture was added to each of the 24-well-plates and IOOll1were added to each well of
the 96-well-plates (According to relevant peptide).
On Day 21: Cells were restimulated as described above.
On Day 28: A cyto-assay was performed to assess the cytolytic activity of the bulk
cultures as well as the cytolytic activity of each semi-clone.
2.2.3.3 Generation of CTL using Dendritic Cells as APC
Day 0: 120 ml of blood was separated, plasma was keptl heat inactivated (56°C 30
minutes) and stored in the fridge until needed.
Half of the PBM C were frozen at 1x 107 cellsimI and called PBM C (1) to be used later as
effector cells. The rest were plated at 2-3xl06 cellslrnl in a T175 flask in RPMI + 10%
FCS. The flask was put at 37°C for 2 hrs. The non-adherent cells were removed, spun
down, resuspended in lrnl of AIM-V and counted. Cells were frozen at lx lO' cellslml
and called PBMC (2). 2mls of RPMI + 10% FCS were added to the adherent cells and
the plate was put back at 37°e.
Day 1: Cells were removed from the flask, washed in PBS, resuspended in lrnl of
medium and counted. 5xl06 cellslrnl were plated in a 6-well plate (lrnl) and the plate was
incubated at 37°C for 45 minutes. Following the incubation, the non-adherent cells were
discarded, wells were washed gently twice with PBS and filled up with 2rnls of medium
+ 1000 Vlrnl GM-CSF + 500 Vlml IL-4 for the generation of dendritic cells. The plate
was put at 37°C.
Day 2: Cells were pooled together, spun down, resuspended in lrnl of medium and
counted. Cells were diluted to lx IO" cellslmllwell in a 24-well plate in lrnl of medium
containing the same cytokines.
Day 7: Cells were pooled together, spun down, resuspended in lrnl of medium and
counted. Some cells were used for FACS analysis the rest were diluted to 0.5xl06
celllrnl of medium containing GM-CSF and TNF-a. (100 Vlml) and 1rnl was seeded
into each well of a 24-well plate in 1ml.
Day 10: Cells frozen on day 0 (PBMC (2» were thawed out and depleted ofCD4+ cells
as described in Section 2.2.2.3 (Day 7). 2xl06 PBMC (CD4-) were added to 0.2x106
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dendritic cells in 2mls of medium consisting of RPMl + 17% AIM-V, 5% autologous
serum (heated inactivated: 56°C for 30 minutes) from day 0, 10 Vlml IL-2 and 5nglml
IL-7 (all final concentration).
Day 17: Autologous PBMC were thawed out, peptide pulsed + p2-m for lhr at 26°C
and Mitomycin C treated for 2hrs at 37°C. After two washes with PBS the concentration
of these antigen presenting cells was adjusted to 0.1 x 106 cellsimi and were added to
lxl06 responder cells in a 24-well plate in 2mls of medium containing: RPMI, 17%
AIM-V, 5% human serum from day 0 and to U/ml IL-2.
Day 24: Cells were restimulated as follows: To lxI06 responder cells were added
0.IxI06 antigen presenting cells (consisting of autologous PBMC, LCL and Rosi cells, as
feeder cells, all peptide-pulsed, except Rosi cells and Mitomycin C treated) in 2mls of
medium containing RPMI, 17% AIM-V, 5% autologous serum from day 0 and 10 VimI
IL-2.
Day 31: Cells were restimulated as described above.
Day 38: A cyto-assay was performed using appropriate target cells
2.2.4 Chromium Release Assay
2.2.4.1 Target Cells
Target cells were spun down and resuspended in 1ml of growth medium + 10% FCS and
counted with Trypan blue. IxI0
6
cells per target were put in a lSrnl tube. 3.7Mbq of
SICr were added to each target +1- anti-HLA-A2 antibody: MA2.1 (1:2 dilution) tubes
were then put at 37°C for Ihr. Cells were then washed twice with growth medium +
10% FCS and resuspended in lml of the same medium + 1- 10Ilg of peptide. Tubes were
put back at 37°C for another hour. After the incubation cells were washed once more in
medium, resuspended in lml and counted with Trypan blue. For the assay cells were
• 4
resuspended m 2xlO cells/ml and 50111were added to each relevant well of the 96-well-
plate.
2.2.4.2 Effector Cells
Bulk cultures: Each set of cells from each well was resuspended, transferred into a
universal and washed with PBS before counting. A range of E: T (Effector/ Target)
ratios were set up ranging from 100 or 50: 1 with dilutions down to 2.5: 1. Each E: T
50
ratio was assayed in duplicate in a non-sterile 96-well-plate. 40x excess of cold KS62
(NI( sensitive cells) was added to each well and the cells were incubated 1hr at 37°C
prior addition of target cells.
Clones: Cells from each clone were resuspended and 2x SO~1were transferred into 2
wells of a non-sterile 96-well-plate. SO~1of KS62 at 80x 104cells/ml were added to each
well. Cells left from each clone were restimulated as for day 21.
4 wells were used to determine maximum release (containing 50~1 of 1% SDS in AIM- V
+/- SO~1kS62) and 4 others to determine spontaneous release (containing SO~1of AlM-
V +/- 50~1 k562). After addition of the target cells, plates were incubated at 37°C for 4
hours. SO).!1of supernatant were then removed from each well and put into a lumaplate
(containing solid scintillant). Plates were left overnight in the oven to dry and counted.
The percentage of cytotoxicity was calculated for each well as follows:
[(Experimental release - spontaneous release) / (Maximum release - spontaneous
release)] X 100
2.2.5 Preparation of DNA Constructs
2.2.5.1 Preparation of Bactoagar Plates
LB medium containing 1.S% of Bactoagar was prepared according to the recipe
described in Section 2.1.51. Once cooled the selecting antibiotic ampicillin was added and
the mixture poured into 9cm petri dishes and left to set at RT. Once set, the plates were
placed up side down in an oven to dry at 37°C for 2 hrs.
2.2.5.2 Preparation of E. coli XLI Blue Frozen Stock
A cell suspension ofE.coli XLI was plated on aLB-agar (1.S%) plate and incubated o/n
at 37°C. The next day, several colonies of 1-2 mm in diameter were picked and used to
inoculate IOml ofLB medium. The culture was shaken (22Srpm) at 37°C The following
morning, the overnight cultures were diluted with 1 volume of freezing mixture (Section
2.1.Sm), dispensed into O.Sml aliquots and stored at -70°C until required.
2.2.5.3 Preparation of Competent XLI-Blue
An XLI stock tube (Section 2.2.4.2) was taken and kept in liquid nitrogen to prevent
thawing of the cell. The surface of the frozen cell suspension was scratched using a
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sterile pipette tip to obtain a clump of cells, which was streaked for a single colonies on
an agar plate. The plate was then incubated at 37°C o/n. and several colonies were
subsequently picked and transferred into 10 ml ofLB and shaken (225 rpm) oln at 37°C.
The following morning 200 ml of LB was inoculated with 2 ml of one of the oln cultures
and shaken at 37°C until the optical density reached 0.375 at 590 nm wave length. Cells
were then put into 4x 50ml tubes and spun at 3000rprnl1600g for 10 minute at 4°C. The
supernatant was discarded, making sure that all drops were removed, and each pellet was
resuspended in 10ml of ice-cold CMl (Section 2.15b). After 20 minutes incubation on
ice cells were spun at 1100g for 5 minutes and resuspended in 1 ml of ice-cold CM2
(Section 2.1.5b). Aliquots ofO.2 ml were either frozen at -70°C or used immediately.
2.2.5.4 Transformation of Xl.I-Blue
Aliquots of competent cells (Section 2.2.4.3) were thawed out and kept on ice. To each
0.2 ml of cells 3.4 J.1lof 10% (v:v) 2-mercaptoethanol were added and mixed by gently
swirling. Cells were left on ice for 10 minute, mixing by hand occasionally. For each
transformation, 100 J.1lof the above mixture was placed into a pre-chilled falcon tube,
and 1 to 5 J.1lof DNA was then added to each tube and mixed gently. Tubes were placed
on ice for 30 minutes before immersion and gently shaking in a 42°C water bath for 45
seconds and then returned to incubate on ice for a further 2 minutes. Subsequently 800J.1l
of LB were then added to each tube and the tubes were shaken at 37°C for 1 hour. A
50J.1laliquot of the transformed cells were plated on an LB-agar plate (containing 100J.1l
of ampicillin) and incubated oln at 37°C o/n. As a control for the efficiency of
transformations, a control transformation was performed with 1ng of circularised
plasmid pTZ18R (Section 2.1.5p). A negative control in which no DNA was added was
also included to ensure that cells did not already contain an amp'' plasmid. and that the
solutions were not contaminated with an amp" plasmid.
2.2.5.5 Mini-Prep DNA Isolation from Transformed XLi-Blue
Colonies were picked from transformation plates (Section 2.2.4.4) using a sterile pipette
tip, inoculated into 10ml of LB supplemented with 100 ug/ml ampicillin and incubated at
37°C o/n with shaking (225 rpm). The next day 0.5ml of sterile freezing mixture was
mixed with 0.5 ml of oln culture and stored immediately at -70°C for use as long term
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stocks of transformants. The remammg cells of the o/n culture were pelleted by
centrifugation at 3000g for 10 minutes at RT. The supernatant was removed completely
and the cells were resuspended in 200111of GTE solution (Section 2.1.5d). Cells were
then transferred to a 1.5ml ependorf tube, ensuring that all cells were resuspended, and
the tube was left to stand for 5 minutes at RT. Subsequently 400 III of NaOHlSDS
solution (Section 2.1.5e) was added to each ependorf and tubes were inverted several
times to ensure sufficient lysis of the cells. Tubes were then placed on ice for 5 minutes.
Finally 300 III of ice-cold acetate solution was added to each tube to cause re-annealing
of the plasmid DNA, and after a further incubation on ice for 5 minutes the tubes were
centrifuged at 13,OOOgfor 5 minutes. Approximately two thirds of the supernatant was
transferred into a fresh tube, and *an equal volume of phenol-chloroform was added.
Gently, each tube was inverted several times and then spun at 13,000 rpm in a
microcentrifuge for 1 minute. Two thirds of the aqueous top layer, containing the DNA,
was transferred into a fresh tube and an equal volume of isopropanol was added to the
plasmid solution, and mixed by inverting the tubes several times. Tubes were left for 2
minutes at RT to precipitate the DNA and then spun at 13,000 rpm for 5 minutes. The
supernatant was removed and the pellet was washed in 1 ml of 75% ethanol and spun at
7000 rpm for 5 minutes. The supernatant was removed and any traces of ethanol allowed
to evaporate by leaving tubes with the lid open at RT for 5-10 minutes. The pellet was
then dissolved in 50 III ofTE buffer and stored at -20°C*.
2.2.5.6 Digestion of Plasmid DNA with Restriction Enzymes
RNA contained in plasmid mini-preps (Section 2.2.4.5) was degraded by adding -0.5-
1III RNase (500~g/m1) into the restriction digest. The appropriate restriction enzyme and
buffers were then added as per manufacturers instructions, and the reactions incubated at
37°C water bath for 1-2 hrs and then analysed by gel electrophoresis.
2.2.5.7 Agarose Gel Electrophoresis
A 0.8% electrophoretic gel was prepared with SeaKem agarose and TAE buffer (Section
2.1.Sh) with 0.51l1ethidium bromide per 100 ml gel and allowed to set in an appropriate
sized gel tray with gel comb inserted. Electrophoresis buffer was supplemented with
0.5 III ethidium bromide per 100 ml buffer. Electrophoresis buffer was added to the
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electrophoresis tank until the gel was just covered. Samples were diluted with 1,4 volume
bromophenol blue buffer and loaded into the wells using a p20 Gilson pipette. The gel
was then run for 2-3hrs at 80 mVolts and photographed on a U.V transilluminator.
2.2.5.8 Purification of DNA Bands from Agarose Gels
DNA bands were excised from agarose gels (Section 2.2.4.7) usmg a scalpel and
transferred into eppendorf tubes. DNA purification from the agarose gel slices was
performed using the QlAEX II kit (QIAGEN), following the manufacturer's protocol.
Briefly gel slices were weighed in eppendorfs and solubilised by adding 3 volumes of
buffer QXI (Section 2.I.Sb) and 2 volumes of water to 1 volume of gel. 30111ofQIAII
(Section 2.1.Sb) was then added and samples incubated at SO°C for la minutes. Samples
were then centrifuged for 30 seconds and the pellets were washed with SOOIlIof buffer
QXl. Pellets were then washed twice with SOOIlIof buffer TE (Section 2.1.Sh) and air-
dried for 10-15 minutes. The DNA was eluted from the bead pellet in 20111of 10mM
Tris-HCI, pH 8.5. The purity as well as the quantity of DNA obtained was checked by
electrophoresis against different dilutions of a mass ladder.
2.2.5.9 Ligation of DNA Constructs
The appropriate mammalian expression vector was linearised using the appropriate
restriction enzyme as described in Section 2.2.4.6, to enable insertion of the required
eDNA. An agarose minigel was run to check that the vector was completely linearised.
In order to avoid the vector religating with itself, the 5' end phosphate was removed as
follows. The equivalent of 1ug of DNA was removed from the linearised vector solution
to serve as a control for the ligation assay see below. To the remaining DNA solution
(20Ill) was added Sill of lax SAP buffer (Section 2.1.Sr), 1III of SAP and the final
volume adjusted to SOIlIwith water. The tube was then briefly centrifuged and incubated
for 30minutes at 37°C. The DNA was extracted with phenol-chloroform, precipitated
with Ethanol and dissolved in 20111ofTE buffer as described in Section 2.2.S.S from* to
*). In an ependorf tube 60ng of the purified cDNA insert (Section 2.2.4.8) was mixed
with 100ng of SAP-treated vector (molar ratio between insert: vector being 3: 1), 1 unit
of T4 DNA ligase and 4111T4 ligase buffer and adjusted to 20111with water. To assess
the effectiveness of SAP in preventing religation of the vector to itself, two controls
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were also prepared with T4 DNA ligase, buffer and water but with either SAP-treated
vector alone or untreated vector alone (saved above) in the absence of cDNA insert. All
the tubes were incubated at 14°C overnight. The ligated DNAs were then transformed
into XLI as described in Section 2.2.S.4.
2.2.5.10 Maxi-Prep DNA Isolation from Transformed XLI-Blue
Agar plated single colonies obtained from frozen stocks of transformed cells (Section
2.2.S.4) were grown in a S m1 culture at 37°C at 300 rpm for 8 hours to obtain mid-log
phase cells. This culture was diluted 1 in SODinto 100-S00 ml LB-amp and cultures o/n.
The plasmid DNA was then purified using the QIAGEN Maxiprep Kit. Briefly, the
bacterial cell pellet obtained from the culture was re-suspended into 10ml of solution PI
(Section 2.l.Sb), making sure that no cell clumps were left. To this cell suspension 10ml
of buffer P2 (Section 2.l. Sb) was added and the mixture was incubated for S minutes at
RT. After this incubation period 10mls of chilled buffer P3 (Section 2. l. Sb) was added
and mixed by inverting the tube a 4-S times and subsequently transferred into a QIAfilter
cartridge.
The mixture was left undisturbed for 10 minutes at RT. In the meantime a QIAGEN
TIPSOO column was equilibrated with lOrnls of buffer QBC (Section 2.l.Sb). The lysate
was then filtered through the QIAfilter into the TIPSOOand allowed to enter the column
by gravity. The column was washed with 2x 30 ml of buffer QC (Section 2.l.Sb) and
DNA bound to the column was eluted with IS ml of buffer QF (Section 2.l.Sb). The
DNA was precipitated with 10.Srnls of isopropanol and spun at lS000g for 30 minutes at
4°C. The supernatant was then discarded and the pellet washed with Sml of 7S %
ethanol. After spinning tube at 15000g for 10 minutes at 4°C the supernatant was again
discarded and the pellet left to air dry for 5 minutes. The DNA was then dissolved in
400-500111 of TE (Section 2.l.Sh). A small amount of DNA was digested with the
appropriate restriction enzyme and run on an agarose gel to check the identity of the
construct.
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2.2.5.11 Sterilisation of Plasmid DNA for Transfection
To sterilise the DNA obtained from a Maxiprep (Section 2.2.5.10) 1110 volume of 3M
sodium-acetate and two volumes 100% ethanol were added to precipitate the DNA. The
precipitate was spun at 13 000 rpm in a micro centrifuge for 5 minutes and washed in
75% ethanol. Tube was then spun at 7000 rpm for 5 minutes and the supernatant
removed in a sterile flow cabinet. The pellet was left to air dry for 1 minute in the sterile
cabinet and dissolved in sterile TE buffer (Section 2.I.5h). The concentration of the
DNA was estimated using a spectrophotometer.
2.2.6 Transfection of Mammalian Cells
2.2.6.1 Geneticin Selection
The concentration of Geneticin required to select for transfected cells was evaluated by
growing the parent cell lines in various concentrations of Geneticin for a minimum of
two weeks. The lowest concentration amount of Geneticin that killed all the cells after
two weeks of culture was chosen as the concentration to be used to select for transfected
cells. This experiment was performed in 24-well-plates with 2 ml of medium per well.
The cells were seeded into the wells such that they could undergo 2-3 doublings before
reaching confluence. Cells were left to adhere oln before addition of Geneticin.
Concentrations of Geneticin were 0, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900
and 1000 ug/ml final concentration.
2.2.6.2 Transfection of SaOs-2 cells
2.2.6.2.1 Determination of Most Effective Liposome Preparation
In order to determine the most effective liposome reagent for transfecting SaOs-2 cells
they were transiently transfected with pCMV -p, a reporter gene which express the E.
coli l3-galactosidase gene under the control of the human CMY promoter. Cells were
grown in a 24-well plate until 70-80% confluence was reached. To prepare the DNA:
Liposome mixtures, 300111 OPTIMEM was added to wells AI, BI, Cl and DI ofa 24-
well plate and the following was added to each well:
AI: 20111ofLIPOFECTIN,
BI: 10111ofLIPOFECTAMINE,
Cl: I Sill ofCELLFECTIN,
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01: 1Oul of DMRIE-C
The plate was left at RT for 30minutes during which the culture medium from the cells
was removed and replaced by l ml of serum free OPTlMEM. Then 4.32111of DNA at
3.7~g/~1 was transferred into an ependorf tube containing 1.5 ml of OPTlMEM to
obtain a final concentration of 10.66 ng/ul. and then 300111of this mixture was then
added to each well containing the liposomes. The plate was then left at RT for a further
15 after which wells A 1-0 1 were double diluted across the plate in OTIMEM to obtain
serial dilutions of each liposome: DNA mix. The medium from the cells was then
removed and replaced with the contents of the corresponding well in the liposome: DNA
plate. The cells were then incubated at 37°C for 5hrs after which the liposome: DNA
mixtures were removed and replaced by cell culture medium and the cells cultured for 24
hours. Cells were stained for f3-galactosidase expression (Section 2.2.6.3).
2.2.6.2.2 Determination of the Optimum Concentration of DNA/Lipofectamine
Cells at 80% confluence in a 24-well plate were used for this experiment. Eppendorfs
containing 0.68, 1.35,2.71 and 5.41 ug of plasmid DNA stock pCMVP were diluted to
a final volume of 136.5 ul in OPTlMEM. In separate eppendorfs 1.87, 3.75, 7.59, 11.24,
14.99 and 20.60 III Lipofectamin were diluted to a final volume of94 III in OPTIMEM.
Then 21 III of each DNA solution was mixed with 21 III of each Lipofectamin solution so
that a total of24 different DNA: Lipofectamin combinations were generated.
These mixtures were then left at room temperature for 45 minutes. During this time
incubation, the medium from the cells was replaced with serum free DMEM.
Subsequently 166111of OPTIMEM was added to the DNA: Lipofectamin mixtures and
the medium in each well was replaced one by one with the appropriate DNA:
Lipofectamin mixture. The plate was then incubated for 5 hrs at 37°C, after which wells
were emptied and 1ml of pre-warmed medium was added and the plate was cultured at
37°C for 24 hours. The cells were then stained for p-gal expression (Section 2.2.6.3).
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2.2.6.3 Assessment of J3-galactosidase Reporter Gene Expression
Cells transfected with pCMVJ3 in a 24-well plate were washed once with PBS and fixed
with 0.5 m1 of fixative solution (Section 2.1.5s) for 5 minutes at room temperature. The
cells were then washed twice with PBS and then 0.5 ml of substrate/stain solution
(Section 2.1.5s) was added and the plate incubated for 2 hrs at room temperature. Wells
were observed under a light microscope and the proportion of blue (l3-gal-positive) cells
was evaluated.
2.2.6.4 Transfection of SKBr3 and A431 Cells
Cells were harvested and resuspended in 1ml of growth medium and counted with
Trypan blue to assess viability and cell density. The concentration was adjusted to 5
xl 06/ml and 0.4 ml was dispensed into electroporation cuvettes in addition to 10jJ.g of
linearised DNA in 10J..l1.Cells were electroporated in a Gene Pulser (Biorad) at various
voltages with the capacitance set at 960 jJ.FD. The cells were then transferred into 10mls
of fresh culture medium in a T25 flask and incubated at RT for 20 minutes to allow cells
to recover before culturing them at 37°C for 24-48 hours.
The efficiency of the electroporation was assessed by antibody staining followed by
FACs analysis.
2.2.7 Immunofluorescence Staining of SaOs-2 Cells Transfected with Mutated p53
or Vector Alone
Cells were grown in chamber slides until 60% confluency was reached. Cells were then
washed with PBS and fixed for 10 minutes at RT with 1% parafonnaldehyde. Cells were
washed again with PBS and then permeabilised by incubation with 70% of methanol for
10 minutes. After washing the cells three times with PBS, 2% of blocking agent in
TBS/Tween (Section 2.1.10b) was added and the cells were incubated for 30 minutes at
RT in a moist box. P53 antibody was diluted in I: 100 in 1% of blocking reagent
(Solution at 2% diluted with TBS) and added to the cells after removal of the blocking
reagent solution, cells were incubated at 37°C for 1hr. Cells were then washed three
times with TBS (Section 2.1.10a) and the secondary antibody, F\c.T-~~anti-mouse
antibody was added to the cells after dilution 1:100 in 1% blocking reagent. The
chambers were left at 37°C for 30 minutes in a moist box. Slides were washed 3x 5
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minutes in TBS and then DAPI (Section 2.1.1 Oc) or ethidium bromide were added to the
cells for 2 minutes. Then cells were washed 3x 1minute in TBS. Slides were drained and
mounted carefully under an ethanol-washed coverslip using the DAKO fluorescent
mounting medium. Slides were observed under a fluorescent microscope using the
middle (UV) and green filters.
2.2.8 Determination of pS3 Expression in HNSCC Sections by
Imm unohistochemistry
Sections of 8Jl thick were cut from a frozen block and layered on APES coated slides.
These were left to air dry over-night. The following day sections were fixed in acetone
for 1D minutes and then stored at -20°C until needed. The staining was done using the
mouse ABC kit and the avidin-biotin amplification system. Briefly sections were re-
hydrated in PBS for 5 minutes before addition of blocking serum, nonnal rabbit serum,
for 30 minutes. The excess was then removed and either the first antibody 007, or the
control isotope antibody, IgG2b, were then added (50Jll of 111 00 dilution) for 2 hrs. All
sections were washed three times with PBS and the second antibody (goat anti-mouse)
supplied with the kit, was then added to all sections for 30 minutes. The sections were
again washed three times with PBS. The avidin-biotin complex was then added to the
sections and left for 30 minutes. Sections were washed again, then the substrate DAB,
added and left for 2 to 8 minutes. The sections were rinsed with double distilled water
and the nuclei stained with Haematoxilin (30 seconds). Sections were washed with tap
water first and then in Scott water (turning the Haematoxilin into a bluish colour).
Using increased alcohol bath concentrations (70%, 95% then absolute ethanol twice)
sections were dehydrated and were finally put into a xylene bath and mounted in
Picolyte. Sections were left to dry at 56°C before cleaning with a quick bath in the
xylene to remove the excess of Picolyte.
2.2.9 LAK Assay
PBMC were freshly isolated from healthy donors as written in method Section 2.2.3.1.
4x106 PBMC/ml were incubated in AIM-V with 5DOU/ml IL-2 in a T25 flask for four
days at 37°C. Another flask was set up with the same amount of PMBC but without any
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IL-2. Cytotoxic activities of IL-2 activated PBMC were assessed in a standard 4hrs
chromium release assay as written in Section 2.2.4.
Briefly all transfected cells were versene/trypsinised, counted and labelled with 3.7Mbq
of 51Cr for 1hr at 37°C. Cells were then washed twice in RPMI+ 10% FCS and
resuspended in 1ml of medium and incubated for another hour at 37°C. Cells were
washed again, resuspended in 1ml of medium and counted. Each transfected cell line was
added to IL-2 activated PBMC or untreated PBMC at different Effectors: Targets ratios,
all were tested in duplicate.
2.2.10 RNA Extraction from Frozen Tumours
A small piece of loose tumour was placed into a homogenizer along with 1ml of
RNAzol. The tumour was broken down in the homogenizer and solution was transferred
into an ependorf Small pieces were further broken by sucking and plunging the solution
through a syringe 10-15 times. IOOIlI of chloroform was then added to all eppendorfs,
which were then vigorously shaken. Tubes were incubated on ice for 5 minutes.
*Eppendorfs were then centrifuged for 15 minutes at 4°C, maximum speed. The top
layer was removed and transferred into fresh eppendorfs to which was added an equal
amount of isopropanol. These were then put at -70°C for a least 30 minutes and spun
down for 15 minutes at maximum speed. The supernatant was discarded and the pellet
washed in lml of 80% ice-cold ethanol*. Pellets were dissolved in a mixture containing
DEPC water, NaCl, and ethanol. Tubes were put back at -70°C for 2 hours. Thereafter
the procedure * was repeated. After removal of all ethanol RNA was dissolved in a small
amount of DEPC water and 1III was removed and added to 99lll of DEPC water for
spectrometry analysis. For long term storage at -70°C, RNA was re-precipitated by
addition of more DEPC water, NaCl, and ethanol.
2.2.11 Mixed Lymphocyte Reaction
200!l1 of2xl05/ml dendritic cells, obtained from healthy HLA-A2+ donor after 10 days in
culture with cytokines, see Section 2.2.3.3, were put into each well of the first column of
a U/bottom 96-well plate. These were then diluted to 5x 102 dendritic cells/ml in RPMI +
10% FCS, final volume IOuul/well. Then 1OOll1of 2x 106/m! of either autologous or
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allogeneic non-adherent PBMC, obtained as described in Section 2.2.3.3, were added to
each of the well containing dendritic cells.
Cultures of dendritic cells mixed with non-adherent PBMC were assayed in triplicate.
Dendritic cells and non-adherent PBMC were also cultured on their own at the highest of
the concentrations as controls for proliferation in RPM! + 10% FCS.
The plate was then incubated for four days at 37°C + 5% CO2 in humidified incubator.
Then IJlCi (0.037Mbq) of~H-thymidine was added to all the wells for I8hrs. The plate
was then harvested, the cellular content of each well was recovered onto a plate
containing filter paper and original wells were washed. The plate with filter paper was
then left oln to air dry. A Gamma Counter detected the amount of 3H-thymidine
incorporated by cells after addition of 25JlI liquid Scintillin and after the plate was sealed.
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3.1 Introduction
The immune system has evolved to respond to and eliminate dangerous foreign
organisms such as bacteria that invade the body or virally infected cells, without in
normal circumstances, damaging any healthy cells. This is achieved by immune defence
mechanisms. Bacteria and toxins are normally eliminated by antibodies, whereas infected
cells are killed by cytotoxic T cells (CTL). These cells are able to recognise small
processed fragments of viral proteins, called peptides, in association with MHC c1ass-I
molecules on the surface of infected cells. It has long been hopkl by immunologists that
tumour cells would also display 'antigenic' fragments, differents from those expressed by
normal cells, which would mount an immune response that would result in the
eradication of abnormal cells. It is only recently, however, with the work of Thierry
Boon and co-workers that definite evidence of the existence of such tumour associated
antigens has been demonstrated. In addition, recent advances in understanding antigen
processing and presentation has provided insight into the importance of the amino-acid
sequences of pep tides for binding to particular MHC class-I molecules and subsequent T
cell recognition.
These new developments have led to renew interests in the possibilities of using the
immune system to fight cancers. A major pre-requisite for antigen specific
immunotherapies are the identification of tumour associated antigens (TAA). Several
different types of TAA have been identified and classified into different groups such as
unique tumour antigen (E.g. Melanoma antigens), shared tumour-specific antigens (E.g.
MAGE gene family products), tissue-specific differentiation antigen (E.g. MART-
l/Melan-A, gplOO and tyrosinase), oncogenes and tumour suppressor gene products
(E.g. Ras, pS3, Her-2/neu) and virus-associated antigens (p16 and pl8 from HPV).
These are discussed in Section 1.2. Several different techniques have been developed to
identify TAA. These include genetic, biochemical and reverse immunology, approaches
detailed below.
3.1.1 Identification of Tumour Antigens
3.1.1.1 Genetic Approach
The identification of tumour antigens had for many years involved the fractionation of
cell extracts or membrane preparations. These fractions were then tested for their ability
67
to confer a protective immunity in murine models. Most of these techniques failed and so
were replaced by a molecular approach involving expression cloning of cDNA libraries.
This work was pioneered by Thierry Boon and co-workers (Boon, 1993), who
discovered that clones generated from tumour cells exposed to a potent mutagen when
re-injected into mice did not produce any tumour whereas the parent cells did. These
tumour negative clones (called tum- variants) were found to be eliminated by the immune
system. However when the parent tumour cells were re-injected in animals previously
treated with the tum- no tumour growth develop. They had acquired resistance to the
original tumour cells but not to unrelated cancer cells. DNA from tum- variants was
removed, cleaved and inserted into plasmids (rings of bacterial DNA) bearing a gene
which imparts resistance to a toxic drug. On exposing the cells to the toxic drug only
those that incorporated the plasmid survived. These cells were then allowed to multiply
and each clone was exposed to T lymphocytes that specifically recognise the tum- cells or
antigen of interest. Any cell that induced a lymphocyte response (such as proliferation or
cytokine production) was assumed to produce the antigen, and thereby the
corresponding gene (Boon, 1993). Surprisingly, it was found that the gene identified
(PIA gene) was also present in the original tumour cells, but somehow, expressed only
weak antigens that are not able to induce a powerful immune response (van den Eynde,
et aI., 1991). Therefore, it was postulated that some human tumours similar to murine
tumours can be antigenic (express antigens that can be used to generated an immune
response) without being immunogenic (incapable of generating an immune response) and
could be rendered immunogenic. Using this technique tum- variants (antigen loss
variants) were made from a cell line derived from a mastocytoma, p81S and a cosmid
library was prepared using the genetic material of the newly obtained p8IS turn'. These
were, in tum, transfected back into the parental cell line, p8IS, which do not express the
gene. These were then tested for their ability to stimulate T cells (generated by
immunizing mice with killed tum- variants) to multiply. The gene responsible for the
stimulation of the T cells was identified and found to be expressed not only by the tum-
variants but also by the parental cell line and in normal mouse tissue. However, in the
tum- variants a point mutation had occurred within the gene giving rise to proteins with a
single amino-acid substitution. These proteins were chopped into small peptides with
different abilities to bind to MHC class-I molecules and therefore be presented at the
surface of the cell to be surveyed by T-cells. The point mutation within the tum- variant
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protein had rendered a non-binding peptide to a binding one. From a different tum-
variant clone a different gene was identified and shown to be present but was not
expressed in normal cells.
Using this genetic approach, with the availability of tumour specific CTL, the first human
tumour associated antigen was identified. The MAGE (melanoma antigen) gene family
was cloned from a melanoma cell line derived from a patient with melanoma, MZ-2 (van
der Bruggen, et aI., 1991), BAGE (van der Bruggen, et aI., 1991), and GAGE (van den
Eynde, et aI., 1995).
The technique was then modified and simplified to search for additional melanoma
antigens. cDNA libraries were made from tumour cell lines and transfected into COS
cells (chimpanzee cells) where the vectors expressing the cDNA multiplied episomally
(DNA do not integrate into the host genome) to reach a very high copy number.
Selected clones were then co-transfected with the appropriate HLA gene. These were
then tested for their ability to stimulate TNF-release by tumour specific cytotoxic T
lymphocytes. Using this method the tumour associated antigens tyrosinase (Brichard, et
al., 1993), melan-A (Coulie, et al., 1994), gp-lOO (Kawakami", et aI., 1994) were
discovered. This approach has also led to the identification of several tumour associated
antigens in some cases unique antigens (E.g. CDK-4, Wolfel, et aI., 1995~ casp-8,
Mandruzzato, et al., 1997).
These gene cloning methods rely however on having a good supply of cytolytic T cells
specific for the tumour studied.
Another approach to identify TAA relies on protein biochemical methods, whereby MHC
bound peptides are acid eluted, purified and sequenced.
3.1.1.2 Elution Technique
The lll,A-A2 molecules on the surface of cells can be purified by papain digestion of
plasma the membrane. Indeed, papain cleaves the heavy chain at residue 271, 13 residues
from the transmembrane region, resulting in a molecule composed of aI, a2, a3 and fJ2-
m (Springer, et aI., 1976). Subsequently, purified lll,A-A2 molecules can be crystallised
to learn more information of the groove structure where peptides bind their amino-acid
sequence (Bjorkman", et al., 1987). Peptides can then be eluted by acid treatment and
fractions run through HPLC and mass spectrometry. This can provide information on
peptide length and amino-acids which might be important for binding. Many tumour-
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associated peptides have been extracted either from immunoaffinity purified or directly
from the tumour cell surface by acid elution. These bulk peptides have then been
resolved by reverse phase high performance liquid chromatography (RP-HPLC)
(Storkus, et aI., 1993~ Slingluff, et aI., 1993; Franksson, et aI., 1993). HPLC
fractionated tumour peptides were then pulsed onto irrelevant target cells bearing the
appropriate HLA allele, and were used as targets to tumour-specific T-cells. This
technique allowed the identification of a number of potentia) T-cell epitopes perceived by
the immune system in situ without any information of the identity of the original tumour
protein involved in generating the immunogenic peptides (E.g. melanoma antigens).
Peptides bound to MHC class-I molecules have been found to be mainly of nine amino-
acids in length with predominant amino-acid at position 2 and 9 (Leucine or Isoleucine at
position 2 and a valine at position 9 for HLA-A2 molecules) for each MHC class-I allele
(Bjorkman", et aI., 1987; Falk, et aI., 1991; Hunt, et aI., 1992; Drijfhout, et aI., 1995).
These residues are called 'anchor residues', and can be described as either 'preferred' or
'tolerated' which indicates whether the amino acid at a particular position associates with
a specific HLA molecule with respectively either a strong bond or a weak bond.
Examples of anchor residues for common HLA alleles are shown in Table (1). Peptides
of 10 and 11 amino-acid in length have also been identified, as well as residues at non-
anchor positions playing an important role in the binding affinity of the peptide bearing
them (Drijfhout, et aI., 1995). Identification of 'anchor residues' make it possible to
screen any protein sequences for the identification of potentially immunogenic peptides
that could be used for the production of a cancer vaccine.
3.1.1.3 Protein Sequence Screening Approach
T cell epitopes are nowadays mainly discovered by screerung the potential tumour
antigen sequence for nine amino-acids long peptides bearing 'preferred' or 'tolerated'
anchor residues for any particular HLA-molecules. Once the peptides are identified and
synthesised it is necessary to know the interaction between peptide and MBe. This
determines an important intermediary step in antigen presentation. Immunogenic
peptides form indeed relatively stable MHC-peptide complexes with a low dissociation
rate in comparison with non-immunogenic peptides (van der Burg, et al., 1996).
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3.1.2 Peptide Binding Assays
A number of different methods have been used to determine peptide binding to MHC
molecules, including the use of purified MHC class-I molecules and techniques based on
stabilisation of empty MHC class-I molecules at the cell surface.
3.1.2.1 Using Purified MBC class-I Molecules
Cells (usually T2 cells) were lysed and MHC class-I molecules were purified using
immunoaffinity columns of protein A-purified monoclonal antibodies and then eluted
from these columns. Either T2 cells lysat alone (Connan, et a!., 1994) or purified MHC
class-I molecules were incubated with different concentrations of cold or radio-labelled-
peptides (Olsen, et a!., 1994; Celis, et a!., 1994) along with 132-mfor a set time. The
amount of bound peptide was then determined either by gamma scintillation counter,
ELISA or FACS analysis depending on the method followed. The ability of test peptides
to compete with a radiolabelled standard peptide for binding to a class-I molecule was
measured in these assays. Alternatively E. coli (Parker, et aI., 1992) or drosophila cells
(del Guercio, et aI., 1995) can be used to produce MHC class-I molecules. Using this
method more details have been found about peptide binding motifs (Ruppert, et a!.,
1993). (The purification of MHC molecules combined with the elution technique has
allowed the discovery of naturally occurring peptides from the MHC class-I pathway
(Rotzchke, et aI., 1991). Secondary pockets within the HLA-A2 molecule have indeed
been discovered. Amino-acid at position 1, 3 and 7 were found capable of strengthening
(case of Y, F, W, S, T, or C) or reducing (case of D, E, P, R, K, H) the binding of
peptides nine amino-acid in length still bearing the proper anchor residues at positions 2
and 9.
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Table 1: HLA-Specific Binding Motifs.
Amino Acid Position
HLA Allele 2 3 9110 References
Kubo. et al .. 199-':
Al TMS DE Y *Di Brino. et al.. 1994
AS
Rammensee. et al., 1993:
A2 LM LIV Ruppert. et al .. 1993:
IVAT AM
Kast, et al .. 1994:
Kubo. et al .. 1994.
Di Brino. et al .. 1993:
A3 LMIVSATF KRY Kubo. et al., 1994.
CGD A
Kubo. et al.. 1994.
All MLVSATGN K
CDF R
Kubo. et al .. 1994.
A24 YF FLIW
M
Bold type indicates 'preferred' amino acids
Normal type indicates 'Tolerated' amino acids
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3.1.2.2 Using RMA-S Cells or T2 Cells
The mutant mouse cell line RMA-S was derived from the Rauscher virus-induced H-2b
lymphoma RBL-5 by exposure to the mutagen ethyl methane sulphate (EMS) and
repeated rounds of treatment with antisera against class-I molelcules and complement
(Ljunggren, et al., 1985; Karre, et al., 1986). These cells synthesise both class-l heavy
chains and 132-m, but most of the heavy chains do not associate with 132-mand remain
intracellular (Ljunggren, et al., 1989). The human cell line (T2) was derived between the
Tl cell line (a fusion between the human cell line .174 which contains a homozygous
deletion of the class-Il region of the MHC) and the T Iymphoblastoid cell line (CEM) but
without the two intact copies of chromosome 6 derived from the CEM cells (Salter, et
aI., 1985/1986; Cerundolo, et aI., 1990). T2 cells lack the TAP 1 and TAP2 genes, which
encode the transporter proteins, but still produce high amounts of the MHC heavy chain
and 132-m,but are unable to present endogenously synthesised peptides. The amount of
HLA-A2 molecules expressed on the surface of these mutants is very low due to the
degradation of unstable empty complexes (MHC class-I molecules/132-m). However, if a
peptide, with high affinity for the lll..A-A2 molecules, is added exogenously it will bind
to the molecules and thereby stabilise the complexes. This in tum can be detected by
indirect staining of the HLA-A2 or H-2b molecules on the surface of the T2 cells or
RMA-S cells respectively using a FACS machine, see Section 2.2.2.
These mutant cell lines with defects in antigen processing have great potential and have
been extensively used for the determination of the binding affinity and detailed motifs of
selected peptides (Nijman, et al., 1993; Drijfhout, et al., 1995). Different conditions for
the assay have been set up including one, using the T2 cells, which is used in our lab
(established by McIntyre, et aI., 1995).
In addition to methods using biological assays, computer programs are now available to
find out all potential binder of 8, 9 or 10 amino-acid in length as well as their half-life
(HLA binding motifs program).
3.1.3 p53 peptides as CTL epitopes
P53 protein is the most commonly mutated gene in human cancers. Mutations within the
gene induce an accumulation of the p53 protein due to its increased half-life. This
therefore allows more peptides to be synthesised and thus presented at the cell surface in
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association with MHC class-I molecules. Self-peptide do not, normally, elicit an immune
response but an overexpression of it might. Indeed, CTL have been shown to be able to
discriminate between the amount of p53 peptide present on normal cells and that present
on tumour cells (Vierboom, et aI., 1997). p53 represents therefore an ideal candidate for
immunotherapy against cancer. A number of studies have evaluated p53-encoded
peptides for binding to MHC molecules and their ability to induce CTL activity. The
protein sequence has been screened for any 8 or 9 amino-acids long peptides with the
two anchor residues at position 2 and 9. A summary of published work is shown in Table
(2). Peptides binding to MHC molecules was assessed by one of the method mentioned
earlier and most results were comparable. Peptides 24-32, 25-33, 65-73, 65-74, 66-74,
69-76,69-78,78-86,122-130,129-137,187-197, 210-218, 263-272, 264-272, 322-330
were fond to bind with strong affinity to HLA-A2 molecules. However only peptides 25-
35, 65-73, 65-74, 129-137, 149-157, 187-197, 263-272 and 264-272 were capable of
generating CTL ill vitro either in human or in transgenic mice bearing the a 1 and a2
domains of the human HLA-A2 molecules. These CTL killed peptide pulsed target.
Interestingly peptide 149-157 does not belong to the high binder group. Peptides 264-
272 and 149-157 have so far been the only ones generating CTL capable of killing
tumour targets as well as peptide-pulsed targets indicating that these are naturally
endogenously processed. Peptide 187-197 has been found by Theobald, et al.,(1997)to
be tolerated by HLA-A2 restricted CTL in transgenic mice.
The aim of this work was to identify new p53 peptides capable of binding with strong
affinities to HLA-A2 molecules on the surface of T2 cells. These will then be used to
generate CTL response in vitro.
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3.2 Results
3.2.1 Selection of P53 Peptides
The protein sequence screening approach has been extensively used on the p53 protein.
Many peptides of 9 to 11 amino-acid in length, bearing the 2 preferred anchor residues,
have been identified and tested for their ability to bind or stabilise MHC class-I molecules
using one of the methods mentioned earlier. All these studies are summarised in Table
(2). Looking at the p53 protein sequence one region has never really been studied. This
region (residues 193-237) corresponds to the epitope RHSVV (residue 213-217) known
as the 240 epitope. In normal cells or in non-conformational mutants (mutants that retain
the wild-type conformation of the protein) this epitope is not exposed but rather buried
in a high hydrophilic mass. On the other hand, conformational mutants (175-like) 100sepelll'rlOl~
-~~ the native conformation of the protein and as a result of the mutation expose that region
which can be detected by the monoclonal antibody 240. In this study 9, 10 and l l-rners
peptides from the 193-237 region and slightly extended region, bearing either 2, 1 or
none of the preferred or tolerated anchor residues, were identified and synthesised, to be
assessed for their binding properties to MBC class-I molecules. Peptides 187, 263 and
264 have been chosen as positive control for their well documented binding capability.
These peptides are listed in Table (3).
Indeed, wild-type and mutant phenotypes represent alternative conformations of the p53
protein with the wild-type phenotype associated with the suppressor function of the
protein, and mutant phenotype associated with cell proliferation. This change of
conformation induced by cell growth is critical for p53 function but transient (Milner,
1990).
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Table 3: DETAILS OF p53 ENCODED PEPTIDES ASSESSED FOR MBC
BINDING
Anchor Residue at position: ..
Peptides Sequence
position 2 9/10 11
186-194 DGLAPPQHL - P
*187-197 GLAPPQHLIRV P - P
0188-197 LAPPQHLIRV T P
193-221 HLIRVEGNL P P
194-222 LIRVEGNLR T -
196-224 RVEGNLRVE T -
202-210 RVEYLDDRN T -
210-218 NTFRHSVVV T P
211-219 TFRHSVVVP - -
217-225 VVPYEPPEV T P
224-232 EVGSDCTTI T P
225-233 VGSDCTTIH - -
229-237 CTTIHYNYM T T
0263-272 NLLGRNSFEV P P
264-272 LLGRNSFEV P P
T: Tolerated anchor residue
P: Preferred anchor residue
*11-mer
o lO-mer
As can be seen four peptides have the 2 preferred anchor residues at position 2 and 9 or
11; peptides 193-221, 187-197, 263-272, and 264-272. One peptide has only one
preferred anchor residue at position 9, peptide 186-194. Two peptides do not have any
anchor residues, peptides 211-219 and 225-233. Three peptides have only one tolerated
anchor residue at position 2, peptides 194-222, 196-224, and 202-210. Four peptides
have two anchor residues, a tolerated one at position 2 and a preferred one at position 9,
peptides 188-197,210-218,217-225, and 224-232. One peptide has only two tolerated
anchor residues at position 2 and 9, peptide 229-237.
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3.2.2 MBC Stabilisation Assay: Titration of HLA-A2 Antibody
In order to determine the optimum concentration of the primary antibody required to
bind all the available surface peptide/MHC complexes in the T2 peptide binding assay
every new batch of antibody were titrated in the same way.
Isolated HLA-typed human PBMC (see Section 2.2.3.1), stored in liquid nitrogen, were
quickly thawed out, washed in PBS, and counted by Trypan Blue exclusion and used for
the antibody titration. Flow cytometric analysis, as described earlier, was used to
determine the optimum concentration of antibody to use. A typical result is shown in
Table (4).
Table 4: Staining of HLA-A2-typed PBMC with Various Volumes of Monoclonal
Antibody HB-82.
Volume of Antibody added to the Median Channel of Fluorescence
cells (Jll)
o 24.0
25 338.0
50 359.5
75 358
100 351
As can be seen from these data and figure (I) there was a steady rise in the median
channel fluorescence with increasing volume of HB-82 up to 50Jll which then started to
decrease by 75Jll and 100Jll. In order to be sure to saturate all of the binding sites 751-11
of antibody was chosen for use in the experiments.
3.2.3 MD C Stabilisation Assay: Evaluation of Method.
The MHC Stabilisation assay was carried out as described In the method chapter
Section2.2.1.2. Briefly, empty HLA-A2 molecules expressed on the surface of the T2
cells can be stabilised by addition of exogenous peptide, if peptide possesses any binding
affinity for the HLA-A2 molecules. The number of stabilised molecules, which is
indirectly proportional to the amount of peptide bound on the surface of the cells can be
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Figure 1: Titration of a New Batch of Primary Monoclonal Antibody HB-82
on HLA-A2- Typed Human PBMC
detected by indirect staining using an HLA-A2 antibody (HB-82) as first antibody and a
goat anti-mouse F(ab)'2 as secondary antibody. The fluorescence, emitted per cell, is
measured by a FACS-sorted machine. An fluorescence ratio (FR) is then calculated as
follows:
FR= Mean channel fluorescence of tested peptide
Mean channel fluorescence ofDMSO
Any peptide with an FR> 1.5 was considered as a high binder, with an 1<FR<1.5 peptide
was considered as moderate binder and with an FR< 1 peptide was considered as non-
binder. Before testing the ability of any of the p53 peptides chosen to stabilise the HLA-
A2 molecules at the surface of the T2 cells, it was necessary to first establish the
efficiency of the positive (HLA-A2 Flu peptide, Bednarek, et aI., 1991) and negative
(DMSO) controls.
Table 5: Positive And Negative Controls For Peptide Binding To HLA-A2 At
26°C.
Controls Mean Fluorescence Ratio
o (JlM) 1 (JlM) 10 (JlM) 100 (JlM)
Cells alone 1.06
'True' Negative Control DMSO 1.00
Positive Peptide Control
Influenza virus Matrix A2Flu 1.14 1.67 2.61
AA 58-66: GILGFVIT
It can be seen from these results and figure (2) that the Flu peptide showed a high affinity
for the ffi.,A-A2 molecules since it reached a mean FR of 2.61 at 1001lM and was
therefore suitable for use in the T2 binding assay as a positive control. DMSO was
chosen as a 'true' negative control since all the peptides were dissolved in it. The cells
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Figure 2: Positive and Negative Controls for MBe Stabilisation Assay
Performed at 26°C.
alone showed no greater fluorescence than the DMSO and therefore no stable HLA-A2
molecules on their surface.
3.2.4 MOC Stabilisation Assay: Results of pS3 Encoded Peptides in the Assay
Performed at 26°C.
T2 cells were incubated with 1~M, 1O~M or 1OO~Mof each pS3 peptides, or A2Flu or
DMSO for a minimum of 18 hrs at 26°C. After antibody staining, the level of
fluorescence, corresponding indirectly to the amount of peptide bound, was detected by
flow cytometry. The fluorescence ratio was obtained by dividing the mean channel
fluorescence of each peptide by the mean channel fluorescence of the DMSO.
All peptides were tested 3 times in 3 independent assays. Peptides with a mean
fluorescence ratio > 1.5 were considered as 'high' binders and are shown in bold.
Peptides with a mean fluorescence ratio < 1.1 were considered as non-binders, peptides
with an FR comprised between 1.1 and 1.5 were considered as intermediate binders.
Results are summarised in table 6.
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Table 6: T2 Binding Assay of p53 Peptides at 26°C
PEP TIDES SEQUENCE MEAN FR AT MEAN FR AT MEAN FR AT
1jjM 10jjM 100jjM
186-194 DGLAPPQHL 0.56 1.07 1.32
187-197 GLAPPQHLI 1.62 2.30 2.82
RV
188-197 LAPPQHLlR 0.98 1.03 2.04
V
193-201 HLiRVEGNL 1.00 1.43 2.07
194-202 L1RVEGNLR 0.99 1.00 1.27
196-204 RVEGNLRVE 1.01 1.10 1.63
202-210 RVEYLDDRN 0.92 0.95 1.32
210-218 NTFRHSVW 0.99 1.01 0.96
211-219 TFRHSVWP 0.69 0.80 1.42
217-225 WPYEPPEV 1.43 2.28 2.18
224-232 EVGSDCTTI 1.23 0.40 1.27
225-233 VGSDCTTIH 1.00 0.95 1.03
229-237 CTTIHYNYM 1.24 1.38 1.24
263-272 NLLGrNSFE 1.25 1.53 2.22
V
264-272 LLGRNSFEV 1.28 1.84 2.17
As can be seen from table (6) and figure (3) 7 peptides (in bold) stabilised HLA-A2
molecules with high affinity (FR> 1.5) and were considered as high binders. Of which
peptide 196 gave a range FR of < 1 and > 1.5. 6 other peptides stabilised the MHC
molecules with moderate affinity (1< FR< l.5) and were considered as moderate binders.
Two peptides did not show any binding affinity (FR<1) and were considered as non-
binder.
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3.2.5 MBC Stabilisation Assay Performed at 37°C
The MBC stabilisation assay was also performed at 37°C a more physiological
temperature. Initial experiments validated the assay by using positive and negative
controls (as described previously) at 37°C and these results are listed below in table (7).
Table 7: Positive and Negative Controls for Peptides Binding to HLA-A2 at 37°C
Controls Mean Fluorescence Ratio
o (J.lM) 1 (J.1M) 10 (J.lM) 100 (J.lM)
Cells alone 1.2
'True' Negative Control DMSO 1.00
Positive Peptide Control A2Flu* 2.36 2.72 2.90
*A2Flu peptide used as a positive control gave consistantly high FR at all 3
concentration used in the assay. The p53 encoded peptides were assessed in the T2
binding assay at 37°C and the results are shown in Table (8) and Figure (4).
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Table 8: T2 Binding Assay of p53 Peptides at 37°C
186-194 DGLAPPQHL 1.12 1.36 1.28
187-197 GLAPPQHLI 1.66 2.36 2.95
RV
188-197 LAPPQHLlR 0.81 1.11 1.40
V
193-201 HLiRVEGNL 1.23 1.05 2.99
194-202 LlRVEGNLR 1.38 1.31 1.40
196-204 RVEGNLRVE 0.84 1.19 1.27
202-210 RVEYLDDRN 1.24 1.47 1.27
210-218 NTFRHSVVV 1.34 1.02 1.04
211-219 TFRHSVVVP 1.16 0.89 0.94
217-225 WPYEPPEV 0.63 1.25 5.39
224-232 EVGSDCTTI 1.66 1.14 1.39
225-233 VGSDCTTIH 1.03 1.20 1.18
263-272 NLLGNSFEV 1.35 1.25 5.20
264-272 LLGRNSFEV 1.34 1.36 6.51
111M 10!-,M 100!-,M
PEP TIDES SEQUENCE MEAN FR A T MEAN FR A T MEAN FR AT
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From Table (8) and Figure (4) it can be seen that most of the peptides which showed a
strong binding affinity for HLA-A2 molecules, with an FR > 1.5, at 26°C also showed a
strong binding affinity for HLA-A2 molecules at 37°C. Only two peptides did not.
Peptide 196, however, was found to be border line with an FR between the two side of
1.5 when the assay was performed at 26°C, at 37°C the same trend seemed to happen.
3.2.6 Effect of Amino Acid Replacement on MHe Stabilisation Assay of the 217
Peptide.
Peptide 217 is one~he peptides that have not been, so far, studied for its ability to bind to
HLA-A2 molecule. In these experiments it was found to have, both at 26°C and 37°C,
an FR > 1.5 even though it contains only a tolerated anchor residue at position 2 and a
preferred one at position nine. Changing a 'non-preferred' anchor residue for a preferred
one has proven in the past to improve the binding affinity of the peptide for HLA-A2
molecule (Lipford, et a!., 1995). In order to assess whether amino-acid substitution had
an effect on binding of peptide 217, the second amino-acid was changed for a preferred
one. These have the same amino-acid sequence than the original 217-peptide except for
the position two where a substitution has been made. Peptide 217 -L contains a Leucine
instead of the Valine and peptide 217-M a Methionine instead of the Valine. These
peptides were tested for their ability to stabilise MHC class-I molecules at the surface of
the T2 binding assay along with the original peptide 217. As can be seen, from table (9)
and figure (5), the 217-L peptide had the highest FR of the three, however the
improvement was not really significant.
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Table 9: Effect of A Single Amino-Acid Substitution on Peptide Binding Efficiency
of Peptide 217 in a T2 Binding Assay.
MEAN FRAT MEAN FRAT MEAN FR AT
PEPTIDES SEQUENCE 111M 10llM 100llM
26°C 37°C 26°C 3]oC 26°C 3]oC
217-225 WPYEPPEV 1.43 0.63 2.28 1.25 2.18 5.39
217-L VLPYEPPEV 1.71 1.03 2.61 1.47 2.83 5.44
217-M VMPYEPPEV 1.75 1.52 2.31 2.71 2.46 4.72
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3.3 Conclusions
Results obtained with peptides 187-197,229-237,263-272,264-272, were in
accordance with published work. Peptides 193-201 and 210-218 however gave opposite
results to published work.
Nine new peptides have been tested for their ability to bind and stabilise the MHC
complexes on the surface of the T2 cells in a T2 binding assay. Two peptides, peptide
188 and 217, have been found to bind strongly to the HLA-A2 molecules of the T2 cells
and were considered as high binders. These have never been, so far, considered as
potential immunogenic peptides. The 217 peptide was chosen for its particular interest
since it corresponds to the p53 protein region exposed in 175-like mutant, epitope 240
and has not previously been used to generate CTL.
3.4 Discussion
3.4.1 Assay
The T2 binding assay is a very easy, quick and non-hazardous (no raodio-labelled
isotope involved) assay for testing the ability of a given peptide for its ability to bind to
HLA-A2 molecules. The results obtained with this assay using well-known peptides
where similar in FR and conclusions. The assay was first carried out at 26°C because it
as been previously reported (Cerundolo, et al., 1991; Stuber, et aI., 1994) that by
incubating the peptides with the T2 cells at 26°C, rather than 37°C, it was possible to
increase the sensitivity of the assay. However because of its non-physiological use in
prospective of patient immunotherapy all the peptides were also tested at 37°C. Binding
affinity properties of most peptides were found similar at 26 and 37°C. Assays performed
at 26°C however detected more peptides binding (total of 7) than assays performed at
37°C (total of5).
3.4.2 Anchors Residues and Binding Affinity
- Presence of anchor residues is necessary for peptides binding ....
Peptides containing no anchor residue (peptides 211 and 225) were not found to stabilise
the HLA-A2 molecules at the surface of the T2 cells whereas peptides containing two
preferred anchor residues (peptides 187, 193, 263 and 264) showed strong binding
properties (FR >1.5). Peptides with only one tolerated anchor residue did not show high
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binding capability. However, peptides with one preferred anchor residue at position 9
and either one or none tolerated anchor residue at position 2 did show strong affinity for
lll.A-A2 molecules (FR > 1.5) with the exception of peptides 210 and 224. This
illustrates the need of two anchor residues for peptide binding even though peptide can
bind with only one anchor residue.
- but not sufficient.
Factors other than size and anchor residues are also critical in determining whether or
not a peptide will bind HLA-A2 molecules. Indeed the presence of other residues at non-
anchor positions can either increase or abolish completely the binding affinity of peptide
bearing them. So for peptide of nine amino-acid in length the presence of charged amino-
acid (Acid: P, E, or D) at position 1 or position 6 (Basic: H, R or K) are of most
detrimental effects on the peptide binding affinity (Ruppert, et aI., 1993; Drijthout, et aI.,
1995). On the other hand aromatic residues were associated with high affinity binding at
position 3 and 7. Residues with OH- or SH- containing side chains such as S, T, or C
were favoured at position 4 while A was favoured at position 7 and P was favoured at
position 8. In addition positive contribution as been found for aromatic and positively
charged residues at N-terminus especially Y and K as well as T (Drijfhout, et aI., 1995).
The trend was found to be similar for peptides of 10 amino-acid in length with non-
anchor position shifted to the right and an exception for position 3 where aliphatic rather
than aromatic residues were associated with high binding affinity (Ruppert, et aI., 1993;
Drijthout, et aI., 1995).
Not only do peptides have to bind to MHC molecule with sufficient binding affinity but
they have to remain attached. Computer programs are now available to determine the
half-life of a given peptide.
3.4.3 Peptide Affinity and Immunogenicity
Despite the presence, in a given antigen, of peptides with both anchor residues only a
few will generate CTL ill vitro. One important parameter is the determination of the
efficiency of peptide to bind to MHC molecules. Indeed a strong correlation between
immunogenicity and the stability of MHC-peptide complex has been reported (van der
Burg, et aI., 1996). A peptide with a poor ability to bind to HLA-A2 molecules was also
found to be non-immunogenic. By improving its binding ability it was possible to
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enhance its immunogenicity (Lipford, et aI., 1995). This however does not automatically
imply that peptides with moderate binding affinity are immunologically non-important.
This was the case of the WT p53 149 peptide found to have a moderate binding affinity
(Nijman, et aI., 1994) and yet capable of eliciting CTL in vitro capable of killing peptide-
pulsed target as well as tumour targets (Theobald, et aI., 199511997). Another important
point is that a peptide naturally processed and possessing a strong binding affinity for
MHC. class-I molecules would have been presented to naive T-cells in the thymus and
any reactive T-cells would have therefore been eliminated. This has been reported for
peptide 187-197 where T-cells recognised and killed targets when they were elicited in
mice with no pS3. Whereas T-cells from mice with a normal pS3 did not kill the same
target but were able to kill T2 (transfected with a mouse equivalent for HLA-A2: H-2b)
cells pulsed with the peptide (Theobald, et al., 1997).
When looking at a protein sequence if one selects peptides only based on their amino-
acid sequence and length one would miss potentially immunogenic peptides. To test
every single peptides for binding and then for their ability to generate CTL in vitro would
however be time and money consuming. Kern, et aI., 1998, came up with an attractive
alternative. Peptides of 15 amino-acids in length were used to stimulate PBMC which
were then analysed by a four colours flow cytometry after 6h of incubation. Intracellular
IFN staining serving as an indicator of T-cell activation. Time is indeed gained by using
PBMC instead of CTL clones, by using large number of peptides at the same time and
assessing PBMC after only 6 hours. Using this method Kern, et aI., discovered two new
peptides capable of eliciting an IFN response by PBMC stimulated with them while these
did bot bear any anchor residues in their sequence.
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CHAPTER 4: GENERATION AND CHARACTERISATION OF
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4.1 Introduction
There are many reasons for introducing genes into cells. Indeed, after cloning an
unknown gene the only way to analyse its characteristics is by re-introducing it into
various cell types. Genetic elements responsible for its regulation of expression, the
effect of its overexpression in a given cell line or the consequence of its introduction into
a cell that does not normally express it can all then be determined following gene
transfer. Gene transfer has also been used for therapeutic purposes such as in the
treatment of many different classes of disorders including inherited genetic diseases (e.g.
Cystic Fibrosis), viral infections (e.g. HIV) and cancers (Moelling, et aI., 1997). Many
methods of gene transfer are now available, all with different advantages and
disadvantages.
4.1.1 Transfection Techniques
Transfection of cells can either be transient or stable. In a transient transfection, the
transfected cells are normally used 1-7 days after introduction of the DNA. However, to
avoid numerous transfections it is sometimes preferable to perform stable transfection by
permanently maintaining the transfected DNA in the cell using a selectable maker. Gene
transfer techniques are normally divided into viral, using adenoviruses or retroviruses,
both very useful for ex-vivo applications but limited use for in vivo; and non-viral
physicochemical methods such as 'gene gun', in situ injection of naked DNA, use of
polycations and Liposomes, or electroporation. Most non-viral techniques can be used
for transient or stable transfection.
4.1.1.1 Viral Vectors
DNA can be introduced into eukaryotic cells by using viral vectors. Certain viral gene
transfer systems will result in the overexpression of chosen proteins (e.g. vaccinia
systems) or will allow single-copy stable integrants of expressed genes (e.g. retroviral
systems).
DNA viruses such as adenoviruses can infect both dividing and non-dividing cells.
Adenoviruses however, do not integrate into chromosomal DNA but replicate as
episomal (extrachromosomal) elements in the nucleus of the host cell and their
expression is therefore only transient.
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In vivo one of the major disadvantages of using adenoviruses for gene transfer is that a
potent anti-adenovirus immune reaction is elicited involving both cellular response and
humoral mechanisms.
Retroviruses are generally used for stable gene transduction into a cell line or into cells in
an animal. Because retroviral DNA integrates into the genome of target cells it replicates
during mitosis providing each daughter cell with a copy of the transgene. However, one
of the major disadvantages of retroviral gene transfer is that retrovirus can only
transduce proliferating cells, limiting their application in vivo (Giinzburg, et al., 1995).
Viral systems can be much more efficient than non-viral transfection systems since their
efficiencies of gene transfer are far superior. However, the construction of a recombinant
virus requires considerable effort, and like non-viral systems they are inefficient for
tissue-targeted delivery. In addition, some modification of their genetic material is
necessary to reduce immune reaction in the host.
4.1.1.2 Non-Viral Vectors
The two most commonly used non-viral gene transfer techniques for in vitro
transfection, apart from calcium phosphate precipitation, are liposome-mediated and
electroporation-mediated gene transfer.
In liposome-mediated transfection, the mechanism by which liposomes mediate the
transfection into cells is not well understood. Lipids are mixed and left to incubate at
room temperature with pure DNA before adding the mixture to the cells which are then
incubated at 37°C for 2-6 hours, depending on the optimal condition determined for the
specific cell line. It is thought that negatively charged phosphate groups on DNA bind to
the positively charged liposomes in a ratio that results in a net positive charge for the
complex. The positively charged Iiposome-DNA complex then mediates binding to
negatively charged sialic acid residues on the cell surface. It has been postulated that the
liposome-DNA complex either fuses with the cell surface or is taken up by endocytosis
ultimately resulting in the release of the DNA into the cytoplasm and subsequent
transport to the nucleus (Gao, et al., 1995).
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Electroporation uses an electric field to create transient pores in the ceIl membrane. The
DNA is then thought to diffuse into the cell through the pores (Weaver, et al., 1993).
Several parameters involved in the electroporation procedure play an important role in
the success of the gene transfer into sensitive cells. These include ionic strength and
volume of electroporation, medium, voltage, capacity, DNA concentration, temperature
and pulse decay time (Kalinski, et aI., 1997). The most critical parameter is the voltage
of the electric pulse which needs to be fine-tuned for each cell line in order to optimise
the transfection efficiency.
4.1.2 Potential Applications of Transfection in Anti-Tumour Therapy
4.1.2.1 To Eradicate Tumour Cells Directly
Mutations in the tumour suppressor gene p53 represent the most common genetic
alterations observed in human cancers (Hollstein, et al., 1991) and make it an attractive
target for gene-based therapy. Many tumours bearing an inactive p53 gene become
resistant to chemotherapy and radiotherapy (Righetti, et al., 1996). In vitro transfection
of target cells with recombinant adenoviruses expressing the wild-type p53 cDNA
resulted in the expression of wild-type pS3 protein for 1-2 weeks and restored their
sensitivity to chemotherapy and radiotherapy (Gallardo, et al .. 1996; Geng, et al .. 1998).
Recently another way to specifically infect and kill tumour cells using the p53 cDNA has
been established. The EIB region of the human adenovirus encodes a protein of 5SkD
that binds and inactivates pS3 (Yew, et al., 1992). This represents a vital step for virus
replication. Bischoff and co-workers engineered an EIB-defective adenovirus unable to
produce the 55kD protein. Without this gene the virus cannot inactivate pS3 and is
therefore unable to replicate in normal cells bearing functional p53 gene (Bischoff, et aI.,
1996). However this virus when introduced into tumour cells bearing inactive p53, can
replicate and thereby lyse p53-deficient human tumour cells. When used in p53-deficient
human cervical carcinomas grown in nude mice, complete regression was observed in
60% of the tumours (Bischoff, et aI., 1996).
4.1.2.2 Induction of an Immune Reaction against Tumour Cells
Although there is ample evidence for the presence of tumour-associated antigens on a
variety of tumours, an adequate anti-tumour immune response rarely occurs (Boon, et
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al., 1994). Following the development of new gene transfer techniques the two main
approaches in immuno-gene-therapy against cancers have been the genetic manipulation
of tumour cells or of antigen presenting cells.
There are many reasons why effective immune responses against tumour neo-antigens do
not occur. These include loss or down regulation of the antigen by the tumour cell
(Uyttenhove, et al., 1983), down regulation or loss ofMHC molecules (Ferrone, et al.,
1995) as well as the expression of local inhibitory molecules such as Fas ligand
(Rabinowich, et al., 1998). However in order to obtain an effective immune response
effector T-cells need to be fully activated. This requires at least two signals. The first
signal is delivered by the T cell receptor (TCR) following recognition of a specific
antigenic peptide bound in the cleft of an appropriate MHC molecule. The second signal
is provided by costimulatory molecules on the surface of professional antigen presenting
cells (APC). These APC become activated by cytokines released during for example an
inflammation, which are absent during tumour transformation. So even when tumour
cells present on their surface sufficient level of antigen complexed with appropriate MHC
molecules thereby providing signal one to T-cells if they do not receive the other correct
signal no immune response will occur. There are therefore two major explanations to
account for the unresponsiveness of T-cells, either they do not recognise the tumour cell
(because of lack of antigen or MHC molecules) or become anergic as a result of the
absence of the second signal (Staveley-O' Carroll, et al., 1998). For these reasons many
tumours are poorly immunogenic, but with recent genetic advances the immunogenicity
of tumour cells can be enhanced by genetically engineering tumour cells to produce
cytokines which will recruit and activate APC at the site of the tumour or express
costimulatory molecules such as B7.l rendering them capable of directly presenting
antigen to T-cells (Iezzi, et aI., 1996; Hoshino, et aI., 1998).
Alternatively professional antigen presenting cells can be engineered to express either
cytokines or tumour antigen (Westermann, et aI., 1998; Alijagic, et aI., 1995; Reeves, et
aI., 1996). Interleukin-7 has been shown to provide a potent costimulatory signal to
induce the proliferation of T cells and the generation of cytotoxic T cells (Grab stein, et
aI., 1990; Jicha, et aI., 1991). The transfection of dendritic cells (professional APC) with
the IL- 7 gene significantly increased their capacity to induce T-cell proliferation
(Westermann, et al., 1998). Therefore dendritic cells (DC) that have been simultaneously
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loaded with tumour antigen peptides and gene-modified to secrete specific cytokine(s)
may amplify the response of tumour-specific T-cells. This can further be improved upon
if DC are genetically modified to express tumour-associated antigens (TAA), since (i)
presentation of tumour antigen peptides by MHC molecules persists for longer periods
and (ii) other unidentified tumour peptides may be presented by the host cell MHC
molecules. Indeed, genetically modified dendritic cells are able to raise a potent specific
anti-tumour immune response in vitro (Alijagic, et al., 1995; Reeves, et al., 1996).
4.1.3 Selection of Target Cells and DNA
Once a peptide has been shown to bind to an appropriate MHC molecule (using a T2
binding assay), and is recognised by CTL (causing lysis of the peptide-pulsed T2 cells), it
is necessary to demonstrate that it is naturally processed from endogenous ps3 protein
and presented at the cell surface of cancer cells in association with MHC class-I
molecules. Only peptides, which are naturally processed may be relevant targets for
cancer therapy. In order to assess whether peptides are naturally processed, the relevant
genes can be transfected into cells and the resulting transfectants assessed for recognition
by peptide-specific CTL.
pS3 protein overexpression, present in more than 60% of cancers, is often a consequence
of protein stability acquired by point mutation in the gene. These mutant proteins can be
classified into two groups depending on the effect of the gene mutation on the protein
conformation. Mutants may conserve the 'wild type' conformation for example ps3
mutant 273 (e.g. R->H mutation at amino-acid 273) or acquire a new conformation for
example ps3 mutant 175 (e.g. R->H mutation at amino-acid 175) (Milner, et aI., 1995).
Different protein conformations lead to different proteolytic products when compared
with wild type ps3 degradation (Bargonetti, et aI., 1993).
273-like mutants exhibit similar proteolytic fragments to wild type protein while 175-like
mutant fragments are quite differents. Therefore it is possible that different MHC-
binding-peptides are generated from these two classes of mutants. This is in accordance
with the
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Figure 4.1 a:
pCMV neoBam IS an expression vector containing the cytomegalovirus constitutive
promoter and the neomycine resistance gene under the control of the simian virus 40
promoter. pBR322WTpS3 is derived from pCMVneoBam by insertion of a wild-type
pS3 cDNA.
pBR322-273: is derived from pBR322WTp53 by insertion of a single point mutation at
codon 273 Arg->His.
pBR322-175: is derived from pCMVneoBam by insertion ofa mutant p53 cDNA.
Insertion of cDNAs was done using Bam H I restriction site while all other restriction
sites were destroyed.
For pBR322-175 only one Bam H I restriction site remained.
Figure 4.1 b:
pcDNA3 is an expressing vector containing the cytomegalovirus constitutive promoter
and the neomycin resistance gene under the control of the simian virus 40 promoter.
HLA-A2 gene was inserted.
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fact that heat shock proteins (Hsp), such as Hsp70, have been shown to bind specifically
to 175-like mutants (Hinds, et aI., 1990) leading the protein to the MHC class-lor -II
processing pathways (Srivastava, et aI., 1994~ Williams, et aI., 1995). In order to test
this hypothesis a p53 null cell line (SaOs-2) (Masuda, et aI., 1987~Dittmer, et aI., 1993)
was chosen for the transfection of these two different mutants (175 R->H; 273 R->H).
SaOs-2 is a HLA-A2~ osteosarcoma cell line. Two other cell lines A431 and SKBr3,
which express the 175 R->H (for SKBr3) and 273 R->H (for A431) p53 mutant proteins
were also chosen for I-hesestudies. These cells do not express any HLA-A2 molecules at
their surface as shown by flow cytometry (Figure 4.14) even though the SKBr3 cell line
possesses the HLA-A2 gene (Table 1). It was therefore necessary to transfect these two
cell lines with HLA-A2 cDNA to enable them to present the HLA-A2 p53 peptides.
Plasmid maps of these constructs are shown in Figure 4.1. Transcription of the pS3 and
HLA-A2 cDNAs was driven by CMY promoter, which is highly active in many
mammalian cells.
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4.2 Results
4.2.1 Preparation of Transfection Grade DNA Constructs
4.2.2.1 Preparation of pBR322-273 and pBR322-175
Competent E. coli strain XLI-Blue were transformed with plasmid pBR322+273 as
described in Section 2.2.5.4. A number of transformed colonies were then cultured oln in
selective liquid medium and the amplified transforming plasmid DNA was purified from
each mini-culture as described in Section 2.2.5.5. To confirm the identity of the
constructs, purified DNA was digested with restriction enzyme Bam HI and analysed by
agarose gel electrophoresis as described in Section 2.2.5.7. As seen in Figure 4.2,
digestion of the purified plasmids with Bam HI gave two fragments of 6.5 and 1.8 Kb,
corresponding to the expected fragment sizes of pBR322 and pS3 cDNA. Frozen stock
cells of XLl/pBR322-273 clone Iwere used to inoculate a large scale culture (sOOml)
and DNA was isolated as described in Section 2.2.5.10 to generate highly pure DNA
suitable for mammalian transfection. The above procedure was also used to obtain a
sufficient amount of highly pure DNA of plasmid pBR322-17S. Following digestion with
Bam HI a single linear fragment of -8Kb was obtained, consistent with the size of
pBR322-175 (Figure 4.3).
,
4.2.1.2 Preparation of Transfection Grade Empty pBR322 DNA
In order to obtain the empty pBR322 plasmid (i.e. plasmid without ps3 cDNA insert) for
use as a control for p53 plasmid transfections, 10~g ofpBR322-273 were cut using Bam
HI restriction digestion enzyme and run in an agarose gel (Figure 4.4.a). The 6.5 Kb
bands corresponding to the empty plasmid were cut from the gel, pooled and the DNA
was purified using the QIAEX IIkit (as described in Section 2.2.5.8). To determine the
concentration of the purified DNA, for the purposes of DNA ligation, 2, 1 and 0.5 ul of
the solution was electrophoresced on an agarose gel and compared with serial dilutions
of a high mass ladder (see Figure 4.4b). The concentration of the purified DNA was
estimated to be 0.9 J..tg/J..tl. The linearised empty plasmid DNA was then circularised via
intramolecular ligation as described in Section 2.2.5.6 and introduced into competent
XLI-Blue cells (see Section 2.2.5.4).
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Transfection grade empty plasmid DNA was then generated by amplification of a
selected colony and purification of the DNA using the maxiprep method (Section
2.2.5.10).
Pure empty plasmid was cut using Barn m restriction enzyme and electrophoresced on
an agarose gel in order to confirm the absence of p53 cDNA. The only band present on
the gel after digestion with Barn m was a 6Kb fragment corresponding to the empty
plasmid.
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Figure 4.2: Gel electrophoresis of clone 1 pBR322-273
Purified DNA from each clone was digested with restriction enzyme Bam H I or left
unchanged and analysed by agarose gel electrophoresis.
This is representative example of all the DNA preparations from XL I-BluelpBR322-
273.
The two bands appearing on the gel, after digestion (cut), corresponded to pBR322
empty vector (6Kb) and p53 cDNA (l.8Kb) respectively.
-The two faint bands appearing a t around 8.5-9Kb were denatured plasmid DNA which
are resistant to restriction digestion.
Figure 4.3: Gel electrophoresis of clone 1 pBR322-I75
This is a representative of a number of colony DNAs. This is from XLIpBR322-175
clone 1. The two faint bands appearing at around 11 Kb were denatured plasmid DNA
which are resistant to restriction digestion.
Figure 4.2:
Figure 4.3:
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F"tgUre 4.4.: Separation of empty pBR322 vector from pS3 eDNA
Pure DNA was cut using Bam HI restriction enzyme and run in an agarose gel. The 6ICb
bands correspond to the empty plasmid.
Figure 4.4b: Determination of the quality and quantity ofpBR322 empty removed tn.a
the gel (Bands figure 4 .Sa) and purified.
4~1 of high mass ladder contained 200ns of IOKb fragment. 120ng of 6Kb ftIameata.
SOng of 4Kb fragment and 60ng of2Kb fragments. 2 ~ (lane I), 1~ (lane 2) and O.Spl
(lane 3) of solution was electrophoresced on an agarose gel and compared with --
dilutions of a high mass ladder. Purified empty fragment band on lane 1 compared with
6Kb band intensity of high mass ladder. The brightness of the band compared with 90aa
of high mass ladder giving a concentration ofO.91l8"J.Llof purified empty pBR322.
o
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4.2.1.3 Preparation of Transfection Grade pcDNA3-HLA-A2
The pcDNA3-HLA-A2 construct was previously generated by insertion of the HLA-A2
cDNA into the Eco RI site of the multiple cloning sites of pcDNA3 (see Figure 4.1).
XLI-Blue cells transformed with pcDNA3-HLA-A2 were grown in large scale culture
and the DNA extracted using the maxiprep procedure (Section 2.2.5. 10). Prior to use in
transfection by electroporation, the DNA was linearised using the restriction enzyme Sea
I as described in Section 2.2.5.6, which cuts the construct only once (in the ampicillin
resistance gene). Gel analysis confirmed that the entire DNA was linearised (Figure 4.5).
DNA was then purified using the phenol and ethanol precipitation as described in Section
2.2.5.5 (from* to*using sterile TE).
4.2.1.4 Preparation of Transfection Grade Empty pcDNA3
Empty pcDNA3 was required as a vector control in transfection using pcDNA3-HLA-
A2. Therefore HLA-A2 cDNA was excised from 5ng pcDNAJ-HLA-A2 using the
restriction enzyme Eco RI and loaded across 10 lanes of an agarose gel for preparative
purification. The 5.5 kb bands (Figure 4.6a) corresponding to the empty linearised
plasmid were excised, pooled and the DNA extracted and purified using the QlAEX kit
(Section 2.2.5.8). To determine the concentration of the purified DNA, 2, 1 and 0.5 III of
the solution was electrophoresced on an agarose gel and compared with serial dilutions
of a high mass ladder (Figure 4.6b). The concentration of the purified DNA was
estimated to be 0.44 Ilg/Ill, which was circularised by ligation (Section 2.2.5.4) and
transformed into XLI-Blue (Section 2.25.4).
Empty plasmid was also linearised using the Sea I reaction as for pcDNA3-HLA-A2
(Section 2.2.5.6) before its use in transfection by electroporation.
4.2.2 Geneticin Toxicity Titration for Cell Lines Selection
Before cells could be stabely transfected it was necessary to determine the concentration
of the selective agent (Geneticin) required selecting for the transfected cells. Cells were
plated into 24-well plates to obtain -lO~-o confluency and 24hr later, the media was
replaced with fresh media containing increasing concentrations of Geneticin. The cells
were cultured for 2 weeks and assessed for growth as described in Section 2.2.6.1. The
minimum concentration of Geneticin which resulted in 100% cell death was chosen as
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Figure 4.5: Gel electrophoresis of the linearised pcDNA3-HLA-A2 purified DNA
pcDNAJ-HLA-A2 D~A was grown in large scale, purified, using a maxiprep, and then
linearised using Sea I restriction enzyme.
As can be seen by the picture of the gel all DNA was completely linearised and
therefore ready to be used for the transfection of A431 and SKBr3 cells.
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the concentration for transfection of that cell line. The concentrations required for
selection were found to be 500Ilg/ml for SaOs-2 cells, 200Ilg/ml for A431 cells and
300Ilg/ml for SKBr3 cells.
4.2.3 Transfection of SaOs-2 Cells
Liposorne-mediated transfection was assessed for its effectiveness in transfecting SaOs-2
cells. Four liposome reagents were screened in order to determine the most effective
reagent as described in Section 2.2.6.2.1 using plasmid pCMV-P as a reporter plasmid.
This plasmid encodes the E. coli p-galactosidase gene under the control of CMV
promoter for expression in mammalian cells. Expression was assessed as described in
Section 2.2.6.3.
4.2.3.1 Optimisation of Transfection Conditions
The four Liposome reagents used, only the cells incubated with the Lipofectamine could
be transfected. Cells incubated with the three other reagents were either killed by the
procedure or were unable to be transfected. The optimal concentration of
DNAILipofectamin was determined (Section 2.2.6.2.2) and found to be 1.66 III of
Lipofectamine and 0.42 ug of DNA per well of 9.6cm2. Following the determination of
the optimal DNAILipofectamine concentration, the incubation time required for efficient
transfection was then determined.
Cells were incubated for 2, 3, 4, 5, 6 hrs with the DNAILipofectamine mixture in a 24-
well plate, at 37°C before replacing the mixture with lml of normal pre-warmed growth
medium. The cells were then cultured for 24hr and stained for p-gal expression (Section
2.2.6.3). Optimal transfection efficiency was found with an incubation time of 2hr with
the percentage of cells staining positive for p-gal greater than 20%.
4.2.3.2 Stable Transfection of SaOs-2 Cells
Since the optimal conditions for transfection of SaOs-2 cells were now established, cells
were grown in a 9.6cm2 well (e-well plate) and transfected with 0.42~lg of pBR322-273
mixed with 1.66J.l.I Lipofectamine (amount given for one well) for 2hrs. SaOs-2 cells
were transfected in parallel with pBR322-175 or pBR322 alone. Twenty-four hours after
transfection the medium was replaced with fresh medium and cells were subsequently
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Figure 4.6a: Separation of empty pcD~A3 vector from HLA-A2 cDNA
Pure D"KA was cut using Eco RI restriction enzyme and run in an agarose gel. The
5-r-Kbbands correspond to the empty plasmid
Figure 4.6b: Determination of the quality and quantity of pcDNA3 empty removed
from the gel (Bands figure 4.Sa) and purified.
4111of high mass ladder contained 200ng of 10Kb fragment, 120ng of 6Kb fragments,
80ng of 4Kb fragment and 60ng of 2Kb fragments. 2 III (lane 1), 1111(lane 2) and O.SIll
(lane 3) of solution was electrophoresced on an agarose gel and compared with serial
dilutions of a high mass ladder. Purified empty fragment band on lane 1 compared with
6Kb band intensity of high mass ladder. The brightness of the band compared with
120ng of high mass ladder giving a concentration of 0.441lg/1l1 of purified empty
pcDNA3.
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Figure 4.7.: pS3 expression in Saos-2 cells transfected with pBR322-273 be&n
cloning
Saos-2 cells were transfected with pBR322-273, grown on slides and then labelled widl:
pS3 antibody, after fixation with paraformaldebyde and permeabilisation using 7CJtIa
ethanol. Nuclei were counterstained with DAPI which appear Blue under flUORlClllt
light. The nuclei of all cells and therefore the location of all cells can thereby be IeeD.
Figure 4.7b: pS3 expression in Saos-2 cells transfected with pBR322-273 beIbrii
cloning
The expression of pS3 protein, in green fluorescence, can be seen within the same cella
as mentioned above. Only two cells express the protein.
FIGURE4.7: SAOS-2 CELLS TRANSFECTED WITH pBR322-273, BEFORE
CLONING.
Figure 4.7a: N"'C'~' ~t).\"c"..
\ \ 6
Figure 4.88: Saos-2 cells transfected with pBR322-273 after cloning
Saos-2 cells were transfected with pBR322-273, grown on slides and then labelled with
pS3 antibody, after fixation with paraformaldehyde and permeabilisation using 70%
ethanol. Nuclei were counterstained with diluted ethidium bromide which appear reel
under fluorescent light. The nuclei of all cells, and therefore the location of all cells, can
thereby be seen.
Figure 4.8b: pS3 expression in Saos-2 cells transfected with pBR322-273 after cloning
The expression of pS3 protein, in green fluorescence, can be seen within the same cells
as mentioned above. All cells express the protein.
FIGURE 4.8: SAOS-2 CELLS TRANSFECTED WITH pBR322-273,
AFfER CLONING.
Figure 4.8a: tUudei S-\-o.\n;"-a-
Figure 4.8b: F53 ~P~{O"'I (SQnu c.t.Ll~ )
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passaged 1:10 into selective medium (normal growth medium containing SOOlll/ml of
Geneticin) 72hr post-transfection.
4.2.3.3 Analysis of p53 Expression in the Stable Transfectants
Stably transfected cells were initially grown as bulk cultures and expanded to 2Scm2 or
75cm2 flasks. To determine whether the p53 mutants proteins were expressed following
Geneticin selection, cells were grown in 8-well chamber slides and stained using an
indirect immunofluorescence procedure (Section 2.2.7) with p53 specific antibody DO-7,
which binds to the 35-45 amino-acids of the N-terminus of the protein and recognises
both mutant and wild-type conformations. Stained cells were observed under a
fluorescent microscope.
As can be seen from figures 4.7a and 4.7b not all SaOs-2 cells stably transfected with
pBR322-273 expressed the mutant p53 protein. The same was found with cells stabely
transfected with pBR322-175. Bulk cultures were therefore cloned to obtain a
population in which 100% of the cells express the mutant pS3 protein. Clones were
expanded and tested for pS3 protein expression by indirect immunofluorescence as
described above.
For the pBR322-273 transfectants, 100% of cells from clone 6 were shown to express
pS3 protein (figure 4.8a and 4.8b). These results were confirmed by FACS analysis
(Figure 4.9 ) which also indicated the range of intensities of pS3 protein expression.
Similar results were obtained for the pBR322-I75 transfectants (Figure 4. 10).
4.2.4 Transfection of A431 and SkBr3 Cells
Since the A431 and SKBr3 cell lines do not express HLA-A2 at their surface as shown
by flow cytometry (Figures 4.13c and 4.13e) it was necessary to transfect these cells
with HLA-A2 cDNA to enable them to present the HLA-A2 pS3 peptides. Initial pilot
studies showed that liposome-mediated transfection of A431 and SKBr3 cells was
inefficient, in comparison to its ability to transfect SaOs-2 cells (Section 4.2.3).
Lipofectamine, lipofectin, DMRIE-C and CellFectinwere unable to mediate transfection
ofpCMVI3 reporter plasmid to these cells (no cells stained positive when incubated with
the X-gal substrate; Section 2.2.6.3). Electroporation-mediated transfection was
therefore used as an alternative method of transfection.
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4.2.4.1 Optimisation of Electroporation Procedure
As described in Section 4.1.1.2, voltage is the most critical parameter to obtain efficient
transfection by electroporation. The capacitance was set at 960~D and various voltages
were tested to determine which voltage was the optimum for transfection of these cell
types. With the apparatus available the pulse-time could not be pre-set, but rather varied
according to the voltage, volume, or ionic strength of the solution used. To optimise
transfection conditions for A431 and SKBr3 cells, the pcDNA3-HLA-A2 plasmid was
itself used as a reporter plasmid since it was readily detectable at the cell surface by flow
cytometry. 48 hrs after transfection cell surface expression of transfected HLA-A2 was
detected by indirect immunofluorescence staining using the HB-82 antibody as described
in Section 2.2.2.
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Figure 4.11: Effect of electroporation voltage on the transfection of A431 cells using
pcDNAJ-HLA-A2.
Cells labelled with HB-82 antibody were subsequently incubated with FITC conjugated
goat anti-mouse IgG and analysed by flow cytometry. In order to discriminate between
alive and dead cells, propidium iodide was added to the cells after staining just before
being analysed by flow cytometry.
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As seen from Figure 4.11, the number of transfected A43l cells peaked at a voltage of
260 volts. The level of transgene expression in the transfected cell population indicated
by the mean channel fluorescence intensity of cells alive, not stained by prodium iodide
(greater than 70%), did not significantly change with the voltage applied. Therefore,
since 260 volts was shown to mediate transfection of the highest percentage of cells, this
voltage was chosen to stably transfect the A431 cell line.
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Figure 4.12: Effect of electroporation on the transfection of SKBr3 cells with pcDNA3-
HLA-A2.
Cells labelled with HB-82 antibody were subsequently incubated with FITC conjugated
goat anti-mouse IgG and analysed by flow cytometry. Untreated cells were used as a
negative control for background staining by HB-82. In order to discriminate between
alive and dead cells, propidium iodide was added to the cells after staining just before
being analysed by flow cytometry.
As can be seen from the results presented in Figure 4.12 the number of transfected
SKBr3 cells peaked at a voltage of 280 volts. The level of transgene expression in the
transfected cell population, indicated by the mean channel fluorescence intensity of cell
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alive (greater than 70%), did not significantly change with voltage applied. Therefore,
since 280 volts was shown to mediate transfection of the highest percentage of cells, this
voltage was chosen to stably transfect the SKBr3 cell line.
Table I: Revised Summary Table
Cell Line P53 Status HLA-A2 Expression Transfected with
SaOs-2 Null +++ 1)pBR322-273
2)pBR322-175
3)pBR322 (empty)
A431 Point Mutation - 1)pcDNA3-HLA-A2
273 (R->H) 2)pcDNA3 (empty)
-
SKBr3 Point Mutation 1)pcDNA3-HLA-A2
175 (R->H) 2)pcDNA3 (empty)
4.2.4.2 Stable Transfection
A431 and SKBr3 cells were stably transfected by electroporation with pcDNA3-HLA-
A2 using the voltages determined in Section 4.2.4.1. Immunostaining of cells for HLA-
A2 expression 48hr post-transfection indicated that 76.45% of SKBr3 cells and 37.82%
of A431 cells expressed the transfected HLA-A2 cDNA (Figures 4.13d and 4.13f). Cells
expressing high levels of HLA-A2 were sorted, using a Vantage FACSsort (Section
2.2.2.2) and subsequently selected for stable transfectants by culture in medium
containing 200 ug/rnl or 300llglml Geneticin for A431 and SKBr3 respectively (see
Section 4.2.2). Stably transfected cultures were regularly assessed for HLA-A2
transgene expression. A summary of all generated transfectants is presented on Table 1.
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Figure 4.9: pS3 protein expression in Saos-2 cells untransfected (1), after transfection
with pBR322-273 before cloning (2) and after cloning (3).
Cells were fixed with paraformaldehyde and permeabilised with 70% ethanol before the
addition of either isotype control (IgG2b) antibody (A) or pS3 antibody (DO-7) (B).
Cells were then incubated with FITC conjugated goat anti-mouse IgG and analysed by
flow cytometry.
Graphs show no pS3 protein expression in Saos-2 cells (B 1), different population of
cells expressing pS3 protein in Saos-2 1273 cells before cloning (B2) and a single
population of Saos-2 1273 cells expressing pS3 protein after cloning.
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Figure 4.10b: p53 protein expression in Saos-2 cells transfected with pBR322-175 after
cloning.
Cells were fixed with paraformaldehyde and permeabilised with 70% ethanol before the
addition of either isotype control (IgG2b) antibody (A) or pS3 antibody (00-7) (B).
Cells were then incubated with FITC conjugated goat anti-mouse IgG and analysed by
flow cytometry.
A single population of Saos-2-17S cells can be seen expressing pS3 protein.
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Figure 4.14: Cell surface HLA-A2 expression on transfected A431 and SKBr3 cells.
Cells labelled with HB-82 antibody or no first antibody were subsequently incbated
with FITC conjugated goat anti-mouse IgG and analysed by flow cytometry.
(A) JY cells no first antibody, (B) JY cells positive control, (C) SKBr3 cells transfected
with HLA-A2 vector control, (0) SKBr3-A2, 76.45% positive, (E) A431 transfected
with HLA-A2 vector control, (F) A431-A2, 37.82% positive.
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Figure 4.15: Effect of cytokines treatment on the cell surface HLA-A2 expression on
transfected cells.
Cells labelled with HB-82 antibody were subsequently incubated with FITC conjugated
goat anti-mouse IgG and analysed by flow cytometry. Cells were either untreated (filled
blue) or pre-treated for 24hr with 200U/ml rhIFN- and lOOU/ml rhTNF- before staining
(red line). (A) A431-A2, (B) A431 cells transfected with HLA-A2 vector control, (C)
SKBr3-A2, (D) SKBr3 cells transfected with HLA-A2 vector control, (E) Saos-2/175,
(F) Saos-2/273, (G) Saos-2 cells transfected with pBR322 vector control.
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4.2.5 EtTect of IFN-y and TNF-a on the Expression of HLA-A2 Transgene
IFN-y and TNF-a are known to up regulate MHC class-I molecules. Increased numbers
of lll..A-A2 molecules on the surface of target cells increases the possibility of antigen
recognition by T cells (Andalib, et aI., 1995). Therefore, IFN-y and TNF-a have the
potential to enhance antigen presentation. Pilot studies using SW480 and MCF7 cell lines
found that the optimum concentration of and incubation time with IFN-y and TNF-a for
the upregulation of lll..A-A2 molecules, used together, was 200 Vlml for IFN-y and
1000 Vlml for TNF-a when the cells were incubated for 24hr.
All transfected cells were therefore treated with this optimal cytokine combination for
24hrs and the affect on lll..A-A2 molecule expression was determined as described in
Section 2.2.2.2.
As shown in Figure 4.15, the combination of IFN-y and TNF-a increased the expression
of lll..A-A2 in cells possessing either an endogenous lll..A-A2 gene (SaOs-2 cells and
SKBr3) or cells transfected with pcDNA3-HLA-A2 (A431 and SKBr3). No change was
observed for A431 cells transfected with empty pcDNA3 vector. However SKBr3 cells
transfected with the same empty vector showed an upregulation of HLA-A2 expression
in response to the cytokine treatment, suggesting that activation of the normally silent
endogenous HLA-A2 gene may have occurred. However, the level of HLA-A2
expression was relatively low and approximately one order of magnitude lower than
either SKBr3 transfected with pcDNA3-HLA-A2 or IY cells.
4.2.6 Targets Cells Sensitivity to LAK Cell Mediated Lysis
Before transfectants could be used as targets for CTL, it was necessary to ensure that
they were susceptible to lymphocyte killing; for these assays IL-2-activated PBMC
effector cells were used. Fresh PBMC were separated from whole blood of healthy
donors as described in Section 2.1.6. These were then cultured in medium only or in
medium supplemented with IL-2 (500 Vlml) (see Section 2.2.9) for 4-5 days to generate
LAK cells. The sensitivity of all target cells to LAK activity was determined by standard
chromium release assay (described in Section 2.2.4). Results are shown Figures 13-a, -b,
and -c. As can be seen all target cells were sensitive to LAK cytotoxicity, but relatively
insensitive to unactivated PBMC.
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Figure 4.15: Sensitivity of all target cells to LAK activity
All target cells were labelled with 51Cr and mixed with either IL-2 activated PBMC
(noted +) or with non-activated PBMC (noted-) at different effector: target ratios.
These were done in duplicate for at least two different donors.
Figure 4.15a: Column blue, yellow and red show the sensitivity of the Saos-2 cells
transfected with pBR322 empty plasmid, pBR322-273 and pBR322-175 respectively to
IL-2 activated PBMC (+).
Figure 4.15b: Column blue and yellow show the sensitivity of the A431 cells
transfected with pcDNA3-ffi.A-A2 and pcDNA3 empty plasmid respectively to IL-2
activated PBMC (+).
Figure 4.15c: Column blue and yellow show the sensitivity of the SKBr3 cells
transfected with pcDNA3-ffi.A-A2 and peDNA3 empty plasmid respectively to IL-2
activated PBMC (+).
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4.3 Conclusion and Discussion
SaOs-2 cells were successfully transfected with pBR322-17S and pBR322-273 pS3
constructs or vector alone using the liposome Lipofectamine after optimisation of the
conditions. A431 and SKBr3 cells lines were successfully transfected by electroporation
with pcDNAJ-HLA-A2 cDNA or vector alone. Protein expression from the transgenes
was confirmed by indirect immunofluorescence followed by flow cytometry and/or
fluorescence microscopy. All transfected cell lines were susceptible to killing by IL-2
activated PBMC (LAK cells), but not by untreated-PBMC, and were therefore
considered to be suitable targets for anti-pS3 peptide CTL studies.
As described previously, transfer of genetic material can be achieved by different
methods. The pS3 peptide repertoire displayed by MHC at the surface of a given tumour
cell might depend upon the conformation state of the pS3 protein (Section 4.1.3) and the
efficiency of protease processing. In order to test the hypothesis, that protein
conformation differences affect processing mechanisms, resulting in different peptide
repertoires on the surface of cells expressing these protein (SaOs-2 transfected cells,
A431 and SKBr3 cells), it is necessary to assess the sensitivity of these cells to lysis
induced by pS3 peptide-specific CTL. This chapter details the preparation and
characterisation of these targets.
SaOs-2 cells were successfully transfected with either mutated pS3 cDNA or vector only
using the liposome-mediated method with Lipofectamin reagent. Wild-type pS3 gene
could not be transfected into the pS3 null SaOs-2 cells because of its detrimental effect
on the cell cycle. The pS3 protein was expressed to high levels in a cloned line (clone 6)
as assessed by immunofluorescence and flow cytometry, and A431 and SKBr3 cells
expressing mutant pS3 protein (see Section 2.2.6) were successfully transfected with
HLA-A2 cDNA using the electroporation since liposome-mediated transfection did not
prove to be a successful method for transfecting these cells. Although, non-viral methods
can be used to transduce genes for the permanent expression of a given transgene the
optimal method remains cell type dependent.
Transfection is a powerful technique, but it is essential to standardise the procedure for a
given cell line. A number of parameters need to be determined before the transfer of
genetic material can be applied in vivo. It is essential to define the target cells as well as
efficiency of gene delivery, protein modification, immunological status, and accessibility.
In contrast to in vivo gene delivery systems, in vitro methodology can and has been used
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for the successful transduction of genetic information. Antigen presentation capability of
tumour cells is very often either impaired or inefficient. By fusing tumour cells with
allogeneic, activated dendritic cells, ill vitro, Geng, et aI., were able to stimulate naive T
cells in the primary mixed lymphocyte reaction (MLR) and induce a tumour-specific CTL
ill vivo. These resulting hybrid cells showed to present tumour antigen via MHC c1ass-I
molecules to cytotoxic T cells, and at the same time to activate efficiently T helper cells,
via allogeneic MHC class-II molecules. More over the first clinical trials with hybrid cell
vaccination have provided evidence of tumour regression in renal cell carcinoma and
melanoma patients (Kugler, et al., 1998). Therefore by increasing tumour antigen
presentation capabilities one improve their immunogenicity. The transfection of dendritic
cells with tumour-associated antigens and / or cytokine genes have shown to induce
tumour specific cellular immunity both in vitro and in vivo (Bakker, et aI., 1995; Tilting,
et al., 1997).
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5.1 Introduction
5.1.1 Cell Mediated Immunity
Immune responses are mediated by a variety of cells and by the soluble molecules they
secrete. Although leukocytes are central to all immune responses, other cells in the
tissues also participate by signalling to the lymphocytes and by responding to the
cytokines released by T-lymphocytes and macrophages. Leukocytes, white cells of the
blood, include three groups:
- Lymphocytes: B-cells producing antibodies, T-cells (Th 1 and Th2) producing
cytokines, Large granular like lymphocytes amongst which the Natural Killer cells (NK
cells) producing cytokines.
- Phagocytes: Mononuclear phagocytes (Dendritic cells, Monocytes, Macrophages),
Neutrophils and Eosinophils.
- Auxiliary cells: Basophils, Mast cells and Platelets, all producing inflammatory
molecules.
One more group can be added: Tissue cells, producing IFN and other cytokines.
Different pathogens will elicit different immune responses involving different cell types.
Extra-cellular pathogens and toxins are generally eliminated by antibodies, whereas
virally or bacteria infected cells are eliminated by activated- T-lymphocytes: Cytotoxic T-
Lymphocytes (CTL).
Virally infected cells and tumour cells bear some resemblance in the way they present
antigen to the immune system and one would assume that they would therefore generate
similar immune reaction following their appearance in the body. This is, however, not the
case and is explained below.
5.1.1.1 Viral Immunity
Viruses are a group of organisms that must enter a host cell to proliferate, since they lack
the necessary biochemical machinery to manufacture proteins and metabolise sugars.
Some viruses also lack the enzymes required for nucleic acid replication, and are
dependent on the host cell for these functions as well. Once inside the cell they take over
the cell's own biosynthetic machinery to produce new virus particles that are, for some
of them, endogenously processed and presented on the cell surface as peptides
complexed with MHC class-I molecules. In doing so, the virus often kills the cell whose
content, poured out, may cause some tissue damage. This provides the danger signal
132
necessary to trigger an immune response. Tumour cells, however, which arise from
inappropriate (anarchic) activation or inactivation of genes involved directly, or
indirectly, in the control of cellular growth, differentiation, and cell death, grow, as a
result, in an uncontrolled manner but with very little, if any, cell damage. Therefore no
danger signals are provided to the immune system and leukocytes are neither attracted
nor stimulated. As a result of tissue damaged phagocytes are attracted to the injury site
and clear up any potentially harmful molecules as well as virus proteins and virus
themselves. These are processed and presented to T-helper cells through class-Il
molecules and to pre-cytotoxic T-cells through the MHC class-I molecules. The two
different processing pathways giving rise to peptides associated with either MHC class-I
or class-Il molecules are explained in detail in Section 1.1.2. Once activated the T-helper
cells secrete many important cytokines such as IL-4 and IL-5, which stimulate the pre-
activated B-cells to produce antibodies, and IL-2, which is required for activation of
CTL. However, resting T-cells which recognise antigen without any 'help' signal become
tolerant (Guerder, et al., 1992), and cytokine secretion by T-helper cells into an
environment containing no cytotoxic T cells would be ~ UI"\do.rv-t .
. Therefore, for effective CTL priming, this 'help' must be provided in
a cognate manner such that both T-helper cell and CTL recognise antigen on the same
antigen-presenting-cell (APe) (Keene, et aI., 1982~Bennett, et aI., 1997). The chance of
a rare T-helper cell and equally rare eTL coming in contact with the same APe is very
low indeed and moreover this would not explain why some immune responses can be
elicited without the need for T helper cells (Buller, et aI., 1987).
Matzinger and co-worker (Ridge, et al., 1998), suggested instead a sequential activation
mechanism where by T-helper cells deliver a signal that activates the APe by recognising
antigen on them. The activated APC would then directly stimulate the eTL. These
professionals APe have been identified as being dendritic cells. They take up antigen in
the whole body tissues and migrate to lymph nodes where they present antigen to T cell
(Steinman, et aI., 1991). The molecules responsible for the interaction between the T-
helper and dendritic cells are eD40L, a membrane molecule expressed by T cells that
have been stimulated, and CD40, a surface receptor expressed on dendritic cells
(Banchereau, et al., 1998). Their interaction results in the activation of dendritic cells. As
a result their capacity to present antigen and co-stimulatory capacity are increased,
rendering them capable of signallingdirectly, avoiding the requirement for T-helper cells
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(Sallusto, et aI., 1994; Caux, et aI., 1994; Cella, et aI., 1996). However, in the case of
tumour where tumour-specific-antigens are normally encountered outside any cell
damaged or inflammatory context this concept opens new possibilities to elicit potent
immune responses. For example by stimulating dendritic cells, using CD40 antibodies, or
pulsing them with peptides recognised by specific- T-helper cells, one could boost a
normally weak response to tumour-specific antigen (Bennett, et aI., 1998; Schoenberger,
et al., 1998).
How CTL then kill the infected cells or tumour target is discussed below.
5.1.1.2 How Do CTL Kill?
Two molecular mechanisms of cellular cytotoxicity appear to have evolved independently
in lymphocytes. The first one is the granule exocytosis pathway. In this pathway, upon
interaction with the target cell, the cytotoxic effector cell releases the content of its
cytoplasmic granules in a direct manner into the intercellular space between lymphocyte
and target cell. These cytoplasmic granules contain granzymes and perf orin. Perf orin is a
glycoprotein of 534 amino-acids with sequence homology to the membrane attack
complex-forming complement C9. In analogy to C9, perf orin is able to integrate into the
target cell membrane and polymerase in the presence of Ca++ forming polyperforin pores
comprising 12-18 monomers of 10-20nm diameter. The permeabilisation of the target
cell membrane finally leads to the death of the target cell.
Perforin expression is mainly confined to CD8+ T cells, NK cells and yc5 T cells (Smyth,
et al., 1990; Nakata, et aI., 1990), and the expression level of perforin in vivo during a
viral interaction correlates with the kinetics of the cytotoxic activity (Mueller, et aI.,
1989; Young, et al., 1989). The granules-associated serine esterases, called granzymes,
and especially granzymes B, enter the target cells through the perforin channel and then
initiates apoptosis by cleaving and activating members of the ICE! Ced-3 family of cell
death proteases (Hudig, et al., 198111993).
Other effector mechanisms account for lymphocyte-mediated cytotoxicity. These include
effector molecules such as TNF (Liuu, et al., 1987) and induction of cell death in the
target cell by the interaction of Fas ligand expressed on activated T cells with Fas
receptor expressed on the surface of the target cells (Kagi, et al., 1994a11994b; Lowin,
et al., 1994). Fas, also called Apo-I or CD95, was originally isolated with two
independent antibodies that induced apoptosis in various human cell lines (Trauth, et al.,
134
1989). Fas belongs to the tumour necrosis factor (TNF) receptor and nerve growth
factor receptor family, and it shares with TNF receptor a conserved extracellular region
and a cytoplasmic domain, which is essential for the induction of apoptosis (Nagata, et
al., 1995). Dependent on the target cell, CD8+ T cells confer lysis by either a perf orin-
dependent pathway alone or by the concomitant action of the perf orin-dependent and the
Fas-dependent pathway.
Perf orin-dependent granule exocytosis pathway has been found however to be the main
cytotoxic pathway (Kagi, et aI., 1994a).
5.1.1.3 Cellular Responses against Tumour in Vivo
It is now clear that at least some human tumours can elicit a cellular immune response
(Boon, et aI., 1994). Lymphocytes derived directly from tumours lesions and draining
lymph nodes have been isolated and used in adoptive immune transfer protocols with
some success in patients with melanoma and with significant clinical responses in patients
with renal cell carcinoma (Rosenberg, et al., 1988; Topalian, et aI., 1988; Kradin, et al.,
1989). These CTL recognised antigens that are tumour specific and MHC restricted.
This restricted specificity is the result of the in vivo antigenic priming of the CD8+ cells
with antigen expressed on the tumour they infiltrate (Barth, et aI., 1990).
Autologous tumour-specific CTL have indeed been found among TIL, lymph node
lymphocytes or PBL- T cells in patients with metastatic melanoma (Topalian, et aI.,
1989); ovarian cancer (Ionnides, et aI., 1991); renal cell carcinoma (Finke, et aI., 1992)
and many other cancers. Their isolation and manipulation ex-vivo has allowed the
discovery of many antigens (see Section 1.2). Immunotherapies using the patients' own
immune system to participate in the elimination of the tumour cells can therefore be used
to complement conventional therapies that are unsuccessful for many cancers. Cervical
cancer is one example where after optimal primary treatment of low-risk early-stage
disease, recurrent disease is found in 15% of the patients (Larson, etal., 1988). More
over treatment results of recurrent disease are relatively poor (Lawhead, et aI., 1989).
Some tumour variants resistant to TIL have been shown to be present in the tumour
population (Topalian, et aI., 1990). This represents a critical finding since CTL resistant
tumour variants can escape TIL therapy. In addition, freshly isolated TIL have a low
cytolytic potential because of the micro-environment of the tumour which profoundly
affects the cytotoxic capacity of these immune cells (Miescher, et aI., 1986).
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Many strategies have since been developed to expand or stimulate in vitro these immune
cells derived either from TIL or PBMC of the patient. These include the cloning and
expansion in vitro of therapeutic CTL found in TIL, the stimulation of PBMC from
patients using different antigens recognised by more than one HLA-allele (to avoid
escape) or using combined MHC cJass-I and class-II antigens. The search for tumour-
specific antigens is still ongoing and a number of potential candidates have already been
found, especially in melanoma, but also in other tumours. These are reviewed in detailed
in Section 1.2.
5.1.1.4 Cancer Vaccines Prospects
A tumour vaccine is aimed at activating or boosting weak immune responses against
tumour-antigens to which the immune system has, in most cases, already been exposed,
and should lead to tumour rejection. It must be safe, must produce immunity in a very
high proportion of the people to whom it is given and must be cheap. A successful
vaccine will generate long-live immunological memory, meaning that the vaccine must
prime both Band T-cells.
There are, mainly, two types of tumour vaccines, (1) cell-based cancer vaccines, or (2)
peptide-based vaccines. These can either be used to stimulate the patient's own immune
system to eradicate the tumour (Active immunotherapy) or to directly fight the tumour
(Adoptive immunotherapy). Active immunotherapy requires that the patient is
immunologically competent and that tumours can be selectively recognised by the
immune system. On the other hand adoptive immunotherapy main problem is to generate
sufficient numbers of cells with the correct homing ability. Cell based-vaccines have
originally consisted of killed tumour cells or tumour lysates mixed with adjuvants (Berd,
et al., 1990). In most cases these did not induce strong tumour-specific immunity due to
the inadequate co-stimulation on activation of tumour-specific T-helper cells (Kern, et
al., 1986). It was therefore thought that their antigen presentation could be enhanced by
genetically moditying them. So by transfecting irradiated tumour cells with co-
stimulatory molecules such as B7 molecules or with cytokines genes such as IL-2 or
GM-CSF, CD8+ cells could directly be stimulated without the need of APC or T-helper
cells (van Elsas, et al., 1997~Gansbacher, et al., 1990~Fearon, et al., 1990~Townsend,
et al., 1993). In this approach, however, the antigen content as well as cytokine level
produced and secreted are unknown and there is the problem of inherent genetic and
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phenotypic diversity resulting from the in vitro culture of tumour cells. In addition the
method is patient-specific and therefore costly and labour intensive. Since MHC
compatibility between patient and tumour is not required, one way to obviate the need
for culture or transduction of each patient's tumour cells, is to use allogeneic tumour cell
lines as vaccines (Toes, et al., 1996).
When tumour antigens are known, peptide-based vaccines can be administrated together
with appropriate vehicle (adjuvant) to the patient. This has indeed proved very promising
with patients with advanced melanoma (Marchand, et aI., 1995). Many different
adjuvants have been tried, amongst which are complete or incomplete Frafti's adjuvant,
peptide conjugated with KLH (Keyhole Limpet Hemocyanin) or BCG, all of them aiming
at boosting the immune response by stimulating the T-helper cell. More recently,
approaches to immunise without the use of adjuvants include the use of dendritic cells.
These have successfully been used as vehicle to transport and present tumour antigen
directly to CTL in vivo. Dendritic cells were either pulse with known immunogenic
peptide, unfractionnated acid-eluted peptides or with tumour lysates. Peptide-pulsed
dendritic cells resulted in the generation of CTL-mediated cytoxicity against peptide-
positive tumour targets providing a complete and long lasting protection against
challenge (e.g. epitope from the E7 protein, De Bruijn, et al., 1998; mutated p53
peptide, Gabrilovich, et aI., 1996). These were also effective at rejecting tumour, even
when the tumour was already established such as 3LL lung cancer (Mayordomo, et al.,
1998). As stated before active immunotherapy depends upon the intact host immune
system, which is frequently not the case. In adoptive immuntherapy however CTL are
generated in vitro and their clear sensitisation and specific cytotoxic abilities towards
tumour cells only can be demonstrated. Successful adoptive immunotherapy have been
reported in immuno-suppressed persons where EBV -specific CTL were generated and a
response to the virus for up to eighteen month was detected (Heslop, et aI., 1996). Good
clinical response rates (33%) was observed in patients with advanced melanoma when
TIL (Tumour Infiltrating Lymphocytes) were cultured with low doses of IL-2 before re-
infusion (Arienti, et aI., 1993). These responses were found to correlate with tumour-
lysis by TIL in vitro. The way TIL are cultured before reinfusion may greatly influence
their composition and function, and therefore therapeutic efficacy. IL-2 in combination
with IL-12 in vitro strongly enhanced the development of tumour-specific CDS'" CTL
and prevented overgrowth of non-specific, LAK cells as reported for TIL derived from
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breast cancer, renal cancer and neuroblastoma (Kuge, et aI., 1995).
Combined sequential active then adoptive immunotherapy may be another approach to
boast responses the tumour. Chang, et ai, 1997, started by irradiated autologous tumour
cells and injected them to the patients with BCG. A week later, draining lymph node cells
were isolated and reactivated by culturing them with CD3 mAb and IL-2 and finally
reinfused to the patients, partial and complete responses were so obtained.
Different APC have been used for the generation of CTL in vitro and these are described
below.
5.1.2 Generation of CTL in Vitro
Peptides that have been found to bind to HLA-A2 molecules, with high affinity, need to
be tested for their capability of inducing a CTL response ill vitro before they can be
considered as potential candidate for immunotherapy. The primary stimulation of CTL in
vitro is important and requires correct presentation of the peptide as explained in Section
5.1.1.2. Many different techniques have taken advantage of different cell types for the
induction ofCTL in vitro some of them are reviewed below.
5.1.2.1 Using T2 cells
T2 cells are lymphoblastoid, HLA-A2+, cells that are deficient in antigen processing (see
Section 3.1.2.2). Their inability to process and present their own peptides but on the
other hand their capacity to present empty HLA-A2 molecules that can be stabilised by
exogenously added peptides has been used to study ill vitro binding capacity of different
peptides. Their potentially high number ofMHC class-I molecules on their surface made
them good APC candidate for the induction of eTL ill vitro. T2 cells loaded with high
concentration of p53-peptide were indeed capable of generating stable peptide-specific
CTL clones (Houbiers, et al., 1993). Using the same protocol more peptides from the
pS3 protein capable of inducing eTL and a novel conserved CTL epitope in an HIV -1-
seronegative donor were identified in vitro (Nijman, et aI., 1993; Gnjatic, et aI., 1995;
van der Burg, et al., 1995). More over eTL generated with the 264-272 peptide from
the p53 protein were showed to kill not only peptide-pulsed target as previously reported
but also human carcinoma cells overexpressing p53 protein (Ropke, et aI., 1996). These
results were important since they meant that, as far as p53 protein is concern, using in
vitro stimulation of eTL with T2 cells as APe natural tolerance could be broken.
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As mentioned earlier the main advantages in using T2 cells as APC is their potentially
high number of MHC molecules on their surface and the certainty that peptide chosen for
the induction of CTL does bind to HLA-A2 molecules. However these cells lack some
important co-stimulatory molecules that are necessary for the activation of CTL
especially for weaker antigen.
5.1.2.2 Using B Cell Blasts or Whole PBMC
Alternatively B cells, either alone (B cell Blasts) or as part of leukocyte mixture (PBMC)
can be used as APC. These have the advantage of expressing co-stimulatory molecule
B7.1, which stimulates the capacity of the responder cells to produce IL-2 (van der
Bruggen, et al., 1994). B-cells or PBMC pulsed with p53 or MAGE-3 peptides were
showed to induce CTL that recognised tumour cells expressing pS3 protein and MAGE-
3 respectively (van der Bruggen, et al., 1994; Ropke, et al., 1995; Gnjatic, et al., 1998).
It seemed therefore unnecessary to specifically isolate B cell Blasts for the induction of
CTL in vitro.
5.1.2.3 Using Dendritic Cells
It is now clear that dendritic cells play a strategic role in the control of immunity and
their use in the induction of CTL in vitro has become crucial. They, indeed, combine
advantages of both T2 cells, with their large number of MHC-peptide complexes at their
surface, and B cells, expressing many accessory molecules that enhance adhesion and
signalling (co-stimulation) of T-cells (lnaba, et al., 1997~ Caux, et al., 1994). In addition
they secrete high levels of IL-12, known to increase both innate (natural killer) and
acquired (B and T cells) immunity (Cella, et al., 1996). The presence of dendritic cells in
small numbers, within whole blood as well as the lack of specific markers has, until
recently, limited their use. Advances in methods to generate large numbers of DC from
precursors in blood or bone marrow have overcome these limitations. Several methods
of maintenance and in vitro expansion of DC have been described involving culture in
GM-CSF and! or other cytokines such as IL-4, TNF and stem cell factor (Romani, et al.,
1994). DC represent the most potent APC known so far and one dendritic cell is capable
of stimulating up to 3000 I-cells (See Section 5.2.2.2). Another important characteristic
of dendritic cells is their ability not only to present exogenously added peptides but also
actively pick up and process exogenous antigen, and presenting them through the MHC-
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class-I pathway (Shen, et al., 1997). More over it has been shown that they can acquire
antigen from apoptotic cells and induce class-I restricted CTL (AJbert, et al., 1998);
explaining the correlation with the number of dendritic cells found in tumour and good
prognosis for the patient (Becker, 1993).
Dendritic cells pulsed with either peptide or unfractionated tumour-derived peptide
induced not only in vitro antigen-specific immunity but also clinical responses (Hsu, et
al., 1996; Nair, et al., 1997; Nestle, et al., 1998).
5.1.3 Aims
The aim of this study was to assess the ability of the p53 peptide 217-225 to generate
peptide-specific CTL in vitro capable of killing first peptide-pulsed target then tumour
cells expressing HLA-A2 'naturally' or transfected with the gene and overexpressing
mutated p53 protein either 'naturally' or transfected with mutated p53 gene.
Of particular interest was the potentially different processing pathways of the pS3 protein
depending on its conformation (mutant or wild-type) and the expression and recognition
by these CTL of peptide 217-225 and 264-272.
p53 peptide 264-272 was used as positive control for the generation of CTL in vitro
once optimum conditions were found.
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5.2 Results
5.2.1 Generation of CTL Using Whole PBMe
PBMC isolated from healthy donors (see Section 2.2.3.1) were separated and cultured as
described in Section 2.2.3.3. Briefly, PBMC were cultured with 50llg of peptide in AIM-
V medium containing IL-7 and KLH. On day 3 IL-2 was added to the cultures. On days
7 and 14 responder cells were restimulated with peptide-pulsed and Mitomycin C treated
autologous PBMC in AIM-V medium containing IL-2. On day 21 the cytolytic activity
of the generated CTL cultures was assessed in a standard 4hr SICr release assay as
described in Section 2.2.4.
The first experiment to generate peptide specific CTL utilised whole PBMC: A number
of conditions (culture and cyto-assay) were then assessed, in order to improve the
sensitivity of detection of peptide specific lysis. These conditions included the
recognition of target cells by CTL, initial number of potential CTL and promoting the
development of killer cells.
5.2.1.1 Cytotoxicity Enhancement Using MA2.1 Antibody
Monoclonal antibodies against HLA-A2 molecules normally inhibit the recognition of
target cells by specific CTL. Antibody MA2.1 however not only does not inhibit this
recognition but has also been shown to actually enhance it. When target cells were pre-
incubated with MA2.I antibody, followed by incubation with peptide, higher percentage
of cells were killed and less peptide were required for the same effect than when targets
were not treated (Bodmer, et al., 1989). The antibody seems to enable HLA-A2
molecules to bind peptide at the cell surface more efficiently, thereby stabilising the
MHC-peptide interaction. Preliminary experiments were performed in order to determine
whether inclusion of the MA2.1 antibody in the cyto-assay could increase the sensitivity
of lysis using peptide pulsed T2 or N cells as targets. MA2.1 was added to the target
cells at the time of SICr labelling, the cells were washed twice and incubated with the Flu
matrix peptide (M58-68). These cells were then added the responder cells at different
Effector: Target ratio. The responder cells were CTL generated with the Flu peptide. As
can be seen from Figure 5. 1, which is a representative of two donors with each ratio
performed in triplicate, the level of cytotoxicity was increased by almost 25% when
target cells were treated with the antibody. Therefore, in further experiments with T2 or
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Figure 5.1: Effect of pre-treatment of target cells (JY) with MA2.1 antibody on the
level of cytotoxicity of CTL.
CTL were generated after following stimulation of PBMC from healthy HLA-A2+
donors with Flu peptide and two subsequent restimulations with peptide-pulsed and
mitomycin C treated autologous PBMC.
Cytotoxicity of effector CTL was determined by percentage release of SlCr from 51Cr
labelled JY target cells pre-treated with MA2.1 and peptide-pulsed (Red column), pre-
treated with MA2.l but no peptide-pulsed (Yellow column), peptide-pulsed JY cells
(Pink column) and JY alone (Blue column).
Figure 5.2: Effect of CDS+ enrichment on the level of cytotoxicity of CTL against
JY pre-treated with MA2.1 and +/- peptide-pulsed.
CTL were generated after following stimulation of PBMC from healthy HLA-A2+
donors with Flu peptide and two subsequent restimulations with peptide-pulsed and
mitomycin C treated autologous PBMC.
Cytotoxicity of effector CTL was determined by percentage release of 51Cr from 51Cr
labelled JY target cells pre-treated with MA2.l and peptide-pulsed (Red column), pre-
treated with MA2.1 but no peptide-pulsed (Yellow column), peptide-pulsed JY cells
(Pink column) and JY alone (Blue column).
Cytotoxicity of CTL enriched in CD8 -r- cells against JY cells pre-treated with MA2.1
and peptide-pulsed (Yellow column), against JY cells pre-treated with MA2.1 (Pink
column).
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Figure 5.2
IY cells, they were pre-incubated with MA2.1 antibody prior to incubation with peptides
in the cyto-assays.
5.2.1.2 Effect of CD8+ Cell Enrichment on the Level of Cytotoxicity
The levels of peptide-specific cytolytic activity were generally low after stimulation of
whole PBMC and their activity or detection might have been diminished or obscured by
the presence of other cells. One way to increase their final number is by removing all
unnecessary cells at the beginning of the culture. Amongst the leukocytes, monocytes,
macro phages and B cells tend to stick to the plastic plate and were therefore removed as
the culture was expanding. C08+ T cells are the main effector cell for cytolytic activity,
and enrichment for C08" T cells may therefore enhance levels of cytolytic activity. This
can be achieved by removing C04T cells. To test whether this would indeed increase the
number of target cells killed on day 21, PBMC were depleted of C04+ cells on day 7
using magnetic beads coated with anti-C04 antibody as described in Section 2.2.3.3 day
14. The rest of the CTL generation procedure was followed unchanged as described in
Section 2.2.3.3. As can be seen on Figure 5.2, which is a representative of two
experiments with each ratio performed in triplicate, the level of cytotoxicity was
increased by a further 25%. Cultures were therefore, from there on, depleted in C04+
cells on day 7.
5.2.1.3 Comparison between IL-2 + IL-12 Versus IL-2 Alone in Clones Generated
with p53 Peptide 217-225
Even though treatment of target cells with both MA2.l antibody and depletion of C04 +
cells at the beginning of the cultures have increased the level of specific cytotoxicity, it
still remained relatively low for a secondary response. More over when the same
technique was applied for the generation ofCTL ill vitro using p53 peptide 217-225 very
low levels of specific cytotoxicity were detected. So, in order to try to increase further
the number of peptide-specific CTL, responder cells were semi-cloned on day 14 as
described in Section 2.2.3.3 and the level of cytotoxicity was assessed between clones
where C04+ cells had been removed and those where C04' cells had been left in the
culture. By cloning and removing C04+ cells, C08+ cells were, most certainly, lacking
the beneficial effects of an important cytokine, interleukin-12, produced mainly by APC
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Figure 5.1,:Dendritic cell population runs on normal blood setting.
Dendritic cells were generated from PBMC following culture of adherent cells for 7
days with 1000 U/ml GM-CSF and 500 U/ml IL-4 and a further 3 days with 1000 U/ml
GM-CSF and 100 U/ml TNF-a. Cells were then run on normal blood setting.
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CD4+ Cells Not Depleted CD4+ Cells Depleted
CTLNo +IL-2 +IL-2+IL-12 +IL-2 +IL-2+IL-12
12 + I I I I I I ++++ I I I I I
I I I I I Y2 Plate
13 0 0 + 0
14 0 0 0 I I I I I
IS ++ ++ I I I I I I I I I I
++++
16 / 0 / +
17 / / / +
21 / 0 / ++++
++
Table 1: Summary of Effect of IL-12 Addition and CD4+ CeU Depletion on
Cytolytic Activities of CTL Generated from Different HLA-A2+ DORon
PBMC.
CTL were generated after stimulation of PBMC with 217-225 peptide and two
subsequent restimulations with peptide-pulsed and Mitomycin C treated
autologous PBMC. Responder cells were semi-cloned on day 14.
n.,-12 was added to some cultures on day 3 and at each stimulation. CD4+ cells
were removed from some of the cultures on day 7 with anti-CD4 coated magnetic
beads.
Results show number of positive semi-clones generated.
cells but also by B cells (Stem, et aI., 1990; D'andrea, et aI., 1992). This cytokine has
been shown to directly affect the differentiation of CD4-expressing T-helper cells, both
naive and memory, into IFN-y-producing Thl cells when present in the first few days of
culture of the clones (Manetti, et aI., 1995). IFN-;' together with IL-12 then promotes
the differentiation of T-cells into cytotoxic T-lymphocytes (CTL). The effect of the
addition of IL-12 on day 3 of the cultures was therefore also assessed.
Using this method it was possible using the p53 217-225 peptide to induce a CTL
response as can be seen from Figures 5.3. These CTL were capable of specificallykilling
peptide-pulsed target cells. More positive clones were generated when cultures were
depleted in eD4 + cells (Figures 5.3Band 5.3D and Table 1). The addition of IL-12 not
only increased further the number of positive clones (Figure 5.3C in comparison with
Figure 5.3A and Table 1) but also increased the level of cytotoxicity (Figure 5.3D).
The results of eTL generation for several donors are summarised in Table 1. Taking all
these results together optimum conditions were established when target cells (T2 or lY)
were pre-incubated with MA2.1, and when cultures were depleted in CD4+cells as well
as when cells were semi-cloned and IL-12 was added at the beginning of the cultures.
5.2.2 Generation of CTL Using Dendritic Cells
While the conditions optimised above led to the generation of peptide-specific CTL, the
numbers of eTL obtained by the semi-cloning method were low and not sufficient to
assess their specificity against a wide panel of target cells. In order to generate a large
number of peptide-specific CTL it was decided to utilise dendritic cells as APC. During
the course of my thesis, methods to generate CTL using dendritic cells were being
developed in other laboratories indicating their potential (Bakker, et aI., 1995; van Elsas,
et al., 1996; Nair, et aI., 1997). These represent the most potent APC known so far.
Following stimulation they, indeed, express high level of MHC molecules and co-
stimulatory molecules and secrete IL-12.
S.2.2.1 Generation and Characterisation of Dendritic Cells
Dendritic cells were generated following Romani, et al., (1994) method (see Section
2.2.3.3). Briefly PBMC were isolated from HLA-A2 positive healthy donors and
cultured in RPM! + 10% FCS in T125 flask for 2 hours at 37C. Nonadherent cells were
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Figure 5.5a: Dendritic cells: 7 days of culture.
Dendritic cells were generated from PBMC following culture of adherent cells for 7
days with 1000 Vim! GM-CSF and 500 Vim! IL-4. Observed at xlOO.
Figure 5.5b: Dendritic cells: 10 days of culture.
Dendritic cells were generated from PBMC following culture of adherent cells for 7~ ~
days with 1000 Vlml GM-CSF and 500 Vlml IL-4 and a further 3 days with 1000 U/ml
GM-CSF and 100 Vim! TNF-a.. Observed at xlOO.
Figure 5.5: Dendritic Cells after A) 7 Days of Cultures and 8) 10 Days of
Cultures. Magnification xlOO.
It. 8
removed and frozen at lxl07 cells/mJ in AIM-V medium containing 60% FCS and 10%
DMSO (to be used as effector cells in the generation ofCTL). The adherent celis, which
were used to generate dendritic cells were cultured in RPMl + 10% FCS for 24hrs. Fresh
medium containing 500 Vlml of IL-4 and 1000 Vlml of GM-CSF were added to the cells
first plated at a high density (day 1) and then plated at a lower density (day 2), and
incubated at 37°C (see Section 2.2.3.3). On the fourth day, cells were then plated at
O.5x106 cellslwell in Iml ofRPMI +10% FCS containing 1000 Vlml GM-CSF and 100
U/ml TNF-a. Cells were incubated for another three days.
Before these cells could be use as APC in the generation of CTL in vitro it was necessary
to certify their identity as dendritic cells. Characterisation of dendritic cells is based on at
least three criteria, (1) morphology, (2) expression of cell surface markers, and (3) their
function.
5.2.2.1.1 FACS Analysis of Cell Surface Markers
The cell population obtained, following the above method for dendritic cell generation,
was analysed on the FACi by running on normal blood setting. As can be seen from
Figure 5.4 the generated cell population constituted mainly of large cells (cells shifted to
the right) and granular celis (cells shifted towards the top of the panel). These also
possessed many dendrites and showed typical morphological and phenotypic
characteristics of dendritic cells (Figures 5.5). No real morphological differences were
observed between dendritic cells observed on day 7 (Figure 5.5a) and on day 10 after
addition and culture with maturation factor, TNF-a (Figure S.5b).
The generated cells were stained for cell surface markers C03, CD19, CD]4, CD54,
COla, C086, MIlC Class-I and MIlC Class-II using FITC labelled goat anti-mouse IgG
as second layer (Section 2.2.2.2). A typical result is shown in Table 2. As can be seen the
cells did not express T-cell markers (C03 negative) or B-cell markers (COI9), but did
express high levels of COla molecules, MHC Class-I and Class-II molecules, co-
stimulatory molecules (C086 and CD80) but no or low level ofCD14 molecules.
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Marken All Gated
Fluorescence Intensity 0/0 of cells stained
FITC Control 8.88 56.11
Isotype Control 41.29 52.52
Isotype Control" 13.36 52.62
CD3· 13.93 58.30
CD19· 18.57 51.50
CDla· 337.52 56.92
CD14Control 10.80 53.04
CDI4 10.57 50.12
CD86. 94.56 58.12
CD80 80.41 54.96
CD83 72.93 57.80
CD54. 144.66 48.74
Clul-I (ABC) 1952.06 56.02
Class-U(DR) 2043.18 56.52
Table 2: Cell surface characterisation of dendritic cells.
Dendritic cells were generated from PBMC following culture of adherent cells for 7
days with 1000 Vlml GM-CSF and 500 Vlml IL-4 and a further 3 days with 1000Vlml
GM-CSF and 100 U/ml TNF-a. Cells were labelled for 30 minutes with antibodies
specific for cell surface markers, washed and labelled with FI conjugated anti-mouse
IgG for a further 30 minutes and analysed by flow cytometry.
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5.2.2.1.2 Mixed Lymphocytes Reactions (MLR)
To test the functionality of the dendritic cells a mixed lymphocyte reaction was
performed as described in Section 2.2.11. Briefly autologous or allogeneic nonadherent
cells were mixed with different numbers of dendritic cells in RPM! containing 17% AIM-
V and 5% autologous serum and cultured for four days at 37°C_ PBMC cultured on their
own and medium only served as negative controls. Thymidine was then added to all wells
and 18hr later plates were harvested and level of thymidine incorporated by cells was
detected using a gamma counter-Topcount TM.
MLR results for two different donors are shown in Figure 5.6. As can be seen dendritic
cells generated following the method described in Section 2.2.3.3 were capable of
stimulating both autologous and allogeneic T-cells with a greater response obtained with
allogeneic cells.
The morphological, cell marker expression and Ml.R results suggest that the cells
generated by the culture method described above are dendritic cells, in agreement with
previous reports and therefore suitable for use as APC in the generation ofCTL.
5.2.2.2 Generation of CTL
Peptide specific CTL using either the p53 217 or 264 peptides and dendritic cells as APC
were generated following the method described in Section 2.2.3.3. Briefly, on day 0,
nonadherent cells, stored as frozen stock from day one, were thawed, washed, counted
and depleted of CD4+ cells using anti-CD4 dynabeads. Effector cells were co-cultured
with peptide-pulsed dendritic cells at an effector: APC ratio of 10: 1 (Figures 5.7) with
IL-2 and IL-7. Effector cells were restimulated seven days later with peptide-pulsed and
mitomycin C treated autologous whole PBMC. Every subsequent seven days, effector
cells were restimulated with a mixture of peptide-pulsed and mitomycin C treated
autologous PBMC, allogeneic l-ll...A-A2· PBMC and! or LCL and Rosi cells at a ratio of
effector: APC of 10: 1 in AIM-V containing 5% autologous serum and IL-2. Cytotoxic
activities of CTL thereby generated were tested on day 38 in a standard 4hrs chromium
release assay (Section 2.2.4).
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Figure 5.6 (a&b): Two Mixed Lymphocytes Reactions using dendritic cells as
stimulator cells from two donors.
Dendritic cells were generated from PBMC following culture of adherent cells for 7
days with 1000 V/ml GM-CSF and 500 V/ml IL-4 and a further 3 days with 1000 V/ml
GM-CSF and 100 V/ml Th'F-a. On day 10 cells were mixed with non-adherent
~jIO~I""
autologous or allogeneic PBMC at different ratio for 5 days with addition of 3H for the
last I8hrs. ~"':.l;1Ll
Proliferation of autologous non-adherent PBMC as reported by 3H incorporated (Red
columns), proliferation of allogeneic non-adherent PBMC (Blue columns), medium
only (Yellow column).
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Figure 5.7a: Picture of dendritic cells mixed with non-adherent, CD4+ ceDs
depleted autologous PBMC. Observed dO.
Dendritic cells were generated from PBMC following culture of adherent cells for 7
days with 1000 Vlml GM-CSF and 500 Vlml IL-4 and a further 3 days with 1000 Uzml
GM-CSF and 100 Vlml TNF-a. On day 10 dendritic cells were mixed with non-
adherent, CD4- cells depleted autologous PBMC at an APC: responder cells ratio of
1:10.
Figure 5.7b: Picture of dendritic cells mixed with non-adherent, CD4+ cells
depleted autologous PBMC. Observed dOO.
Dendritic cells were generated from PBMC following culture of adherent cells for 7
days with 1000 U/ml GM-CSF and 500 Vlml IL-4 and a further 3 days with 1000 U/ml
GM-CSF and 100 U/ml TNF-u. On day 10 dendritic cells were mixed with non-
adherent, CD4- cells depleted autologous PBMC at an APC: responder cells ratio of
1:10.
Figure 5.1: Dendritic Cells Obtained after 10 Days of Cultures and Mi ed
with non-Adherent CD4- autologous PBMC. A) Magnification xlO, B) 100.
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5.2.2.2.1 Induction of Peptide Specific CTL
Using the above method, CTL could successfully be generated to p53 peptides 217-225
and 264-272. Peptide 264-272 was used as a positive control as it has previously been
shown to induce CTL. Figure 5.8, which is representative of three donors with each ratio
performed in triplicate, shows that T2 cells pulsed with either 217-225 or 264-272 were
specifically killed by CTL-217 (Figure 5.8a) and CTL-264 (Figure 5.8b) respectively.
Similarly, JY pulsed with the relevant peptide were lysed by CTL-217 (Figure 5.9).
These CTL lines did not however kill cells expressing wild-type p53 (T2 and JY).
5.2.2.2.2 Recognition of Tumour Targets Expressing Mutant pS3 Protein
In order to assess whether the 217-225 was endogenously processed and presented at
the surface of tumour cells a number of cells expressing mutated p53 protein were
prepared (see Sections 4.2.3 and 4.2.4) and used as targets. CTL lines generated to
peptides 21 7-225 and peptide 264-272 were assessed for lytic activity against transfected
tumour targets expressing mutant p53. Both CTL-217 and CTL-264 were able to lyse
SaOs-2/175 but not SaOs-2 cells transfected with control vector (Figures 5.10, red
columns compared with green columns). In contrast, SaOs-2/273 was only recognised by
a CTL line generated to the 217-225 peptide from one out of three donors (Figures 5.10,
A, Band C yellow colomns) and was not killed by CTL lines generated with the 264-272
peptide (Figures 5.10, D, E and F, Yellow columns).
Transfected cell lines A431-A2 (expressing p53 protein mutated at codon 273 Arg->His)
and SKBr3-A2 (expressing pS3 protein mutated at codon 175 Arg->His) when pulsed
with either the 217-225 or 264-272 peptide were killed by CTL-217 (Figures 5.11, A
and B, blue columns) and CTL-264 (Figures 5.11, C and D, blue columns) respectively.
SKBr3-A2, but not A431-A2 cells were also sensitive to lysis by both CTL lines without
peptide pulsing (Figures 5.11 A and 5.11 C, red columns).
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Figure 5.8: Cytotoxicity of CTL lines CTL-217 and CTL-264 against T2 cells.
CTL lines were generated following initial stimulation with peptide pulsed autologous
dendritic cells and three subsequent rounds of restimulation with first peptide-pulsed
and mitomycin C treated autologous PBMC, then for the next two restimulation with
peptide-pulsed and mitomycin C treated autologous PBMC, allogeneic HLA-A2+
PBMC and/or LCL, and Rosi cells.
Cytotoxicity of effector CTL lines was determined by percentage release of SlCr from
"c- labelled T2 target cells pulsed with appropriate peptides: (A) 217-225 peptide
(Yellow columns) or T2 cells alone (Blue columns); (B) cytotoxicity of CTL-264
against T2 cells pulsed with 264-272 peptide (Yellow columns) T2 cells alone (Blue
columns).
Figure 5.9: Cyotoxicity of CTL lines CTL-217 against JY cells.
CTL lines were generated following initial stimulation with peptide pulsed autologous
dendritic cells and three subsequent rounds of restimulation with first peptide-pulsed
and mitomycin C treated autologous PBMC, then for the next two restimulation with
peptide-pulsed and mitomycin C treated autologous PBMC, allogeneic HLA-A2+
PBMC and/or LCL, and Rosi cells.
Cytotoxicity of effector CTL lines was determined by percentage release of SlCr from
"c- labelled JY target cells pulsed with 217-225 peptide (Yellow columns) or JY cells
alone (Blue columns).
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Figure 5.10: Sensitivity ofSaos-2 transfectants to lysis by CTL-217 and CTL-264.
Saos-2 cells were transfected with pS3 cDNA mutated at amino-acids position 175 (R-
>H) or 273 (R->H) to generate Saos-2/175 and Saos-21273 transfectants, respectively.
Sensitivity of the transfectants to lysis mediated by CTL-217 (A. B and C) and CTL-
264 (D, E and F) was assessed by determining the percentage release of SlCr from SlCr
labelled targets. Target cells were Saos-2/273 (Yellow columns), Saos-2/17S (Red
columns) and Saos-2 transfected with control vector (Green columns). Three donors
were used in these experiments: Donor 1 (A and D)~Donor 2 (B and E)~ and Donor 3 (C
and F).
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Figure 5.1t: Sensitivity of A431-Al (A and C) and SKBr3 (B and D) transfectants
to lysis mediated by CTL-217 and CTL-164.
Cell lines A431 and SKBr3 were stabely transfected with HLA-A2 eDNA and used as
SICr labelled targets for CTL-217 (A and B) and CTL-264 (C and D) generated from
Donor 1. Target HLA-A2 transfectants pulsed with peptide 217-225 (A and B; Blue
columns) or peptide 264 (C and D~Blue columns), unpulsed HLA-A2 transfectants
(Red columns) and cells transfected with control vector (Green columns).
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S.3 Conclusions
The induction of a CTL response ill vitro proved to be a more difficult task than
anticipated from published reports. Levels of cytotoxicity were shown to be improved by
the treatment of target cells with the MA2.1 antibody followed by peptide-pulsing. The
precise mechanism of action of this antibody remains, however, unclear. Depletion of
CD4+ cells and the addition of IL-12 followed by semi-cloning also increased the number
of positive clones as well as their cytotoxic activities. It is however, noteworthy to
mention that these responses were mostly peptide and donor dependants. The use of
dendritic cells as APC however, led to the generation of pS3 peptide-specific CTL in
sufficient numbers to characterise them further. These studies demonstrated that pS3
peptides 217-225 and 264-272 were naturally endogenously processed and presented on
the surface of the SaOs-2117S and SKBr3-A2 cells.
Transfected HLA-A2 cDNA was functional since transfected cells A431-A2 and SKBr3-
A2 were killed by CTL lines when pulsed with relevant peptide.
SaOs-2117S cells and SKBr3-A2 cells bear the same R->H mutation of the pS3 gene at
amino-acid position 175. On the other hand A431-A2 cells bear the R->H mutation at
position 273 of the pS3 protein which may have affected the processing pathway and
subsequent presentation of these epitopes.
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5.4 Discussion
The use of peptide vaccines derived from T-cell epitopes of tumour associated antigens
or overexpressed molecules in tumour cells is now an acceptable approach to elicit anti-
tumour immunity and a number of peptide vaccine clinical trials are in progress (Nestle,
et al., 1998; Hsu, et al., 1996). The p53 suppressor gene is mutated in 50-60% of human
cancers (Hollstein, et aI., 1991) and results in the stabilisation and accumulation of the
inactivated protein within the cancer cell. Conformational changes in the p53 protein,
generated as a result of point mutations, are frequently recognised by the monoclonal
antibody Pab240, due to the exposure of the 240 epitope, RHSVV (amino-acids 212-
217) (Milner, et al., 1990). It is possible that peptides in this exposed region could be
processed in a different manner to the wild-type protein, presented on the tumour cells
surface in the context of MHC class-I and therefore, have the potential to be recognised
by tumour specific CTL.
The pS3 gene is a tumour suppressor gene present in all cells, and mutations within the
gene represent the single most common genetic alterations observed in human cancers
(Hollstein, et al., 1991). The majority of mutations ofp53 result in the stabilisation and
accumulation of the protein in tumour cells (Bodmer, et al., 1992) making p53 an ideal
candidate for immunotherapy against a wide variety of cancers. Mutations, commonly
point missense mutation, are mainly clustered around four hot spots (175, 248, 249, 273)
in highly conserved domains in the central region of the protein (Hollstein, et al., 1991).
These can further be classified into two groups according to the effect they have on the
protein conformation of pS3. One class of mutants (273, 248) does not significantly
affect the conformational structure of the protein (Hinds, et al., 1990), does not
associate with heat shock protein 70 (hsp-70), and are Pab240-lPab1620+ (Milner,
1995). The other class of mutants (175, 249) results in the unfolding of the protein, and
exposure of the 240 epitope which is normally cryptic and inaccessible to antibodies;
these mutant proteins are associated with the hsp70 and were found to be highly sensitive
to proteolytic enzymes (Lee, et aI., 1994). The frequency of pS3 mutations is strongly
correlated with the presence of antibodies against the pS3 protein in several types of
cancers (Agelopoulou, et aI., 1994; Lubin, et al., 1995), as a result of an active
secondary self-immunisation. Moreover Davidoff and co-workers (Davidoff, et aI.,
1992) showed that tumours which elicit an antibody response contain HSP70 complexed
to mutant p53. These findings and the fact that several HSPs have been shown to have a
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role in antigen processing (Vanbuskirk, et a!., 1989~Srivastava, et a!., 1994), suggest
that antigen processing of the mutant pS3 conformational protein could be different from
mutations which do not affect the conformation of the pS3 protein which may result in
markedly different peptide repertoires being displayed on the surface of the cells.
Peptides 217-225 and 264-272 were successfully used for the generation of CTL lines,
which were able to specifically kill peptide-pulsed targets as well as tumour targets
overexpressing the p53 protein. Tumour targets expressing mutant pS3 conformation
were preferentially killed as opposes to tumour targets expressing wild-type
conformational mutants providing evidence for the hypothesis of differential processing.
These results confirm and extend the recent findings of Theobald, et a!., 1998, who
demonstrated that the R->H mutation at residue 273 of human pS3 alters protesomal
processing of the protein due to inhibition of proteolytic cleavage between residue 272
and 273. Target cells bearing this mutation were not recognised by CTL generated to the
wild-type pS3 peptide 264-272 in vitro or in vivo, as this epitope was not generated.
However, a HLA-A2 restricted CTL line specific for human wild-type pS3 peptide 149-
157 lysed transfected cell expressing this mutation, indicating efficient processing of
other p53 epitopes. Here, target cells with the R->H mutation at position 273 were not
lysed by CTL-264 lines and in addition, were only lysed by CTL lines to wild-types pS3
217-225 peptide in one out of three donors. Whilst the former observation is in
agreement with that of Theobald et al (Theobald, et al., 1998), their results suggested
that the 273 mutation may only affect a flanking peptide epitope and a precursor peptide.
Here, the lack of recognition of the 273 mutated pS3 observed with CTL lines generated
to 217 in some donors could be due to differences in the affinitiesof the TCR of the CTL
lines generated or relative expression of pS3 and HLA-A2 molecules; alternatively,
regions of the protein distant to the mutation may fail to donate peptides to the
processing pathway.
All these conclusions, however, were drawn after analysis of standard 4hr chromium
release assay results. The relevance of this assay as a surrogate immunologic
measurement of anti-tumour activity has, however, been questioned after a lack of
correlation between CTL induction in vitro and clinical response was found in two
vaccine trials using HLA-A2-restricited MAGE-3 or gpl00 peptides (Marchand, et aI.,
1995~Rosenberg, et al., 1998). New assays are now being used as a replacement of or in
combinations with in vitro standard 4hr-chromium release assay. These include ELISA
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and ELISPOT techniques, detecting cytokines released, such as IL-2, IFN-y or TNF-a,
as a result of CTL induction.
As for the induction of CTL ill vitro and their use ill vivo many methods have been
developed as described in Section 5.1.2, among them methods using dendritic cells as
APC have obtained the most promising results. Clinical trials, using dendritic cells from
patients with B cell lymphoma pulsed with idiotypic protein demonstrated measurable
anti-tumour cellular responses in four patients with one complete tumour regression
(Hsu, et al., 1996). More recently a clinical pilot study using DC pulsed with tumour
lysate or a mixture of peptides, known to induce CTL, showed that antigen-specific
immunity could be induced in patients with advanced melanoma. No physical signs of
autoimmunity was found and in 5 out of 16 immunised patients clinical responses were
observed with two complete responses and three regression of metastases in various
organs (Nestle, et aI., 1998). In addition a phase I clinical trial using dendritic cells
pulsed with melanoma cells lysate showed lymphocytes infiltration at the vaccination site
by CD8+ T-cells. These were shown to release TNF-a upon encounter with specific
antigen and cytotoxicity towards cells expressing MAGE peptides (Chakraborty, et aI.,
1998). Future immunisations may not need whole dendritic cells since peptide-pulsed DC
have been shown to secrete antigen-presenting vesicles (exosomes) which were capable
of priming CTL in vivo and resulted in tumour rejection (Zitovel, et aI., 1998). DC
number obtained by ill vitro methods may still be a problem, one possible alternative
might be to fuse them with tumour cell lines. Gong, et al., 1997, fused MC38 carcinoma
cells with DC and showed induction of CTL in vivo by the fusion products. Vaccination
with these hybrid cells induced CTL, which protected even against established
metastases.
Here they have successfully been used as stimulators for the generation of human anti-
p53 specific CTL which has potential clinical application. DC pulsed with mutant pS3
peptide have been shown to be effective at immunisingmice carrying tumours expressing
that p53 mutant (Gabrilovich, et al., 1996). It would be interesting to try to generate
CTL using pS3-overexpressing-cell-lysate-loaded DC as APC.
Key questions are whether patients whose tumours harbour a pS3 mutation have
demonstrable precursor CTL or whether they can be induced, and whether their is an
association between the pS3 gene mutation, HLA type and disease progression.
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CHAPTER 6: P53 AS A POTENTIAL TARGET FOR IMMUNOTHERAPY
AGAINST HEAD AND NECK CANCER
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6.1 Introduction
6.1.1 Head and Neck Cancer Background
6.1.1.1 Epidemiology
Head and neck cancer represents one of the most common cancers with 500 000 new
cases per year (Parkin, et aI., 1988). Most of them are of the squamous cell type, and
therefore only head and neck squamous cell carcinoma (HNSCC) will be discussed here.
The majority ofHNSCC patients are male over 40 years of age, with a male: female ratio
of 4-1 (Sloan, et al., 1991). However with the number of young smokers increasing as
well as the number of women smoking the incidence of HNSCC is changing. Incidence
also varies among different pans of the world, due to environmental differences as well
as different habits of the populations (Sloan, et al., 1991).
6.1.1.2 Head and Neck Cancer Risk Factors
Excessive absorption of alcoholic beverages and smoking are clearly associated with an
increase risk in a number of cancers, but are particularly associated with head and neck
cancers representing the two major causes ofHNSCC (Copper, et al., 1991). More over
the combination of alcohol and smoking seem to exert a greater effect than either alone
and account for about 75% of all oral pharyngeal cancers. Other causes such as bad oral
hygiene, exposure to environmental risk factors like nickel or wood dust and textile
fibres, chronic and viral diseases and genetic pre-disposition have all been associated
with increased risk in HNSCC (Sloan, et al., 1991; Vokes, et al., 1993; Scully, et al.,
1993; Schantz, et al., 1994).
6.1.2 Diagnosis and Treatments
Tumours from the head and neck region very often arise without any obvious symptoms
and tumours are, therefore, generally large by the time they are reponed by HNSCC
patients. Prognosis depends on the size and site of primary tumour, the number of lymph
nodes involved, as well as distant spread, grade of differentiation and the presence of
aneuploidy. A TNM, from the International Union against Cancer, classification is used
to stage the extent of the disease. T stage defining the extent of the primary tumour, N
stage the extent of regional lymph node metastases and M stage the measurement of
distant metastasis. Stages are then divided into IV with Stage I representing an early
disease whereas a Stage IV represents an advanced and disseminated one. Although
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surgery and radiation. given singly or in combination are the best treatment, especially
when the disease is treated early, the overall survival rate remains low. 50% of HNSCC
patients die within 5 years of diagnosis as a consequence of local or regional recurrences
and second primary tumours (Cooper, et aI., 1989). One possible reason for the
development of multiple primary tumours has been related to the 'field of cancerisation'
phenomena (Slaughter, et aI., 1953). The hypothesis is that the mucosa of the upper
aerodigestive tract from predisposed individuals, has been exposed to the same
carcinogens, leading to the accumulation of genetic alterations which in turn result in the
induction of multiple, independent malignant loci. This said, local and distant metastasis
to the lung, for example, can also frequently develop synchronously or metachronously
(Schwartz, et al., 1994). The diagnostic differentiation between metastatic disease and
second primary tumour, during the follow-up period, is, as a consequence, extremely
difficult and the outcome of such a diagnosis is very important for the therapeutic
decision. Since conventional histology is in the case ofHNSCC of no use, other markers
are needed. Indeed, if a biomarker was available and able to identify patients at high risk
of developing second primary tumours or recurrence, it would have profound
implications for therapy decisions and especially for the follow-up of these patients.
Since chemotherapy is a long and costly treatment, radiotherapy and surgery remain the
best treatment for HNSCC. The development of biomarkers to determine which patients
are most likely to develop recurrence of primary disease or second primary tumours and
therefore most likely to benefit from it, would save time and money.
PS3 gene mutations and expression in HNSCC appear to be associated with shorter
relapse-free and overall survival. Therefore, pS3 has been proposed as a biomarker for
identifying individuals at high risk of developing a recurrence of primary disease and
second primary tumours who may benefit from adjuvant therapy and chemoprevention
after definitive local therapy (Shin, et aI., 1996).
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6.1.2 p53 and Head and Neck Cancer
6.1.2.1 Role of p53 in Head Neck Cancer
The evolution from hyperplasia and dysplasia to malignancy and metastasis in the oral
region as for many cancers, is, as mentioned earlier, probably the result of accumulation
of genetic damage such as proto-oncogene mutations, gene amplification, chromosome
breakage, translocation, proto-oncogene overexpression and loss of tumour suppressor
genes. Although specific molecular events accompanying head and neck cancer
formation are not well defined for HNSCC, the p53 gene is most certainly involved.
Indeed, mutations of the p53 gene have been reported in 53-93% of HNSCC and have
been shown to be associated with rapid tumour cell proliferation in this type of cancer
(Boyle, et aI., 1993). These appear to be an early event since they have been detected in
pre-malignant lesions (Pavelic, et aI., 1994). Consistently the same mutation has been
found in premalignant lesions, in recurrent disease and metastasis (Zariwala, et al.,
1994). Tumours that develop from the progression of genetically distinct premalignant
processes in the surrounding epithelial field will have different pS3 mutation whereas
tumours with the same p53 mutation will have come from the same origin (Chung, et aI.,
1993). The possibility that different tumours share exactly the same p53 mutation is,
indeed, extremely remote. Patients who have a p53 alteration in their primary tumours
and/or in the resected margins have been shown to be at a greater risk to develop a
recurrence and thus need more aggressive adjuvant therapy than those who have no pS3
alterations or no p53 mutations present in their resected margins (Brennan, et aI., 1995).
6.1.2.2 p53 as Biomarker of Head and Neck Cancer
Mutations of the p53 tumour suppressor gene, as well as overexpression of the p53
protein in tumour tissues, and the occurrence of serum antibodies to pS3 have been
demonstrated in a variety of human malignancies. The presence of mutations and the
detection of p53 antibody have been shown to be associated with increased risk of
recurrence and overall survival of HNSCC, making pS3 a good molecular marker
(Werner, et aI., 1997). Since most of pS3 mutations lead to the synthesis of stabilised
protein it has been possible to study the accumulation of mutated, inactive pS3 protein by
the use of immunohistochemical techniques (Coggi, et aI., 1997). Strong variations of
intratumoral pS3 staining as well as their clinical relevance, have, however, been found in
head and neck tumours (Shin, et aI., 1994). Accumulation of mutant pS3 protein can
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result, maybe through release during cell necrosis, in the production of anti-pS3 antibody
and a strong correlation between the presence of pS3 antibodies and the frequency of
pS3 mutations has been found in many cancers (Lubin, et al., 1995~Angelopoulou, et al.,
1994). The proportion of patients with HNSCC who have serum pS3 antibodies was,
however, found to be smaller than that of patients exhibiting tumour cell accumulation of
pS3 protein (Bourhis, et al., 1996). Interestingly, only 50% of patients with pS3
mutations in their tumours, had serum pS3 antibodies whereas, serum pS3 antibodies
were not detected in patients bearing no pS3 mutation in their tumours (Cough, et aI.,
1994). So despite the fact that a strong correlation was found between pS3 accumulation
and the presence of p53 antibodies, and the presence of antibodies and poor clinical
outcome, no association was found between pS3 protein accumulation and clinical
outcome (Bourhis, et aI., 1996). This suggests that the humoral response to pS3 could
be a good marker for identifying, among patients with pS3 accumulation, those with a
high probability of failure.
6.1.2.3 p53 as a Potential Tumour Target for HNSCC Patients
Mutations within the pS3 tumour suppressor gene represent the single most common
genetic alterations in human cancers and are detected in a wide variety of cancers
(Soussi, et al., 1994). The recognition of the pS3 alteration is an important characteristic
in clinical diagnosis since it is an independent, unfavourable prognostic factor in many
cancers, including breast, colon and gastric carcinomas (Remvikos, et aI., 1992~Thor, et
al., 1992~ Starzynska, et aI., 1992). More over, tumour cells bearing pS3 mutations have
been shown to be resistant to radiation or chemotherapy, sensitivity which was restored
when the wild-type pS3 gene was introduced in the cells (Gallardo, et al., 1996).
Immunhistochemical analyses have been extensively used for the screening of pS3
alterations in a wide variety of cancers (Soussi, et al., 1994). Accumulation of pS3
protein within tumour cells of cancer patients had, however, no association with clinical
outcome. The level of pS3 antibodies found in patient's sera has, on the other hand,
beenproposed for diagnosis and prognosis of patients with HNSCC and was shown to be
dependent on the protein accumulation (Bourhis, et al., 1996). In addition in lung
cancers, pS3 antibodies were found several years before clinical diagnosis of the tumour
(Lubin, et aI., 1995). Serological analysis of pS3 offers the advantage that no tumour
sample is required, and it can be easily used for follow-up of patients.
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6.1.3 Aim
The aim of this study was to determine the immunological status of HNSCC patients
with respect to pS3, by analysis of pS3 serum antibody, and analysis of pS3 protein
expression by immunohistochemistry, when tumour samples were available. It was also
intended to assess the cellular immune response to pS3 protein by CTL and proliferation
assay and to determine if there was a correlation between the cellular and humoral
responses and protein expression.
170
6.2 Results
6.2.1 Patient Sample Collection
The day before their operation, patients were asked to fill in a consent form, approved by
the South Sheffield Ethics Committee, authorising the use of blood and tumour sample
for research. PBMC isolated from whole blood were used for the proliferation assay as
well as for the generation ofCTL in vitro for patients HLA-A2-.
A total of 14 patients entered the study with, blood sample from all of them but tumour
sample from only 10 of them.
On the day of the operation, 60mls of blood were collected with or without a tumour
sample. The blood was separated as described in Section 2.2.3.1, briefly blood was
diluted in sterile PBS and cells were laid onto J-prep solution. Tubes were spun for 35
minutes at room temperature with breaks off Thereafter some plasma was removed and
stored immediately in 1ml tubes at -80°C until required for p53 antibody analysis.
Leukocyte layers were then removed and washed twice in ice-cold PBS. Cells were
counted and frozen in cryovial tubes at lxl07 cells/ml in AIM-V containing 60% ofFCS
and 10% DMSO. Tubes were stored in liquid Nitrogen until needed with the exception
offew used straight away for HLA-typing. For HLA-typing cells were washed with PBS
and HLA-A2 antibody was added to them for 30 minutes as described in Section 2.2.2.2.
Cells were then washed twice with PBS and a goat anti-mouse antibody was used as
second layer. Cells were incubated for a further 30 minutes followed by another wash.
Cell surface expression ofHLA-A2 molecules was analysed by flow cytometry.
Only four patients were found to be HLA-A2 positive, Table 1.
6.2.2 Serological Analysis
Plasma from each patient was sent to France to Prof Soussi laboratories for pS3
antibody analysis. The method used was briefly as follows: p53-Abs in the sera of
patients were measured using an enzyme-linked immunosorbent assay (ELISA). The
assay was based on the results obtained by Lubin, et aI., 1993. Major sites of antigen
recognition by p53-Abs detected in human serum are the amino- and carboxyl-terminal
segments of the protein (Lubin, et aI., 1993). This epitope restriction has been
demonstrated by binding sera to a series of 77 overlapping peptides that encompass the
171
entire pS3 molecules. The majority (98%) of positive sera reacted with an ammo-
terminal peptide, and 48% reacted with a carboxyl-terminal peptide (Lubin, et al., 1993).
Sera were therefore tested in an ELISA that employed five peptides as follows:
- EPPLSQETFSDLWKLLPENNVLSPL (Amino-terminal)
- DDLMLSPDDIEQ\VFT (Amino-terminal)
- SPDDIEQWFTEDPGP (Amino-terminal)
- EALELKDAQAGKEPGGSRAHSSHLK (Carboxyl-terminal)
- GSRAHSSHLKSKKGQSTSRHKKLMF (Carboxyl-terminal)
The ELISA was performed with sterptavidin-coated plates, biotinylated peptides, and
direct binding of human pS3-Abs in serum that was diluted 1: 100 (with phosphate-
buffered saline, pH 7.6, plus 5% nonfat dried milk) for the assay. The negative control
employed a human serum albumin peptide. Sera were considered positive if a ratio of 1.5
or greater was obtained, with a difference in optical density (at 4S0nm) of at least 0.15.
Antibodies against p53 were found in two of the patient's sera, Table 1.
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Patient Tumour HLA-A2 PS3 Antibodies
Sample Expression
1 No - -
2 Yes - -
3 No - -
4 No + -
5 Yes - -
6 Yes - -
7 Yes + -
8 Yes - -
9 Yes + +
10 Yes - -
11 Yes - +
12 Yes - -
13 No + -
14 Yes - -
Table 1: HLA-A2 Expression and pS3 Antibody Presence in HNSCC Patients Blood or
Sera Respectively.
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6.2.3 pS3 Expression in HNSee Patient's Tumour Sections
p53 protein expression was analysed on frozen sections from 10 HNSCC patients.
Sections of 7J1m were cut and stained following a three-stage immunoperoxidase
technique, using commercially available ABC Elite kit. The technique described in
Section 2.2.8 uses primary antibody (IgG2b or 007 titrated in our laboratories using
p53 overexpressing cell line SW480) followed by a biotynilated second antibody and
then performed avidin and biotinylated horseradish peroxidase macromolecular complex.
The bound peroxidase was visualised by DAB. Endogenous peroxidase activity was
blocked by pre-incubating sections in a solution of hydrogen peroxidase in methanol.
Tumour tissue stained with isotype-matched antibody control (IgG2b) and normal tissue
were used as negative control. Positive control cytospins of MCF7 cells were also used
in staining runs to ensure that any negative result was not due to failure of the
immunohistochemical staining procedure.
Slides were graded independently by 2 viewers, and then viewed together to discuss,
compare and give final grade.
As can be seen in Table 2, 6 out of 10 tumour sections stained positive for pS3 protein
expression. 5 expressed very high level of the protein (75-100%). MetastasHc.tissue
obtained from patient 11 also stained positive. The staining was localised in the nucleus.
Many of the specimens showed a 'diffuse' or 'basal' distribution of positive cells but
significant data could not be obtained for the distribution of positive cells because many
biopsies were too small to determine their type of distribution. Staining intensity and the
percentage of positive cells varied (Table 2, Figures 6.1-6.4).
A summary of results obtained in this study is presented in Table 3.
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% of Cells
Stained 0-5 6-25 26-50 51-75 76-100
/
Patient No
2 +++
S +
6 +++
7 +
8 ++
9 +++
10 -
11 +++
11 (met) +++
12 +
14 +
Table 2: pS3 Staining Results in HNSCC Tumour Specimens
(+++): Positive cells stained black or dark brown
(++): Positive cells stained brown distinct from background unstained cells
(+): Positive cells stained light but apparently stained compared with background cells
(-): Cells remained unstained
175
Patient Date of Age at Sex Tumour Specimen HLA- P53+ve PS3
Number Surgery Surgery Site A2 Abs
1 17.09.97 68 M No Sample - Nd - I
2 24.09.97 M - + -
3 15.10.97 48 F No sample - Nd -
4 29.10.97 38 M No Sample + Nd -
5 12.11.97 39 M Metastasis Lymph - - -
Node
6 10.12.97 38 M Right COM.MANDO - -
Anterior trimmed
margms
7 14.0l.98 57 Right Neck + - -
Dissectomy
8 21.01.98 - + -
9 04.02.98 27 M Total Glossectomy + + +
10 11.02.98 50 M COM.MANDO + - -
Specimen
11 18.02.98 70 M Total Laryngectomy - + +
12 25.02.98 54 M Laryngectomy - - -
13 0l.04.98 72 M No Sample + Nd -
14 29.04.98 67 M Pharungo-Laryngo - + -
Oesophagectomy
Table 3: Summary of results obtained with HNSee patients regarding p53.
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6.2.4 Cellular Immune Response in Patient with HNSCC to pS3
Tilkin, et al., 1995, showed that only patients with p53 gene mutation, p53 protein
accumulation and anti-pS3 antibodies had T cells, which could proliferate when
incubated in vitro with human wild-type pS3. However HLA expression in these patients
was not assessed. Here a similar study was carried out in patients with HNSee
including HLA expression and eTL generation.
CTL were generated as described in Section 2.2.3.3 using PBMe from all HLA-A2+
patients (patient 9 and 10) and two HLA-A2- patients, both overexpressing pS3 protein,
as detected by immunohistochemistry, Section, with one positive for pS3-Abs (patient
11) and one negative for pS3-Abs (patient 8) and peptide 264-272 (Table 4). During the
course of the stimulation however these became contaminated and the experiment was
aborted and due to the too small PBMC number obtained from each patient no other
CTL could be generated.
Patient Number HLA-A2 pS3 Expression p53 antibody
expression
4 + Nd -
7 + - -
9 + + +
10 + - -
13 + - -
8 - + -
11 - + +
Table 4: Summary of HLA-A2 and pS3 Protein Expression and p53-Abs of
Patients whom CTL have been generated.
The aim was to compare the immunological status ofHNSCC patients regarding pS3 and
to link it with HLA expression.
The cellular immune response to pS3 protein using a proliferation assay was also
intended. However due to the lack ofp53 protein no assay could be performed.
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6.3 Conclusion and Discussion
In this study p53 protein accumulation was detected in 60% of HNSCC patients (6/1 0)
and p53 antibodies in 20% (2110) of these patients sera, and 14% in total (2/14 sera
tested). Interestingly the two patients with p53 antibodies were also found to have pS3
protein accumulation. Four patients were HLA-A2. One patient, patient 9, HLA-A2+,
was found to have p53 antibodies and p53 accumulation. mRNA was extracted from all
tumour samples available (see Section 2.2.10) and sent to France for sequencing to
determine if there was a relationsh ip between p53 mutation, protein expression and
development of a humoral immune response. Unfortunately the samples were unsuitable
for sequencing due to the mRNA being degraded. This was probably caused by the long
gap period between surgery and delivery by the pathologist and freezing the tumour
sample, and as a consequence no results were obtained. However, it is likely that the p53
gene would have been mutated in many of them since intense p53 immunostain-positive
cells were shown to exhibit p53 genetic abnormalities (Kim, et al., 1997). Although not
all patients with p53 alterations develop p53 antibodies, patients who develop antibodies
will have a mutated p53 gene. More over only mutations occurring in exons 5 and 6,
which produce a conformational mutant p53 protein which bind to HSP70, will produce
antibodies according to Davidoff et al., (1992). One can therefore assume that patient 9
has a p53 gene that is mutated within these exons. It is also possible that, for an identical
mutation, the humoral response is dependent on the MHC class-I or class-II molecule
expressed by each individual. It is possible that patients 9 and 14 might have the same
p53 mutation, but being of different HLA haplotype, one did not develop antibodies
against the protein. A larger study would be necessary to test this hypothesis.
p53-Antibodies are likely to be the result of self-immunisation process toward the p53
protein which is normally expressed in minute quantities in the body (Lubin, et al.,
1993). Interestingly immunoglobulin subclasses of these antibodies have been found to
be of IgG 1 and IgG2 in all sera of HNSCC patients suggesting an active immunisation,
these being the result of a second immune response (Lubin, et al., 1995).
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The aim of this study was to compare the cellular immune response to p53 protein, the
humoral response to p53 and the p53 protein expression in patients with HNCSS in
relationship with HLA expression. This type has not previously been reported for
HNSCC patients. However, due to time constraints, the lack ofp53 protein and the small
amount of lymphocytes obtained from these patients, it was not possible to pursue this.
Primary proliferative T-cell responses to wild-type p53 protein have been reported in
patients with breast cancer (Tilkin, et aI., 1995). A T-cell proliferative response was
carried out in six breast cancer patients, five bearing a p53 mutation, three demonstrated
significant lymphoproliferative responses to wild type pS3 protein. These patients also
had p53 antibodies in their sera accompanied by pS3 accumulation of mutated protein in
tumour cell nuclei. The other three patients and healthy donors did not however have any
humoral or cellular immune responses to p53 protein. Interrestingly one of the patient
negative for p53 antibody showed a strong p53 protein accumulation. Therefore this
study showed that pS3 can prime a p53-specific T cell response in vivo, and that wild-
type p53 is processed at least in vitro by APC and recognised by T-cells of certain breast
cancer patients.
Studies assessing the proliferative response to wild-type p53 in other patient groups have
not yet been reported. p53 Antibodies recognise immunodominant epitopes in the linear
carboxyl- and amino-terminal domains of the protein. These epitopes do not correspond
to any mutational hot spots (Schlichtholz, et aI., 1992). Yet while no antibody response
can be detected in healthy individuals or in most patients with no mutated p53 gene, if a
mutation occurs disrupting the protein conformation such as mutation at codon 175, a
humoral response will follow (Davidoff, et al., 1992). This indicates that protein
accumulation is necessary but not always sufficient to generate an antibody response
toward p53 protein and no explanations have yet been found to explain this phenomena.
Future studies need to address whether a correlation exists between antibody response,
protein accumulation, mutation and proliferative response to the protein or CTL activity.
The results of these studies may provide information regarding the prognosis of a p53-
Abs response.
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Figure 6.1: HNSCC patient b.
Section stained with: A= Isotype control. B= pS3 antibody DO-7. Magnification x 100.
,Figure 6.2: HNSCC patient 1.
Section stained with: A= Isotype control. B= pS3 antibody DO-7. Magnification x 100.
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Figure 6.3: HNSCC patient II.
Section stained with: A= lsotype control. B= pS3 antibody DO-7. Magnification 100.
Figure 6.4: HNSCC patient 15
Section stained with: A= Isotype control. B= p53 antibody DO-7. Magnification x 100.
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CHAPTER 7: DISCUSSION
The p53 suppressor gene is mutated in 50-60% of human cancers (Hollstein, et aI.,
1991) and results in the stabilisation and accumulation of the inactivated protein within
the cancer cell. Conformational changes in the pS3 protein, generated as a result of point
mutations, are frequently recognised by the monoclonal antibody Pab240, due to the
exposure of the 240 epitope, RHSVV (amino-acids 212-217) (Milner, et al., 1990). It is
possible that peptides in this exposed region are processed in a different manner to the
wild-type protein, presented on the tumour cells surface in the context of MHC class-I
and therefore, have the potential to be recognised by tumour specific CTL. The p53 gene
is a tumour suppressor gene present in all cells, and mutations within the gene represent
the single most common genetic alterations observed in human cancers (Hollstein, et aI.,
1991~Caron de Fromental and Soussi, 1992).
The majority of mutations of pS3 result in the stabilisation and accumulation of the
protein in tumour cells (Bodner, et aI., 1992) making p53 an ideal candidate for
immunotherapy against a wide variety of cancers. Mutations, commonly point missense
mutation, are found within the core domain and are clustered around four hot spots (175,
248, 249, 273 (Hollstein, et al., 1991).
These can further be classified into two groups according to the effect they have on the
protein conformation of p53. One class of mutants (273, 248) does not significantly
affect the conformational structure of the protein (Hinds, et al., 1990), does not
associate with heat shock protein 70 (hsp-70), and are Pab240-lPab1620+ (Milner,
1995). The other class of mutants (175, 249) results in the unfolding of the protein, and
exposure of the 240 epitope which is normally cryptic and inaccessible to antibodies;
these mutant proteins are associated with the hsp70 and were highly sensitive to
proteolytic enzymes (Lee, et al., 1994).
The frequency of p53 mutations is strongly correlated with the presence of antibodies
against the p53 protein in several types of cancers (Agelopoulou, et al., 1994~Lubin, et
al., 1995), as a result of an active secondary self-immunisation.Moreover Davidoff and
co-workers (Davidoff, et al., 1992) showed that tumours which elicit an antibody
response contain HSP70 complexed to mutant p53. These findings and the fact that
several HSPs have been shown to have a role in antigen processing (Vanbuskirk, et al.,
1989~ Srivastava, et al., 1994), suggest that antigen processing of the mutant pS3
conformational protein could be different from mutations which do not affect the
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conformation of the p53 protein which may result in markedly different peptide
repertoires being displayed on the surface of the cells. These peptides remain to be
identified.
The elution of such peptides on the surfaces of tumour cells, however attractive is the
idea remains extremely difficult due to their small amount and the large number of cells
required. Therefore the problem of their identification had to be approached from the
other end. This implied using the amino-acid protein sequence to select HLA-A2
peptides, which would then have to be tested for their ability to bind to HLA-A2
molecules and generate CTL in vitro and then determine whether they are naturally
endogenously processed and presented at the surface of cancer cells.
Here new HLA-A2+ p53 peptides (8-11 amino-acids long) were selected from the p53
protein sequence and investigated for their potential use in future immunotherapy
programmes against cancer.
Peptides were first tested for their ability to stabiliseHLA-A2 molecules at the surface of
T2 cells. The results of this assay were used to select high binder peptides to be used in
the generation of CTL in vitro (Chapter 3). Peptides 217-225 and 188-197 were thereby
selected. Peptide 217-225, chosen to test the hypothesis of different processing pathway
depending on the protein conformation, was used for the generation of CTL generation,
which was first performed using whole PBMC. Dendritic cells were then successfully
generated and used as APC in the assay. Then dendritic cells pulsed with peptide 217-
225 were used to generate CTL ill vitro. Peptide 264-272 was first used as positive
control in the generation of CTL but was then used to test the hypothesis that p53
processing pathway might be different depending on its conformation (Chapter 5). In
order to test this hypothesis a panel of target cells expressing either a conformational
mutated p53 protein (mutation at amino-acid position 175) or 'wild-type' conformational
mutated p53 protein (mutation at amino-acid position 273) and HLA-A2 molecules were
prepared (Chapter 4). CTL generated with peptide 217-225 or peptide 264-272 were
both shown to kill preferentially target cells bearing a p53 mutation at amino-acid
position 175, indicating that the protein conformation might indeed have an influence in
the outcome of which peptides are presented at the surface of the cell.
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Fifteen wild-type p53 peptides were selected and tested for their ability to stabiliseHLA-
A2 molecules at the surface of the T2 cells. The T2 binding assay is a very easy, quick
and non-hazardous (no radio-labelled isotope involved) assay for testing the ability of a
given peptide for its ability to bind to HLA-A2 molecules. The results obtained with this
assay using well-known peptides correlated with published work (Chapter 3). Peptides
containing no anchor residue were not found to stabilise the HLA-A2 molecules at the
surface of the T2 cells whereas peptides containing two preferred anchor residues
showed strong binding properties (FR >1.5). Peptides with only one tolerated anchor
residue did not show high binding capability. However, peptides with one preferred
anchor residue at position 9 and either one or none tolerated anchor residue at position 2
did show strong affinity for HLA-A2 molecules (FR > 1.5) with the exception of two
peptides. This illustrates the need of two anchor residues for peptide binding even
though peptide can bind with only one anchor residue. However factors other than size
and anchor residues are also critical in determining whether or not a peptide will bind
HLA-A2 molecules. Indeed the presence of other residues at non-anchor positions can
either increase or abolish completely the binding affinity of peptide bearing them
(Drijthout, et aI., 1995). Despite the presence, in a given antigen, of peptides with both
anchor residues only a few will generate CTL in vitro. One other important parameter is
the determination of the efficiency of peptide to bind and remain bound to MHC
molecules. Indeed a strong correlation between immunogenicity and the stability of
MHC-peptide complex has been reported (van der Burg, et al., 1996). A peptide with a
poor ability to bind to HLA-A2 molecules was also found to be non-immunogenic. By
improving its binding ability it was also possible to enhance its immunogenicity (Lipford,
et aI., 1995). This however does not automatically imply that peptides with moderate
binding affinity are immunologically non-important. This was the case of the WT p53
149 peptide found to have a moderate binding affinity (Nijman, et aI., 1994) and yet
capable of eliciting CTL in vitro capable of killing peptide-pulsed target as well as
tumour targets (Theobald, et aI., 1995/1997). However if a peptide possess a too strong
an affinity for a given MHC molecule it is likely that CTL reacting with it it would have
be deleted as a saveguard mechanism to avoid later autoimmunity. This has indeed been
reported for peptide 187-197 (Theobald, et al., 1997).
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It is therefore likely that a therapeutic window of binding affinities exists for the
generation of a CTL response, beyond which very low or very high affinity binding
peptides, would for different reasons, fail to elicit a CTL response. The level of HLA
molecules expressed on the surface of tumour cells is also a determining influence, and
different CTL responses have been observed with target cells expressing different levels
ofHLA class-I surface molecules (Rivoltini, et aI., 1995).
Quantitative and qualitative differences in peptide and MHC class-I expression will
determine the efficiencywith which antigen-specific CTL will be generated. For peptides,
this depends mainly on how the cell has processed the protein, fromwhich they derived.
The p53 peptide repertoire displayed by MHC at the surface of a given tumour cell might
therefore depend upon the conformation state of the pS3 protein and the efficiency of
protease processing. In order to test this hypothesis, tumour cells expressing either,
'naturally' or transfected with, conformational pS3 mutants or wild-type conformation
p53 protein and expressing HLA-A2 molecules or transfected with the HLA-A2 gene
were prepared and used as target for CTL generated with either 217-225 or 264-272 p53
peptides. Wild-type pS3 gene could not be transfected into the pS3 null SaOs-2 cells
because of its detrimental effect on the cell cycle. Induction of CTL response in vitro
proved to be a difficult task, especially before dendritic cells were used as APC.
Dendritic cells, indeed, play a crucial role in initiating cellular immune responses and
have been proposed as an adjuvant for cancer therapy (Grabbe, et aI., 1995). Here they
have successfully been used as stimulators for the generation of human anti-p53 specific
CTL which has potential clinicalapplication.
These CTL lines were able to specifically kill peptide-pulsed targets as well as tumour
targets overexpressing the pS3 protein. Tumour targets expressing mutant p53
conformation were preferentially killed as compared with tumour targets expressing
wild-type conformational mutants providing evidence for the hypothesis of differential
processing. However protein overexpression appears not to be prerequisite for the
presentation of p53 epitopes and recognition by the CTL since Ropke, et al., 1996 and
more recently Chikamatsu, et al., 1999, showed that SCC4, a HNSCC cell line HLA-
A2+, bearing a missense mutation at codon 155 and overexpressing p53 protein was not
killed by CTL generated with the 264-272 peptide, whereas SCC9 cells, HLA-A2+,
bearing a deletion at position 275-285, and which do not overexpress p53 protein was
killed by the same CTL. Interestingly CTL clones but not bulks, generated with dendritic
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cells pulsed with p53 peptide 264-272 or 149-157 by Chikamatsu, et aI., 1999 were able
to kill non-peptide-pulsed tumour cells. In addition only bulk CTL populations generated
with peptide 264-272 were able to generated CTL, from two out of five HLA-A2·
donors, which, were able to kill peptide-pulsed tumour target as well as T2 cells. In this
study however bulk CTL generated with either the 217-225 or 264-272 peptides were
able to kill both peptide-pulsed and non-peptide pulsed target. It is possible that the
method used to generate dendritic cells may influence their ability to present to and
activate CDS· cells. Chikamatsu, et aI., 1999 produced dendritic cells CD1a negative
whereas in this study the denritic cells used were CD1a positive.
Results obtained in this study confirm and extend the recent findings of Theobald, et al.,
I99S. They demonstrated that the R->H mutation at residue 273 of human p53 alters
proteosomal processing of the protein due to inhibition of proteolytic cleavage between
residue 272 and 273. Target cells bearing this mutation were not recognised by CTL
generated to the wild-type p53 peptide 264-272 in vitro or in vivo, as this epitope was
not generated. However, a HLA-A2 restricted CTL line specific for human wild-type
p53 peptide 149-157 lysed transfected cell expressing this mutation, indicating efficient
processing of other p53 epitopes. Here, target cells with the R->H mutation at position
273 were not lysed by CTL-264 lines and in addition, were only lysed by CTL lines to
wild-types p53 217-225 peptide in one of three donors. Whilst the former observation is
in agreement with that of Theobald et al (Theobald, et al., 1995), their results suggested
that the 273 mutation may only affect a flanking peptide epitope and a precursor peptide.
Here, the lack of recognition of the 273 mutated p53 observed with CTL lines generated
to 217 in some donors could be due to differences in the affinitiesof the TCR of the CTL
lines generated or relative expression of p53 and HLA-A2 molecules; alternatively,
regions of the protein distant to the mutation may fail to donate peptides to the
processing pathway.
Key questions are whether patients whose tumours harbour a pS3 mutation have
demonstrable precursor CTL or whether they can be induced, and whether there is an
association between the p53 gene mutation, HLA type and disease progression.
The study of HNSCC patients performed here demonstrated a pS3 protein accumulation
in 60% of these patients (6110) and pS3 antibodies in 20% (2110) of sera, and 14% in
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total (2/14 sera tested). Interestingly the two patients with pS3 antibodies were also
found to have pS3 protein accumulation. However p53 accumulation is not always
sufficient for antibody production (Tilkin, et al., 1995). Four patients were found to be
Ifl..A-A2+.One patient, patient 9, HLA-A2+,was found to have both p53 antibodies and
pS3 accumulation. Only 50 % of patients with pS3 mutation will develop antibodies
(Cough, et al., 1994) and the type of mutation itself may influence the production of
antibodies (Davidoff, et al., 11992). It is also possible that for the same mutation one
individual might have pS3 antibodies whereas an another one might not. This might be
due to different MHC class-lor class-II molecules expressed by these individuals.
pS3-antibodies are likely to be the result of self-immunisation process toward the pS3
protein which is normally expressed in minute quantities in the body (Lubin, et al.,
1993). Interestingly immunoglobulin subclasses of these antibodies have been found to
be of IgG 1 and IgG2 in all sera of HNSCC patients suggesting an active immunisation,
these being the result of a second immune response (Lubin, et aI., 1995). pS3 can prime
a pS3-specific T cell response in vivo, and is processed at least ill vitro by APC and
recognised by T cells of certain breast cancer patients (Tilkin, et al., 1995).
In summary new p53 epitope (peptide 217-225) from the 240 region of the protein was
shown to bind with high affinity to HLA-A2 molecules and to generate CTL capable of
killing peptide-pulsed targets as well as tumour cells overexpressing p53 protein. This
peptide was endogenously processed and presented at the surface of tumour cells
expressing a conformational mutant p53 suggesting that pS3 protein processing is
influenced by its conformation.
This study concentrated in the assessement of new class-I restricted antigenic epitopes
from the pS3 protein for their potential use in future immunotherapy programme. It is
now however becoming clear that in order to obtain optimal immunisation both MHC
class-I and class-II antigenic epitopes will be necessary for recognition by CD4+ and
CD8+ cells. Many groups have already started the search for pS3 class-II epitopes and
results obtained in this study concerning class-I epitopes will be carried on and extended
to class-II epieepes in the laboratory of Professor Rees, Trent University,Nottingham.
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